 EX-2.1        

Execution Version

 

Exhibit 2.1

 



 



 



 



 

AGREEMENT AND PLAN OF MERGER

 



 

by and among

 



 

BLACKSTONE MEDICAL, INC.

 



 



 

SUMMIT DEVELOPMENT, INC.,

 



 



 

SPINAL KINETICS, INC.,

 



 



 

and

 



 



 

SHAREHOLDER REPRESENTATIVE SERVICES LLC, 
AS THE EQUITYHOLDERS' REPRESENTATIVE

 



 



 



 



 

dated as of

 



 

March 15, 2018

 



 



 



   

Table of Contents

 



 

    



 |  



 |  

Page

  
---|---|--- 
   

ARTICLE 1 DEFINITIONS AND RULES OF CONSTRUCTION

 |  

2

  
   

Section 1.1

 |  

Definitions

 |  

2

  
   

Section 1.2

 |  

Rules of Construction

 |  

2

  
   

ARTICLE 2 THE MERGER

 |  

3

  
   

Section 2.1

 |  

The Merger

 |  

3

  
   

Section 2.2

 |  

Closing; Effective Time

 |  

3

  
   

Section 2.3

 |  

Effects of the Merger

 |  

3

  
   

Section 2.4

 |  

Charter; Bylaws

 |  

3

  
   

Section 2.5

 |  

Directors and Officers of the Surviving Corporation

 |  

4

  
   

ARTICLE 3 CONVERSION OF SECURITIES; MERGER CONSIDERATION

 |  

4

  
   

Section 3.1

 |  

Conversion of Securities; Merger Consideration

 |  

4

  
   

Section 3.2

 |  

Series D Preferred Stock; Warrants; Convertible Notes; Stock Options

 |  

4

  
   

Section 3.3

 |  

Capital Stock of Merger Sub

 |  

6

  
   

Section 3.4

 |  

Parent to Provide Closing Merger Consideration; Surrender and Exchange of
Certificates; Escrow Amount

 |  

7

  
   

Section 3.5

 |  

Further Ownership Rights in Company Stock

 |  

9

  
   

Section 3.6

 |  

Lost, Stolen or Destroyed Certificates

 |  

10

  
   

Section 3.7

 |  

Dissenting Shares

 |  

10

  
   

Section 3.8

 |  

Purchase Price Adjustment

 |  

10

  
   

Section 3.9

 |  

Earnout Consideration

 |  

13

  
   

Section 3.10

 |  

Achievement of Applicable Milestones; Payment of Earnout Consideration

 |  

17

  
   

Section 3.11

 |  

Other Payments at Closing

 |  

20

  
   

Section 3.12

 |  

Necessary Further Actions

 |  

20

  
   

ARTICLE 4 REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 |  

20

  
   

Section 4.1

 |  

Organization and Qualification

 |  

20

  
   

Section 4.2

 |  

Charter and Bylaws

 |  

21

  
   

Section 4.3

 |  

Capitalization

 |  

22

  
   

Section 4.4

 |  

Authority; Enforceability

 |  

24

  
   

Section 4.5

 |  

Required Vote

 |  

24

  
   

Section 4.6

 |  

No Conflict; Required Filings and Consents

 |  

25

  
   

Section 4.7

 |  

Material Contracts

 |  

26

  
   

Section 4.8

 |  

Compliance

 |  

30

  

 

i  

    

Section 4.9

 |  

Financial Statements

 |  

31

  
---|---|--- 
   

Section 4.10

 |  

Absence of Certain Changes or Events

 |  

32

  
   

Section 4.11

 |  

No Undisclosed Liabilities

 |  

32

  
   

Section 4.12

 |  

Absence of Litigation

 |  

32

  
   

Section 4.13

 |  

Employee Benefit Plans

 |  

33

  
   

Section 4.14

 |  

Employment and Labor Matters

 |  

35

  
   

Section 4.15

 |  

Title to Assets; Sufficiency of Assets; Leases

 |  

37

  
   

Section 4.16

 |  

Taxes

 |  

39

  
   

Section 4.17

 |  

Environmental Matters

 |  

42

  
   

Section 4.18

 |  

Intellectual Property

 |  

43

  
   

Section 4.19

 |  

Information Technology

 |  

46

  
   

Section 4.20

 |  

Insurance

 |  

47

  
   

Section 4.21

 |  

Takeover Statutes

 |  

48

  
   

Section 4.22

 |  

Brokers

 |  

48

  
   

Section 4.23

 |  

Corporate Records

 |  

49

  
   

Section 4.24

 |  

Interested Party Transactions

 |  

49

  
   

Section 4.25

 |  

Accounts Receivable and Accounts Payable

 |  

50

  
   

Section 4.26

 |  

Existing Indebtedness.

 |  

50

  
   

Section 4.27

 |  

Compliance with Privacy Laws.

 |  

50

  
   

Section 4.28

 |  

Medical Device Regulatory and Related Matters.

 |  

52

  
   

Section 4.29

 |  

Health Care Regulatory and Related Matters.

 |  

54

  
   

Section 4.30

 |  

Trade Compliance Matters.

 |  

56

  
   

Section 4.31

 |  

Anti-Money Laundering.

 |  

57

  
   

Section 4.32

 |  

Ethical Practices.

 |  

57

  
   

Section 4.33

 |  

Inventory.

 |  

58

  
   

Section 4.34

 |  

Customers, Suppliers and Distributors.

 |  

59

  
   

Section 4.35

 |  

Product Liability; Product Warranty.

 |  

59

  
   

ARTICLE 5 REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

 |  

60

  
   

Section 5.1

 |  

Organization and Qualification.

 |  

60

  
   

Section 5.2

 |  

Authority; Enforceability.

 |  

60

  
   

Section 5.3

 |  

No Conflict; Required Filings and Consents.

 |  

61

  
   

Section 5.4

 |  

Available Funds.

 |  

61

  

 

ii  

    

ARTICLE 6 COVENANTS

 |  

61

  
---|--- 
   

Section 6.1

 |  

Conduct of Business by the Company Pending the Merger

 |  

61

  
   

Section 6.2

 |  

No Solicitation of Other Proposals

 |  

65

  
   

Section 6.3

 |  

Access to Information; Confidentiality

 |  

66

  
   

Section 6.4

 |  

Regulatory and Other Approvals

 |  

67

  
   

Section 6.5

 |  

Employee Benefits

 |  

68

  
   

Section 6.6

 |  

Notification of Certain Matters

 |  

70

  
   

Section 6.7

 |  

Stockholder Approval; General Release of Claims

 |  

71

  
   

Section 6.8

 |  

Public Announcements

 |  

72

  
   

Section 6.9

 |  

Takeover Statutes

 |  

72

  
   

Section 6.10

 |  

Equityholders and Other Claims

 |  

72

  
   

Section 6.11

 |  

Company Transaction Expenses.

 |  

72

  
   

Section 6.12

 |  

Escrow Agreement.

 |  

73

  
   

Section 6.13

 |  

Delivery of Corporate Records.

 |  

73

  
   

Section 6.14

 |  

Equityholder Agreements.

 |  

73

  
   

Section 6.15

 |  

Payout Schedule.

 |  

73

  
   

Section 6.16

 |  

Treatment of Series D Preferred Stock, Stock Options, Warrants and Convertible
Notes.

 |  

76

  
   

Section 6.17

 |  

Indemnification of Directors and Officers.

 |  

76

  
   

Section 6.18

 |  

280G Approval.

 |  

77

  
   

Section 6.19

 |  

Cayman Subsidiary.

 |  

77

  
   

Section 6.20

 |  

Further Assurances.

 |  

78

  
   

ARTICLE 7 CONDITIONS

 |  

78

  
   

Section 7.1

 |  

Conditions to Each Party's Obligation to Consummate the Merger.

 |  

78

  
   

Section 7.2

 |  

Additional Conditions to Obligations of Parent and Merger Sub

 |  

79

  
   

Section 7.3

 |  

Additional Conditions to Obligations of the Company

 |  

83

  
   

ARTICLE 8 TERMINATION, AMENDMENT AND WAIVER

 |  

83

  
   

Section 8.1

 |  

Termination

 |  

83

  
   

Section 8.2

 |  

Effect of Termination; Termination Fee

 |  

84

  
   

Section 8.3

 |  

Amendment

 |  

85

  
   

Section 8.4

 |  

Waiver

 |  

86

  

 

iii  

    

ARTICLE 9 INDEMNIFICATION AND ESCROW

 |  

86

  
---|--- 
   

Section 9.1

 |  

Survival of Representations, Warranties, Agreements and Covenants

 |  

86

  
   

Section 9.2

 |  

Indemnification; Remedies

 |  

87

  
   

Section 9.3

 |  

Calculation of Losses; Mitigation

 |  

91

  
   

Section 9.4

 |  

Escrow Fund

 |  

92

  
   

Section 9.5

 |  

Equityholders' Representative

 |  

93

  
   

Section 9.6

 |  

Indemnification Claims

 |  

94

  
   

Section 9.7

 |  

Third Party Claims

 |  

95

  
   

Section 9.8

 |  

Payment

 |  

97

  
   

Section 9.9

 |  

Remedy

 |  

97

  
   

ARTICLE 10 TAX

 |  

97

  
   

Section 10.1

 |  

Tax Allocation.

 |  

97

  
   

Section 10.2

 |  

Returns and Payments.

 |  

97

  
   

Section 10.3

 |  

Contests.

 |  

99

  
   

Section 10.4

 |  

Cooperation and Exchange of Information.

 |  

99

  
   

Section 10.5

 |  

Characterization of Payments.

 |  

99

  
   

Section 10.6

 |  

Transfer Taxes.

 |  

100

  
   

Section 10.7

 |  

Tax Records.

 |  

100

  
   

ARTICLE 11 MISCELLANEOUS

 |  

100

  
   

Section 11.1

 |  

Fees and Expenses

 |  

100

  
   

Section 11.2

 |  

Notices

 |  

100

  
   

Section 11.3

 |  

Severability.

 |  

101

  
   

Section 11.4

 |  

Entire Agreement.

 |  

102

  
   

Section 11.5

 |  

Assignment.

 |  

102

  
   

Section 11.6

 |  

Parties in Interest.

 |  

102

  
   

Section 11.7

 |  

Failure or Indulgence Not Waiver; Remedies Cumulative.

 |  

102

  
   

Section 11.8

 |  

Governing Law; Jurisdiction.

 |  

102

  
   

Section 11.9

 |  

Enforcement of Agreement; Specific Performance.

 |  

104

  
   

Section 11.10

 |  

Counterparts.

 |  

104

  
   

Section 11.11

 |  

Due Diligence Materials.

 |  

104

  
   

Section 11.12

 |  

Time is of the Essence.

 |  

104

  
 

 



 



 

iv  

EXHIBITS

 



 

    |   
---|--- 
   

Exhibit A

 |  

Escrowed Stockholder Consents and Agreements

  
   

Exhibit B

 |  

Persons Executing Employee Agreements

  
   

Exhibit C

 |  

Definitions

  
   

Exhibit D

 |  

Form of Certificate of Merger

  
   

Exhibit E

 |  

Certificate of Incorporation of the Surviving Corporation

  
   

Exhibit F

 |  

Pro Forma Payout Schedule

  
   

Exhibit G

 |  

Certain Required Stockholder Consents

  
   

Exhibit H

 |  

Illustrative Calculation of Working Capital

  
   

Exhibit I

 |  

Form of Stockholder Consent and Agreement

  
   

Exhibit J

 |  

Certain Required Approvals and Notices

  
   

Exhibit K

 |  

Form of Escrow Agreement

  
   

Exhibit L

 |  

Required Estoppel Certificates

  
   

Exhibit M

 |  

Equityholders' Representative

  
   

Exhibit N

 |  

Specified Terminated Arrangements

  
   

Exhibit O

 |  

List of Individuals to whom Definition of "Knowledge" or "Knowledge of
Company" Applies

  
   

Exhibit P-1

 |  

M6-C Disc

  
   

Exhibit P-2

 |  

M6-L Disc

  
   

Exhibit Q

 |  

Additional Indemnified Matters

  
 

 



 



 

SCHEDULES

 



 

Company Disclosure Schedule

 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 



 

__________________________

 



 

* All schedules and exhibits, other than Exhibit C and Exhibit M, have been omitted from the filed copy of this document pursuant to Item 601(b)(2) of Regulation S-K. Orthofix International N.V. agrees to furnish a copy of any omitted schedule or exhibit to the Securities and Exchange Commission upon request.

 

v  

AGREEMENT AND PLAN OF MERGER

 

THIS AGREEMENT AND PLAN OF MERGER, dated as of March 15, 2018 (this
"Agreement"), is entered into by and among Blackstone Medical, Inc., a
Massachusetts corporation ("Parent"), Summit Development, Inc., a Delaware
corporation and a direct wholly owned subsidiary of Parent ("Merger Sub"),
Spinal Kinetics, Inc., a Delaware corporation (the "Company"), and Shareholder
Representative Services LLC, a Colorado limited liability company, solely in
its capacity as the Equityholders' Representative. Parent, Merger Sub, the
Company and the Equityholders' Representative are sometimes referred to herein
individually as a "Party" and collectively as the "Parties."

 

RECITALS

 

WHEREAS, upon the terms and subject to the conditions of this Agreement and in
accordance with the General Corporation Law of the State of Delaware (the
"DGCL"), Parent will acquire the Company through a transaction pursuant to
which Merger Sub will merge with and into the Company (the "Merger"), which
Merger will result in, among other things, the Company becoming a direct
wholly owned subsidiary of Parent;

 

WHEREAS, the respective Boards of Directors of Parent, Merger Sub and the
Company have determined that it is advisable and in the best interests of each
respective corporation and its stockholders to consummate the Merger and the
other transactions contemplated by this Agreement, in each case upon the terms
and subject to the conditions set forth in this Agreement;

 

WHEREAS, the respective Boards of Directors of Parent, Merger Sub and the
Company have approved and declared advisable this Agreement and the Merger,
upon the terms and subject to the conditions set forth in this Agreement, and
approved the consummation of the transactions contemplated by this Agreement;

 

WHEREAS, the Board of Directors of the Company has recommended that the
Company's stockholders adopt this Agreement and approve the Merger and the
other transactions contemplated hereby, all upon the terms and subject to the
conditions set forth in this Agreement;

 

WHEREAS, in order to induce Parent and Merger Sub to enter into this
Agreement, following the approval of this Agreement and the Merger by the
Company's Board of Directors, holders of Common Stock and Preferred Stock
holding approximately (i) 75.3% of the voting power of the outstanding shares
of Series C Preferred Stock and Common Stock, voting as a single class on an
as-if converted basis, (ii) 77.0% of the voting power of the outstanding
shares of Preferred Stock, voting on a combined and as-if converted basis, and
(iii) 70.0% of the voting power of the outstanding shares of Common Stock,
voting as a class, have delivered duly executed Stockholder Consents and
Agreements, copies of which are attached hereto as Exhibit A, to the Company
to be held in escrow (the "Escrowed Stockholder Consents and Agreements"),
which Escrowed Stockholder Consents and Agreements shall be released and
become effective immediately following the execution of this Agreement by all
Parties;

 

WHEREAS, in order to induce Parent and Merger Sub to enter into this
Agreement, concurrently with the execution of this Agreement, certain
employees of the Company identified on Exhibit B are executing employee offer
letters with Parent or one of its Affiliates or amendments to

 

  

their existing employment or change of control agreements with the Company
(together, the "Employee Agreements"), to become effective upon the Closing;
and

 

WHEREAS, at the Effective Time, all Stock Options shall be cancelled on the
terms and conditions of this Agreement and in exchange for the consideration
described herein.

 

NOW, THEREFORE, in consideration of the foregoing and the mutual
representations, warranties, covenants and agreements set forth herein, and
for other good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, intending to be legally bound hereby, the
Parties agree as follows:

 

Article 1 
DEFINITIONS AND RULES OF CONSTRUCTION

 



 

Definitions

 

. Capitalized terms used herein without definition shall have the respective
meanings assigned thereto in Exhibit C attached hereto and incorporated herein
for all purposes of this Agreement (such definitions to be equally applicable
to both the singular and plural forms and to the masculine as well as to the
feminine and neuter genders of the terms defined). 

 

Rules of Construction

 

. A term defined as one part of speech (such as a noun) shall have a
corresponding meaning when used as another part of speech (such as a verb).
All terms defined in this Agreement shall have the defined meanings when used
in any certificate or other document made or delivered pursuant thereto unless
otherwise defined therein. Unless otherwise specified, all references herein
to "Articles," "Sections," "Exhibits," "Annexes" or "Schedules" are to
Articles, Sections, Exhibits, Annexes or Schedules of this Agreement. The
words "include," "includes" and "including" shall be deemed to be followed by
the phrase "without limitation." The words "hereof," "herein," "hereunder"
and "herewith" and words of similar import shall, unless otherwise stated, be
construed to refer to this Agreement as a whole and not to any particular
provision of this Agreement. The word "or" will have the inclusive meaning
represented by the phrase "and/or." "Shall" and "will" mean "must," and shall
and will have equal force and effect and express an obligation. "Writing,"
"written" and comparable terms refer to printing, typing, and other means of
reproducing in a visible form. The table of contents and headings, titles and
captions contained in this Agreement are for reference purposes only and shall
not affect in any way the meaning or interpretation of this Agreement.
References to any agreement or instrument herein or in any agreement or
instrument that is referred to herein (including references to this Agreement)
mean such agreement or instrument as from time to time amended, modified or
supplemented, including by waiver or consent. Any reference to a Law herein
shall include any amendment thereof or any successor thereto and any rules and
regulations promulgated thereunder. Unless otherwise expressly provided, any
reference in this Agreement to $, "dollars" or "Dollars" shall mean U.S.
dollars. References to a Person are also to its permitted successors and
assigns. Each Party acknowledges that this Agreement was jointly negotiated
and drafted by the Parties with the benefit of representation by legal
counsel, and any rule of construction or interpretation otherwise requiring
this Agreement to be construed or interpreted against any Party shall not
apply to any construction or interpretation hereof. References in this
Agreement to "consistent with past practice" shall mean consistent with past
practice including as to time, frequency and amount.

 

2  

Article 2 
THE MERGER

 



 

The Merger

 

. Upon the terms and subject to the conditions of this Agreement, and in
accordance with the DGCL and, to the extent applicable, the CCC, at the
Effective Time, Merger Sub shall be merged with and into the Company. As a
result of the Merger, the separate corporate existence of Merger Sub shall
cease and the Company shall continue as the surviving corporation and a wholly
owned subsidiary of Parent. The Company, as the surviving corporation of the
Merger, is hereinafter sometimes referred to as the "Surviving Corporation."

 

Closing; Effective Time

 

. Subject to the provisions of this Agreement, the closing of the Merger (the
"Closing") shall take place at the offices of Hogan Lovells US LLP, 555
Thirteenth Street, NW, Washington, D.C. 20004, as soon as practicable, but in
no event later than the fourth (4th) Business Day, after the satisfaction or,
if permissible under applicable Law, waiver of the conditions set forth in
Article 7 (excluding conditions that, by their terms, cannot be satisfied
until the Closing, but the Closing shall be subject to the satisfaction or, if
permissible, waiver of those conditions), or at such other place or in such
other manner or on such other date as Parent and the Company may mutually
agree in writing. The date on which the Closing actually occurs is
hereinafter referred to as the "Closing Date." Concurrently with the Closing,
on the Closing Date, the Parties shall cause the Merger to be consummated by
filing a certificate of merger substantially in the form attached as Exhibit D
hereto (the "Certificate of Merger") with the Secretary of State of the State
of Delaware, in such form as is required by, and executed and filed in
accordance with, the relevant provisions of the DGCL (the date and time of
such filing, or such later time as is agreed to by Parent and the Company and
specified in the Certificate of Merger, being the "Effective Time"), and shall
make all other filings or recordings required under the DGCL or the CCC in
connection with the Merger.

 

Effects of the Merger

 

. The Merger shall have the effects set forth in this Agreement and the
applicable provisions of the DGCL and, to the extent applicable, the CCC.
Without limiting the generality of the foregoing and subject thereto, at the
Effective Time, all property (whether real, personal, intangible or mixed),
rights, privileges, powers and franchises, and all and every other interest,
of each of the Company and Merger Sub shall be vested in the Surviving
Corporation without reversion or impairment, and all debts, liabilities and
duties of each of the Company and Merger Sub shall become the debts,
liabilities and duties of the Surviving Corporation.

 

Charter; Bylaws

 

.

 

(a)The certificate of incorporation of the Surviving Corporation shall be
amended and restated at the Effective Time to read in the form attached hereto
as Exhibit E, and, as so amended and restated, such certificate of
incorporation shall be the certificate of incorporation of the Surviving
Corporation until thereafter changed or amended as provided therein or by
applicable Law.

 

(b)The bylaws of the Surviving Corporation shall be amended and restated at
the Effective Time to read the same as the bylaws of Merger Sub as in effect
immediately prior to the Effective Time (except that all references therein to
the name of Merger Sub shall be replaced by references to the name "Spinal
Kinetics, Inc."), and, as so amended and restated, such bylaws shall be the
bylaws of the Surviving Corporation until thereafter changed or amended as
provided in such bylaws or in the certificate of incorporation of the
Surviving Corporation or by applicable Law.

 

3  

Directors and Officers of the Surviving Corporation

 

. The directors of Merger Sub immediately prior to the Effective Time shall
be the initial directors of the Surviving Corporation, each to hold office
until the earlier of his or her resignation, removal or death or until his or
her successor is duly elected and qualified, as the case may be, in accordance
with the certificate of incorporation and bylaws of the Surviving Corporation
and applicable Law. The officers of Merger Sub shall be the initial officers
of the Surviving Corporation and each such initial officer shall hold office
until the earlier of his or her resignation, removal or death or until his or
her successor is duly appointed and qualified, as the case may be, in
accordance with the certificate of incorporation and bylaws of the Surviving
Corporation and applicable Law.

 

Article 3 
CONVERSION OF SECURITIES; MERGER CONSIDERATION

 



 

Conversion of Securities; Merger Consideration

 

.

 

 By virtue of the Merger and without any action on the part of Parent, Merger
Sub, the Company or the Equityholders, at the Effective Time, each share of
capital stock of the Company that is issued and held by the Company or any of
the Company's wholly owned Subsidiaries immediately prior to the Effective
Time shall automatically be cancelled and retired and shall cease to exist,
and no consideration shall be issued or delivered in exchange therefor (such
shares, "Cancelled Shares"). Subject to the terms and conditions of this
Agreement, including the provisions of this Article 3, Article 9 and other
applicable provisions in this Agreement, by virtue of the Merger and without
any action on the part of Parent, Merger Sub, the Company or the
Equityholders, at the Effective Time, (i) each share of Common Stock that is
issued and outstanding immediately prior to the Effective Time and (ii) each
share of Preferred Stock that is issued and outstanding immediately prior to
the Effective Time, in each case, other than (A) Cancelled Shares, (B)
Redeemed Series D Shares and (C) Dissenting Shares, shall be cancelled and
extinguished and shall be converted into and become (x) the right to receive
(without interest and subject to applicable Tax withholding) the applicable
portion of the Closing Merger Consideration as set forth on the Payout
Schedule, and (y) a contingent right to receive (without interest and subject
to applicable Tax withholding) the applicable portion of the Contingent
Consideration as set forth on the Payout Schedule, as the same may be updated
from time to time in accordance with Section 6.15(d), with such contingent
right to receive such applicable portion of the Contingent Consideration being
subject to, and with such applicable portion of the Contingent Consideration
being payable in accordance with, the provisions of this Article 3, Article 9
and the Escrow Agreement.

 

Series D Preferred Stock; Warrants; Convertible Notes; Stock Options

 

.

 



 

(a)Each share of Series D Preferred Stock that is issued and outstanding
immediately prior to the Effective Time shall be redeemed by the Company at or
prior to the Effective Time pursuant to and in accordance with Section 8 of
the Charter (each share so redeemed, a "Redeemed Series D Share"). For the
avoidance of doubt, no Redeemed Series D Share shall (i) be converted into a
right to a receive, or otherwise entitle the holder of such Redeemed Series D
Share to receive, any portion of the Merger Consideration, or (ii) otherwise
entitle the holder of such Redeemed Series D Share to any rights hereunder.

 

(b)Immediately prior to and conditioned upon the occurrence of the Effective
Time, (i) each VLL Warrant that then remains outstanding and unexercised (in
whole or in part) shall be automatically exchanged for shares of Series C
Preferred Stock pursuant to and in accordance with Section 4.3 of such VLL
Warrant (provided that, if a "Liquidation Bonus" is due pursuant to

 

4  

Section 4.3(b) of such VLL Warrant, then such VLL Warrant shall not be so
exchanged, but shall be surrendered to the Company in exchange for a cash
payment by the Company in an amount equal to such "Liquidation Bonus" pursuant
to and in accordance with Section 4.3(b) of such VLL Warrant), (ii) the MS
Warrant, if then outstanding and unexercised (in whole or in part), shall be
deemed exercised as to all shares of Series C Preferred Stock subject thereto
pursuant to and in accordance with Section 1.6(b)(2) of the MS Warrant, and
(iii) the SVB Warrant, if then outstanding and unexercised (in whole or in
part), shall expire (without any consideration therefor) in accordance with
Section 1.6(b) of the SVB Warrant and the holder thereof shall have no further
right to purchase or otherwise acquire any shares of capital stock of the
Company or the Surviving Corporation (or to otherwise receive any
consideration from the Company, the Surviving Corporation or Parent) pursuant
thereto. For the avoidance of doubt, (A) any shares of Series C Preferred
Stock issued in exchange for, or upon deemed exercise of, a Warrant pursuant
to clause (i) or clause (ii) of the foregoing sentence shall, for all purposes
hereunder, be issued and outstanding immediately prior to the Effective Time
and shall be subject to cancellation, extinguishment and conversion at the
Effective Time pursuant to and in accordance with Section 3.1 (and the holder
of such shares shall constitute a Stockholder for all purposes hereunder), and
(B) without limiting the foregoing, no Warrant shall be converted into a right
to a receive, or otherwise entitle the holder of such Warrant to receive, any
portion of the Merger Consideration.

 

(c)Each Convertible Note that remains outstanding immediately prior to the
Effective Time shall either (i) be included in the Debt Pay-Off Amount
(including in the Estimated Debt Pay-Off Amount, the Proposed Final Debt Pay-
Off Amount and the Final Debt Pay-Off Amount pursuant to Section 3.8) and be
redeemed or repaid (as the case may be) on the Closing Date pursuant to and in
accordance with the terms thereof (including, in the case of any 2016 Bridge
Note, Section 1(d) thereof, or, in the case of the De Novo Standalone Note,
Section 3 thereof) and Section 3.11(a), or (ii) be converted, immediately
prior to the Effective Time, into shares of Series C Preferred Stock at the
applicable conversion price specified in such Convertible Note pursuant to and
in accordance with the terms thereof (including, in the case of any 2016
Bridge Note, Section 3(b) thereof). For the avoidance of doubt, (A) any shares
of Series C Preferred Stock issued upon conversion of a Convertible Note
pursuant to clause (ii) of the foregoing sentence shall, for all purposes
hereunder, be issued and outstanding immediately prior to the Effective Time
and shall be subject to cancellation, extinguishment and conversion at the
Effective Time pursuant to and in accordance with Section 3.1 (and the holder
of such shares shall constitute a Stockholder for all purposes hereunder), and
(B) without limiting the foregoing, no Convertible Note shall be converted
into a right to a receive, or otherwise entitle the holder of such Convertible
Note to receive, any portion of the Merger Consideration.

 

(d)Subject to the provisions of this Article 3, Article 9 and other applicable
provisions in this Agreement, at the Effective Time, by virtue of the Merger
and without any action on the part of Parent, Merger Sub, the Company or the
Equityholders, each Stock Option outstanding immediately prior to the
Effective Time and not exercised, whether or not then exercisable or vested,
shall, by virtue of this Agreement and the applicable Company Equity Plan and
without any action on the part of the holder thereof, be cancelled,
extinguished and terminated and converted into and become (i) a right
following the Effective Time to receive (without interest and subject to
applicable Tax withholding) the applicable portion of the Closing Merger
Consideration, if any, as set forth on the Payout Schedule (which applicable
portion, if any, for the avoidance of doubt, shall consist of the portion of
the Closing Merger Consideration that would be payable in respect of the
shares of Common Stock for which such Stock Option is exercisable as of
immediately prior to the Effective Time, net of the applicable aggregate
exercise price with respect to such Stock Option), and (ii) a

 

5  

contingent right following the Effective Time to receive (without interest and
subject to applicable Tax withholding) the applicable portion of the
Contingent Consideration, if any, as set forth on the Payout Schedule, as the
same may be updated from time to time in accordance with Section 6.15(d)
(which applicable portion, if any, for the avoidance of doubt, shall consist
of the portion of such Contingent Consideration that would be payable in
respect of the shares of Common Stock for which such Stock Option is
exercisable as of immediately prior to the Effective Time, net of any
remaining portion of the applicable aggregate exercise price with respect to
such Stock Option, after taking into account prior netting in the
determination of Closing Merger Consideration or Contingent Consideration
payable in respect of such Stock Option), with such contingent right to
receive such applicable portion of the Contingent Consideration being subject
to, and with such applicable portion of the Contingent Consideration being
payable in accordance with, the provisions of this Article 3, Article 9 and
the Escrow Agreement. Notwithstanding anything to the contrary contained
herein, (A) each Stock Option with an applicable aggregate exercise price that
is equal to or in excess of the portion of the Merger Consideration that would
be payable in respect of the shares of Common Stock for which such Stock
Option is exercisable as of immediately prior to the Effective Time shall be
cancelled, extinguished and terminated at the Effective Time for no
consideration; and (B) Parent will not assume any Stock Options. As soon as
practicable following the date of this Agreement and prior to the Effective
Time, the Company shall take all action that may be necessary or required
(under any Company Equity Plan, any applicable Law, the applicable stock
option award agreements or otherwise) to effectuate the provisions of this
Section 3.2(d) and to ensure that, from and after the Effective Time, each
holder of an outstanding Stock Option cancelled, extinguished and terminated
as provided in this Section 3.2(d) shall have no rights with respect thereto,
except the right to receive the consideration specified in this Section
3.2(d), if any.

 

(e)Prior to the Effective Time, the Company shall take all actions necessary
to (i) effectuate the provisions of Section 3.2(a), Section 3.2(b), Section
3.2(c) and Section 3.2(d), (ii) ensure that (A) all certificates representing
shares of Series D Preferred Stock shall be surrendered to the Company and
cancelled at or prior to the Effective Time, (B) all shares of Series D
Preferred Stock shall be cancelled and retired and shall cease to exist at or
prior to the Effective Time and (C) from and after the Effective Time no
Series D Holder shall have any rights or interests in the Company or any of
its Subsidiaries (or any of their respective assets) by virtue of the shares
of Series D Preferred Stock held by such Series D Holder, (iii) terminate each
Warrant as of the Effective Time and ensure that from and after the Effective
Time no holder thereof shall have any Warrants or other rights to purchase
shares of Common Stock or Preferred Stock or any other equity interest in the
Company, (iv) ensure that from and after the Effective Time no Convertible
Note shall remain outstanding and no holder of any Convertible Note shall have
any right to acquire or otherwise receive shares of Common Stock or Preferred
Stock or any other equity interest in the Company (subject to Parent's
compliance with its obligations under Section 3.11(a) with respect to such
Convertible Note, if any), and (v) terminate each Company Equity Plan and each
Warrant as of the Effective Time and ensure that from and after the Effective
Time no employee or other service provider of the Company or any of its
Subsidiaries or any participant under the Company Equity Plans or otherwise
shall have any Stock Options or other rights to purchase shares of Common
Stock or Preferred Stock or any other equity interest in the Company (in each
case of the foregoing clauses (i), (ii), (iii), (iv) and (v), without the
creation of any additional Liability of the Company).

 

Capital Stock of Merger Sub

 

.

 

 At the Effective Time, each share of common stock, par value $0.01, of
Merger Sub (the "Merger Sub Common Stock") issued and outstanding as of
immediately prior to the Effective Time shall be automatically converted into
and become one (1) validly issued, fully paid and non-assessable share of
common stock, par value $0.01, of the

 

6  

Surviving Corporation (the "Surviving Corporation Common Stock"), and shall
thereafter constitute all of the issued and outstanding shares of capital
stock of the Surviving Corporation. Each stock certificate representing
shares of Merger Sub Common Stock shall continue after the Effective Time to
represent shares of Surviving Corporation Common Stock.

 

Parent to Provide Closing Merger Consideration; Surrender and Exchange of
Certificates; Escrow Amount

 

.

 

(a)Notwithstanding anything in this Agreement to the contrary, at the Closing,
in no event shall the aggregate consideration payable or allocable to holders
of Common Stock, Preferred Stock, Warrants or Stock Options by Parent or
Merger Sub exceed the Closing Merger Consideration.

 

(b)Prior to the Effective Time, Parent shall designate Acquiom Financial LLC,
a Colorado limited liability company, or such other bank or trust company
designated by Parent that is reasonably acceptable to the Company, to act as
the payments administrator in the Merger (the "Payments Administrator")
pursuant to the terms of the Payments Agreement.

 

(c)On the Closing Date, promptly after the Effective Time, Parent shall
deposit with the Payments Administrator cash in the amount necessary to pay to
each Stockholder (other than any holder of Dissenting Shares) the applicable
portion of the Closing Merger Consideration payable to such Stockholder in
respect of its shares of Common Stock or Preferred Stock issued and
outstanding immediately prior to the Effective Time, as set forth in the
Payout Schedule. At any time following twelve (12) months after the Effective
Time, all cash deposited with the Payments Administrator pursuant to this
Section 3.4(c) that remains undistributed to Stockholders shall be delivered
to Parent upon demand, and thereafter such Stockholders shall be entitled to
look only to Parent (subject to abandoned property, escheat or other similar
Laws), solely as general creditors thereof, for payment, upon due surrender of
their Certificates, with respect to the applicable portion of the Closing
Merger Consideration payable to such Stockholders in respect of their shares
of Common Stock or Preferred Stock issued and outstanding immediately prior to
the Effective Time, as set forth in the Payout Schedule. Any portion of the
Closing Merger Consideration that remains unclaimed immediately prior to the
date on which it would otherwise become subject to any abandoned property,
escheat or similar Law shall, to the extent permitted by applicable Law,
become the property of Parent, free and clear of all claims or interest of any
Person previously entitled thereto.

 

(d)Promptly following the Effective Time, the Payments Administrator shall
mail or deliver (or cause to be mailed or delivered) a letter of transmittal
(the "Transmittal Letter") to each holder of record of a stock certificate or
certificates (the "Certificates") that represented outstanding shares of
Preferred Stock or Common Stock as of immediately prior to the Effective Time
(other than any such holder that held only Redeemed Series D Shares). The
Transmittal Letter shall specify that delivery of shares of Common Stock and
Preferred Stock shall be effected, and risk of loss and title to the
Certificates shall pass, only upon delivery of the Certificates to the
Payments Administrator and shall contain instructions for use in effecting the
surrender of the Certificates in exchange for the payment of the applicable
portion of the Closing Merger Consideration payable with respect to the shares
of Common Stock or Preferred Stock represented thereby, as set forth in the
Payout Schedule. The Transmittal Letter shall also include a consent to the
appointment and authority of the Equityholders' Representative as set forth
herein. Promptly upon the later of (i) the Effective Time and (ii) the
surrender to the Payments Administrator of a Certificate, together with a

 

7  

Transmittal Letter, duly completed and validly executed in accordance with the
instructions thereto, and such other documents as may be required pursuant to
the instructions thereto (collectively, the "Exchange Documents"), the holder
of such Certificate shall be entitled to receive (and Parent or the Surviving
Corporation shall cause the Payments Administrator to distribute to such
holder) in exchange therefor payment by Automated Clearing House (ACH)
transfer (or, at the election of such holder and for a processing fee not to
exceed twenty-five dollars ($25) per check or per wire transfer to be deducted
from such payment, by check or by wire transfer of immediately available
funds) of the cash amount equal to the applicable portion of the Closing
Merger Consideration payable to such Stockholder in respect of its shares of
Common Stock or Preferred Stock represented by such Certificate, as set forth
in the Payout Schedule, after giving effect to any required withholding Taxes,
and the Certificate so surrendered shall forthwith be cancelled. Until so
surrendered, after the Effective Time (except as otherwise provided in Section
3.7 with respect to Dissenting Shares), each Certificate shall be deemed, for
all corporate purposes thereafter, to evidence only the right to receive the
consideration provided for in this Article 3. No portion of the Merger
Consideration shall be paid to any Stockholder until the holder of record of a
Certificate has surrendered such Certificate and delivered the Exchange
Documents pursuant hereto.

 

(e)Promptly after the Effective Time, Parent shall disburse to the Surviving
Corporation the amount necessary to pay to each Optionholder the applicable
portion of the Closing Merger Consideration payable to such Optionholder in
respect of its Stock Options pursuant to Section 3.2, as set forth in the
Payout Schedule. Promptly thereafter, the Surviving Corporation shall cause to
be disbursed (i) to each Optionholder with respect to which the Company has a
Tax withholding obligation, through the Surviving Corporation's payroll system
the amount equal to the applicable portion of the Closing Merger Consideration
payable to such Optionholder in respect of his or her Stock Options, as set
forth in the Payout Schedule, after giving effect to any required withholding
Taxes and (ii) to each Optionholder with respect to which the Company has no
Tax withholding obligation, the amount equal to the applicable portion of the
Closing Merger Consideration payable to such Optionholder in respect of his or
her Stock Options, as set forth in the Payout Schedule.

 

(f)Parent, the Surviving Corporation and the Payments Administrator shall be
entitled to rely entirely on the information contained in the Payout Schedule,
any Updated Payout Schedule and any Exchange Documents delivered hereunder for
purposes of satisfying Parent's and the Surviving Corporation's respective
obligations to deliver any and all portions of the Merger Consideration
payable hereunder.

 

(g)On the Closing Date, promptly after the Effective Time, and subject to and
in accordance with the provisions of Article 9, Parent shall pay to (i) the
Escrow Agent the Escrow Amount to be deposited into an escrow fund (the
"Escrow Fund") and (ii) the Equityholders' Representative the Expense Amount
to be held by the Equityholders' Representative in a segregated account (the
"Expense Fund") in accordance with the terms of Section 9.5(d). The Escrow
Fund shall be held in escrow and, as provided in Article 9, shall be available
to compensate Parent Indemnified Persons and shall otherwise be distributed
pursuant to Section 9.4 to the Equityholders. The Escrow Fund shall be
reduced from time to time in accordance with Section 3.8, Section 6.11,
Article 9 and Section 10.2, and shall be increased from time to time by the
amount of any interest, dividends, earnings and other income received in
respect of the amounts therein in accordance with the Escrow Agreement. The
Parties agree that payments from the Escrow Fund to Stockholders will be
treated for tax purposes as deferred payments of purchase price, except to the
extent treated as payments of interest pursuant to Section 483 or Section 1274
of the Code.

 

8  

(h)If any portion of the cash payment pursuant to Section 3.1 is to be paid to
a Person other than the Person in whose name the Certificate surrendered in
exchange therefor is registered, it will be a condition to such payment that
(i) the Certificate so surrendered will be properly endorsed and otherwise in
proper form for transfer, (ii) the signatures on such Certificate or any
related stock power shall be properly guaranteed, and (iii) the Person
requesting such exchange will have (A) paid any transfer or other Taxes
required by reason of such payment in a name other than the registered holder
of the Certificate surrendered or (B) established to the satisfaction of
Parent, or any agent designated by Parent, that such Tax has been paid or is
not applicable. 

 

(i)The Parties understand and agree that (i) the contingent rights to receive
any Contingent Consideration will not be represented by any form of
certificate, are not transferable, except by operation of Laws relating to
descent and distribution, divorce and community property, and do not
constitute an equity or ownership interest in Parent or the Surviving
Corporation, (ii) no Equityholder shall have any rights as a security holder
of the Surviving Corporation or Parent as a result of such Equityholder's
contingent right to receive any Contingent Consideration hereunder and (iii)
no interest is payable with respect to any Contingent Consideration.

 

(j)Notwithstanding anything to the contrary in this Agreement, none of the
Payments Administrator, Parent, Merger Sub or the Surviving Corporation (or
any Affiliate thereof) shall be liable to a holder of a Certificate for any
amount delivered to a public official pursuant to any applicable abandoned
property, escheat or similar Law. 

 

(k)Notwithstanding anything to the contrary in this Agreement, any of Parent,
the Payments Administrator or the Surviving Corporation (pursuant to Parent's
request) will be entitled to deduct and withhold from the consideration
otherwise payable pursuant to this Agreement to any Equityholder such amounts
as Parent, the Payments Administrator or the Surviving Corporation shall
determine in good faith are required to be deducted and withheld with respect
to the making of such payment under the Code, or any provision of federal,
state, local or foreign Laws relating to Taxes. Such deducted and withheld
amounts remitted to the applicable Governmental Authority will be treated for
all purposes of this Agreement as having been paid to the Equityholders in
respect of which such deduction and withholding was made by Parent, the
Payments Administrator or the Surviving Corporation.

 

Further Ownership Rights in Company Stock

 

.

 

 The applicable consideration paid upon the surrender for exchange of
Certificates in accordance with the terms of this Article 3 (including the
contingent right to receive payment of the Contingent Consideration, if any)
shall be in full satisfaction of all rights pertaining to Preferred Stock and
Common Stock (including any rights to receive accumulated but undeclared
dividends, if any). At the Effective Time, the stock transfer books of the
Company shall be closed, and thereafter there shall be no further registration
of transfers of shares of Preferred Stock or Common Stock outstanding prior to
the Effective Time on the records of the Surviving Corporation. From and
after the Effective Time, the holders of Certificates representing ownership
of shares of Preferred Stock or Common Stock outstanding prior to the
Effective Time shall cease to have any rights with respect to such shares of
Preferred Stock or Common Stock, as applicable (including any rights to
receive accumulated but undeclared dividends, if any), except as otherwise
specifically provided for herein. If, after the Effective Time, Certificates
are presented to Parent or the Surviving Corporation (or any Affiliate
thereof) for any reason, they shall be cancelled and exchanged as provided in
this Article 3.

 

9  

Lost, Stolen or Destroyed Certificates

 

.

 



 

In the event any Certificates representing Preferred Stock or Common Stock
shall have been lost, stolen or destroyed, the Payments Administrator shall
pay in exchange for such lost, stolen or destroyed Certificates, upon the
making of an acceptable affidavit of that fact by the holder thereof and the
delivery of such other documents reasonably requested by the Payments
Administrator, the applicable portion of the Closing Merger Consideration
payable to such holder in respect of the shares of Common Stock or Preferred
Stock represented by such Certificate, as set forth in the Payout Schedule;
provided, however, that Parent may, in its sole discretion and as a condition
precedent to the payment thereof, require the owner of such lost, stolen or
destroyed Certificates to (a) execute and deliver an indemnity agreement with
respect to such Certificate in a form reasonably acceptable to Parent and (b)
post a bond in such reasonable amount and on such customary terms as Parent
may direct as indemnity against any Claim that may be made against Parent or
the Payments Administrator with respect to such Certificate.

 

Dissenting Shares

 

.

 

 Notwithstanding anything in this Agreement to the contrary, any shares of
Preferred Stock or Common Stock issued and outstanding immediately prior to
the Effective Time that are held by any Stockholder (a) who has not voted in
favor of the Merger or consented thereto in writing, (b) who is otherwise
entitled to, and who has perfected, appraisal rights for such shares in
accordance with Section 262 of the DGCL (such rights, "Appraisal Rights") or,
if applicable, dissenters' rights for such shares in accordance with Chapter
13 of the CCC (such rights, "Dissenters' Rights"; and Section 262 of the DGCL
and Chapter 13 of the CCC, collectively, the "Appraisal Rights Statutes"), and
(c) who has neither effectively withdrawn nor lost such Appraisal Rights or
Dissenters' Rights, shall not be converted in accordance with this Article 3
into the right to receive the consideration specified in Section 3.1, but
rather the holders of such shares ("Dissenting Shares") shall be entitled only
to such rights as may be granted to such holders in the Appraisal Rights
Statutes; provided, however, that if any such holder shall fail to perfect or
otherwise shall waive, withdraw, or lose the right to appraisal under the
applicable Appraisal Rights Statutes, or a court of competent jurisdiction
shall determine that such holder is not entitled to the relief provided by the
applicable Appraisal Rights Statutes, then the rights of such holder pursuant
to the applicable Appraisal Rights Statutes shall cease and such Dissenting
Shares shall be deemed to have been converted as of the Effective Time into,
and to represent only the right to receive, the consideration specified in
this Article 3 (without interest thereon), subject in all respects to the
terms and conditions of this Agreement and the Escrow Agreement. The Company
shall deliver prompt notice to Parent of any demand for appraisal received by
the Company, any withdrawal or attempted withdrawal of any such demand, and
any other notice, instrument, or document delivered to the Company pursuant to
the DGCL or CCC relating to appraisal of any shares of Preferred Stock or
Common Stock, which notice shall include a copy of such demand, withdraw, or
other notice, instrument or document. The Company shall provide Parent with
the opportunity to participate in and control all negotiations and proceedings
with respect to demands for appraisal under the DGCL or the CCC, and shall
not, without the prior written consent of Parent, make any payment with
respect to, or settle or offer to settle, any such demands, or agree to do any
of the foregoing. For the avoidance of doubt, no Redeemed Series D Share shall
be entitled to Appraisal Rights or Dissenters' Rights, as such shares will be
redeemed at or prior to the Effective Time in accordance with Section 8 of the
Charter and will not be subject to conversion in the Merger. 

 

Purchase Price Adjustment

 

.

 

(a)Not less than three (3) Business Days prior to the Closing Date, the
Company will deliver to Parent (i) an unaudited balance sheet reasonably
acceptable to Parent prepared by the

 

10  

Company in a manner consistent with the preparation of the balance sheets
included in the most recent Financial Statements, reflecting a good faith
estimate of the consolidated financial condition of the Company and its
Subsidiaries as of 12:01 a.m. Eastern Time on the Closing Date (the "Estimated
Closing Balance Sheet"), and (ii) based on the Estimated Closing Balance
Sheet, a written statement reasonably acceptable to Parent (the "Estimated
Closing Statement") setting forth in reasonable detail the Company's good
faith estimate of the following as of 12:01 a.m. Eastern Time on the Closing
Date, accompanied by any supporting documentation relevant to such
calculation: (A) Working Capital (the "Estimated Working Capital"), (B) Debt
Pay-Off Amount (the "Estimated Debt Pay-Off Amount"), (C) unpaid Company
Transaction Expenses (the "Estimated Company Transaction Expenses"), and (D)
Cash (the "Estimated Cash"). The Estimated Working Capital and other items
set forth on the Estimated Closing Statement shall be prepared in accordance
with the Accounting Rules. The items set forth on the Estimated Closing
Statement shall be used to calculate the Closing Merger Consideration.

 

(b)Promptly following the Closing Date, but in no event later than ninety (90)
days after the Closing Date, Parent will prepare and submit to the
Equityholders' Representative a written statement (the "Closing Date
Statement") setting forth in reasonable detail Parent's calculation of the
following as of 12:01 a.m. Eastern Time on the Closing Date, accompanied by
any supporting documentation relevant to such calculation: (i) Working Capital
(the "Proposed Final Working Capital"), (ii) Debt Pay-Off Amount (the
"Proposed Final Debt Pay-Off Amount"), (iii) unpaid Company Transaction
Expenses (the "Proposed Final Company Transaction Expenses"), and (iv) Cash
(the "Proposed Final Cash"). The Proposed Final Working Capital, Proposed
Final Debt Pay-Off Amount, Proposed Final Company Transaction Expenses and
Proposed Final Cash set forth on the Closing Date Statement shall be prepared
in accordance with the Accounting Rules. If the Equityholders' Representative
disputes or objects to the calculation of the Proposed Final Working Capital,
Proposed Final Debt Pay-Off Amount, Proposed Final Company Transaction
Expenses, or Proposed Final Cash set forth on the Closing Date Statement, the
Equityholders' Representative will notify Parent in writing (such written
notification being the "Objection Notice") of its disputes or objections no
later than thirty (30) days after delivery of the Closing Date Statement and
will set forth, in reasonable detail in the Objection Notice, the reasons for
the Equityholders' Representative's objections. If the Equityholders'
Representative fails to deliver an Objection Notice within thirty (30) days
after delivery of the Closing Date Statement, the Equityholders will be deemed
to have accepted the Proposed Final Working Capital, Proposed Final Debt Pay-
Off Amount, Proposed Final Company Transaction Expenses and Proposed Final
Cash as set forth on the Closing Date Statement, and such amounts shall be
deemed to be the Final Working Capital, Final Debt Pay-Off Amount, Final
Company Transaction Expenses and Final Cash (respectively) for all purposes
hereunder. If the Equityholders' Representative delivers an Objection Notice
within such thirty (30) day period, the Equityholders' Representative and
Parent will endeavor in good faith to resolve any disputed matters no later
than fifteen (15) Business Days after receipt by Parent of the Equityholders'
Representative's Objection Notice. If the Equityholders' Representative and
Parent are unable to resolve the disputed matters in accordance with the
preceding sentence, the Equityholders' Representative and Parent will appoint
the Neutral Auditor to resolve the remaining matters in dispute in accordance
with Section 3.8(c). The fees and expenses of the Neutral Auditor shall be
allocated between Parent and the Equityholders' Representative (on behalf of
the Equityholders) based upon the percentage that the portion of the contested
amount not awarded to each of Parent and the Equityholders' Representative,
respectively, bears to the total contested amount actually submitted to the
Neutral Auditor for resolution pursuant to this Section 3.8(b). The Working
Capital, Debt Pay-Off Amount, the Company Transaction Expenses and Cash as of
12:01 a.m. Eastern Time on the Closing Date, as finally determined pursuant to
this Section 3.8(b) or Section 3.8(c), are

 

11  

referred to herein as the "Final Working Capital", "Final Debt Pay-Off
Amount", "Final Company Transaction Expenses", and "Final Cash" respectively.

 

(c)If the disputed matters referenced in Section 3.8(b) are submitted to the
Neutral Auditor in accordance with Section 3.8(b), the provisions of this
Section 3.8(c) shall apply. Each Party agrees to promptly execute a
reasonable engagement letter, if requested to do so by the Neutral Auditor.
The Neutral Auditor shall be provided with such information and records, which
may include on-site access and access to personnel, relating to such dispute
as it may reasonably request, and Parent and the Equityholders'
Representative, and their respective representatives, shall cooperate fully
with the Neutral Auditor; provided that neither Parent nor the Equityholders'
Representative will meet separately with the Neutral Auditor with respect to
such disputed matters or any other matters contemplated by this Agreement.
The Neutral Auditor shall have the rights, powers and privileges of an
arbitrator and shall resolve only such items that are in dispute and determine
the values to be ascribed thereto, and using those values (together with other
items not in dispute) determine the Working Capital, Debt Pay-Off Amount,
Company Transaction Expenses and Cash as of 12:01 a.m. Eastern Time on the
Closing Date only (prepared in accordance with the Accounting Rules). Parent
and the Equityholders' Representative hereby agree that the Neutral Auditor
shall only decide the specific disputed items, the values ascribed thereto and
using those values (together with the other items included in the Closing Date
Statement) determine the Working Capital, Debt Pay-Off Amount, Company
Transaction Expenses and Cash as of 12:01 a.m. Eastern Time on the Closing
Date, and the Neutral Auditor's decision with respect to such disputed items
and values must be within the range of values assigned to each such item in
the applicable Closing Date Statement and the Objection Notice, respectively.
The Neutral Auditor shall be directed to resolve such disputes, determine such
values, calculate the Working Capital, Debt Pay-Off Amount, Company
Transaction Expenses and Cash as of 12:01 a.m. Eastern Time on the Closing
Date (in accordance with this Section 3.8(c)) and deliver a written
determination of the Working Capital, Debt Pay-Off Amount, Company Transaction
Expenses and Cash as of the Closing Date within thirty (30) days after being
retained as provided in this Section 3.8(c), which determination will be
final, binding and conclusive on the Equityholders' Representative, the
Equityholders and Parent, and their respective Affiliates, representatives,
successors and assigns for all purposes of this Agreement. The Neutral
Auditor's written determination of the Working Capital, Debt Pay-Off Amount,
Company Transaction Expenses and Cash as of 12:01 a.m. Eastern Time on the
Closing Date shall include a schedule setting forth all material calculations
used in arriving at such determination and shall be based solely on
information provided to the Neutral Auditor by Parent and the Equityholders'
Representative in accordance herewith. 

 

(d)If the Final Closing Adjustment Amount is a negative number and the
absolute value of the Final Closing Adjustment Amount exceeds Fifty Thousand
Dollars ($50,000), then an amount equal to the amount by which the absolute
value of the Final Closing Adjustment Amount exceeds Fifty Thousand Dollars
($50,000) shall be paid to Parent from the Escrow Fund. Any amounts payable
to Parent pursuant to this Section 3.8(d) will be made not later than ten (10)
Business Days after the determination of the Final Working Capital, Final Debt
Pay-Off Amount, Final Company Transaction Expenses and Final Cash by wire
transfer of immediately available funds to an account designated in advance in
writing by Parent. If the Final Closing Adjustment Amount is a positive
number and exceeds Fifty Thousand Dollars ($50,000), then no later than ten
(10) Business Days after the determination of the Final Working Capital, Final
Debt Pay-Off Amount, Final Company Transaction Expenses and Final Cash, an
amount (the "Equityholders Final Closing Adjustment Consideration") equal to
the amount by which the Final Closing Adjustment Amount exceeds Fifty Thousand
Dollars ($50,000) shall be deposited by Parent with the Payments

 

12  

Administrator for distribution, in accordance with the Applicable Updated
Payout Schedule, to (i) the Stockholders who have duly surrendered their
Certificates and delivered duly completed and validly executed Transmittal
Letters and (ii) the Optionholders, after giving effect to any required
withholding Taxes. All distributions made to Equityholders under this Section
3.8(d) shall be made in accordance with the Applicable Updated Payout Schedule
and their respective Transmittal Letters and other Exchange Documents, or
other appropriate documentation.

 

(e)Following the Effective Time, the Equityholders' Representative and Parent
shall cooperate and provide each other and, if applicable, the Neutral
Auditor, and their respective representatives, reasonable assistance and
access to such books, records and employees as are reasonably requested in
connection with the matters addressed in this Section 3.8.

 

Earnout Consideration

 

. 

 



 

(a)Certain Definitions. For purposes of this Agreement, the following
definitions apply:

 

(i)"Earnout Consideration" means the aggregate of (A) the FDA Milestone
Consideration, (B) the First Revenue Milestone Consideration, and (C) the
Second Revenue Milestone Consideration.

 

(ii)"Earnout Period" means the period beginning on the Closing Date and ending
on the Earnout Period End Date.

 

(iii)"Earnout Period End Date" means the fifth (5th) anniversary of the
Closing Date.

 

(iv)"FDA Milestone" means the issuance of the FDA M6-C Approval on or before
the Earnout Period End Date.

 

(v)"FDA Milestone Consideration" means:

 

(A)if the FDA Milestone is achieved on or prior to April 1, 2021, Fifteen
Million Dollars ($15,000,000); or

 

(B)if the FDA Milestone is achieved on or prior to the Earnout Period End Date
(but after April 1, 2021), Ten Million Dollars ($10,000,000).

 

(vi) "First Revenue Milestone" means Product Revenue equal to or in excess of
Thirty Million Dollars ($30,000,000) with respect to a Trailing Twelve Month
Period.

 

(vii)"First Revenue Milestone Consideration" means Fifteen Million Dollars
($15,000,000).

 

(viii)"Milestone" means each of the FDA Milestone, the First Revenue
Milestone, or the Second Revenue Milestone.

 

(ix)"Parent Group Entities" means Parent, the Surviving Corporation and their
respective Subsidiaries and other Affiliates.

 

13  

(x)"Product Revenue" means, with respect to any Trailing Twelve Month Period,
(x) the actual gross amount invoiced for worldwide sales of Specified Products
by or on behalf of Selling Parties to Third Party Purchasers during such
Trailing Twelve Month Period, as reduced by (y) the total of the following
charges and expenses during such Trailing Twelve Month Period, to the extent
directly related to Specified Products and actually incurred or reserved, in
each case (x) and (y) as determined in accordance with GAAP consistently
applied by the Selling Party across its operations:

 

(A)trade, cash, prompt payment, quantity and other customary discounts,
including promotional, service or similar discounts;

 

(B)chargeback payments, rebates, allowances, credits, discounts, fees and
other customary payments to (I) managed care entities, (II) Governmental
Authorities, (III) purchasers or reimbursers or (IV) trade customers,
including wholesalers, distributors, group purchasing organizations and buying
groups;

 

(C)retroactive price reductions;

 

(D)freight charges, postal charges, handling charges, insurance charges,
packing costs and other transportation charges;

 

(E)credits, allowances, refunds and reimbursements for damaged goods,
rejections, defects, expired dating, recalls or returns or because of
retroactive price reductions or billing errors, whether cash or trade;

 

(F)Taxes on sales (including sales or use Taxes, value added Taxes, or their
equivalent), excise Taxes, other consumption Taxes, customs duties, compulsory
payments to Governmental Authorities and any other governmental charges
imposed upon the sale of Specified Products (other than Taxes based on
income); and

 

(G)invoiced amounts that are written off as uncollectible (provided that if
any amount that is so written off during a Trailing Twelve Month Period is
subsequently collected during such Trailing Twelve Month Period, such amount
shall be added back to Product Revenue for such Trailing Twelve Month Period);

 

provided that, for purposes of calculating Product Revenue, (1) amounts
invoiced for sales between or among Selling Parties shall not be included in
Product Revenue, (2) with respect to sales of Specified Products invoiced in
currencies other than U.S. Dollars, Parent shall use the Exchange Rate
Methodology for the translation of foreign currency sales into U.S. Dollars,
and (3) none of the following transfers or other dispositions of Specified
Products shall constitute "sales" of Specified Products: (x) transfers or
other dispositions at no charge for academic, preclinical, clinical or
regulatory purposes, (y) transfers or other dispositions at no charge in
connection with patient assistance programs or named patient programs or for
other compassionate use or charitable purposes, or (z) transfers or other
dispositions at no charge to physicians or hospitals for promotional purposes
(including free samples).

 



 

14  

(xi)"Second Revenue Milestone" means Product Revenue equal to or in excess of
Fifty Million Dollars ($50,000,000) with respect to a Trailing Twelve Month
Period.

 

(xii)"Second Revenue Milestone Consideration" means Thirty Million Dollars
($30,000,000)

 

(xiii)"Selling Party" means the Parent Group Entities and their respective
licensees and sublicensees; provided that no distributor, wholesaler or
reseller of any Specified Product, and no end user or consumer of any
Specified Product, shall constitute a Selling Party.

 

(xiv)"Specified Products" means, individually and collectively, M6-C Discs and
M6-L Discs.

 

(xv)"Third Party Purchasers" means any Persons other than Selling Parties.

 

(xvi)"Trailing Twelve Month Period" means any twelve (12) consecutive calendar
month period that begins on or after the Closing Date and ends on or before
the Earnout Period End Date.

 

(b)In the event that the Merger is consummated, as additional consideration
for the Merger, and subject to the set-off rights of Parent and the Surviving
Corporation pursuant to Section 3.10(f) and Article 9 hereof, after the
Effective Time the Equityholders shall be entitled to receive Earnout
Consideration when and if required to be paid in accordance with the
provisions of this Section 3.9 and Sections 3.1, 3.2, and 3.10. The Earnout
Consideration shall not bear interest. For the avoidance of doubt, each of
the FDA Milestone Consideration, the First Revenue Milestone Consideration,
and the Second Revenue Milestone Consideration shall be payable only once upon
the first achievement of the corresponding FDA Milestone, First Revenue
Milestone, and Second Revenue Milestone, respectively, and no amounts shall be
due or payable for subsequent or repeated achievement of the FDA Milestone,
First Revenue Milestone or Second Revenue Milestone

 

(c)Each of Parent, the Company and the Equityholders' Representative hereby
acknowledges that the achievement of the First Revenue Milestone, the Second
Revenue Milestone Consideration and the FDA Milestone is uncertain and that
the Surviving Corporation may not achieve results requiring the payment of any
First Revenue Milestone Consideration, Second Revenue Milestone Consideration
or FDA Milestone Consideration at all, and it is therefore not assured that
Parent will be required to pay any First Revenue Milestone Consideration,
Second Revenue Milestone Consideration or FDA Milestone Consideration at all.

 

(d)Subject to the terms of this Section 3.9(d), Parent, as the sole
stockholder of the Surviving Corporation, and the Board of Directors of the
Surviving Corporation, shall have sole discretion over all matters relating to
the Surviving Corporation and the Specified Products after the Effective Time,
including any research, development, regulatory, marketing, manufacturing,
distribution and sales decisions. Although Parent has a present intention to
continue the operations of the Surviving Corporation during the Earnout Period
(including the development, marketing, manufacturing, distribution and sale of
the Specified Products and efforts to seek the FDA M6-C Approval), the Parties
acknowledge that Parent has no obligation to operate the Surviving Corporation
(or to operate its own business, or cause its Affiliates to operate their
respective businesses) in order to cause the achievement of the First Revenue
Milestone, Second Revenue

 

15  

Milestone or FDA Milestone or to maximize the Earnout Consideration or any
element thereof; provided, however, that Parent hereby agrees that during the
Earnout Period (i) it shall use Commercially Reasonable Efforts to achieve the
Milestones, (ii) it shall not take any actions in bad faith concerning the
operations of the Surviving Corporation with the intention of avoiding
Parent's obligations to make payment of any Earnout Consideration hereunder,
and (iii) it shall not discontinue the marketing, manufacturing, distribution
or sales of any of the Specified Products, or withdraw Premarket Approval
Application, P170036, for the M6-C Disc, during the Earnout Period if it does
not possess a valid commercial reason or legal reason for doing so (which
reason may not be solely to avoid payment of the Earnout Consideration). The
Parties acknowledge that circumstances may exist that (A) prevent or delay the
achievement of the FDA Milestone, thereby eliminating, or reducing the amount
of, the FDA Milestone Consideration, (B) prevent the achievement of financial
results requiring payment of the First Revenue Milestone Consideration or the
Second Revenue Milestone Consideration, or (C) limit, reduce or otherwise
negatively impact Product Revenue during the Earnout Period and each Trailing
Twelve Month Period, thereby eliminating the First Revenue Milestone
Consideration or the Second Revenue Milestone Consideration. Accordingly,
except as expressly provided in Section 3.9(d)(i) above, nothing herein shall
be deemed to be an agreement on the part of Parent, Merger Sub or the
Surviving Corporation to (I) obtain, or otherwise cause the issuance of, the
FDA M6-C Approval during the Earnout Period (or by any particular date), or at
all, or (II) achieve financial results or Product Revenue requiring the
payment of the First Revenue Milestone Consideration or the Second Revenue
Milestone Consideration. For the avoidance of doubt, and in consideration of
the Closing Merger Consideration to be paid to the Equityholders promptly
after the Effective Time, except as expressly provided in Section 3.9(d)(i)
above, none of Parent, Merger Sub or the Surviving Corporation shall be
required to use any level of effort (including commercially reasonable
efforts, reasonable efforts, best efforts, diligent efforts or reasonable best
efforts) to (x) obtain, or otherwise cause the issuance of, the FDA M6-C
Approval during the Earnout Period (or by any particular date), or at all, or
(y) achieve financial results or Product Revenue requiring the payment of the
First Revenue Milestone Consideration or the Second Revenue Milestone
Consideration.

 

(e)From the Effective Time until the earlier to occur of the Earnout Period
End Date or the date on which all Earnout Consideration has become due and
payable (subject to any reduction thereof as a result of the exercise of any
right of set off pursuant to Section 3.10(f)), neither Parent nor the
Surviving Corporation shall sell, assign or transfer all or substantially all
of the rights to develop or commercialize the Specified Products unless, as a
condition to such sale, assignment or transfer, the purchaser, assignee or
transferee (as applicable) assumes in writing all obligations of Parent set
forth in this Section 3.9 and Section 3.10 with respect to the Specified
Products (subject to all limitations and qualifications included in this
Agreement with respect to such obligations), including the obligation to pay,
upon the achievement of any Milestone that has not, prior to the date of such
sale, assignment or transfer, been achieved in accordance with this Section
3.9 and Section 3.10, the applicable Earnout Consideration payable with
respect to such Milestone in accordance with the terms hereof (and such
purchaser, assignee or transferee shall thereafter be deemed to be a Selling
Party for all purposes hereunder); provided that Parent shall remain liable
(subject to the limitations and qualifications set forth in this Agreement)
for, and such purchaser, assignee or transferee shall not be required to
assume, any obligation to pay any Earnout Consideration payable with respect
to any Milestone achieved prior to the date of such sale, assignment or
transfer.

 

16  

Achievement of Applicable Milestones; Payment of Earnout Consideration

 

. 

 



 

(a)Within ten (10) Business Days after the achievement of the FDA Milestone,
Parent shall provide notice to the Equityholders' Representative that such FDA
Milestone has been achieved. From and after the date hereof and until
achievement of such FDA Milestone (or, if the FDA Milestone is not achieved,
until the Earnout Period End Date), (i) Parent shall provide the
Equityholders' Representative, on a semi-annual basis, a written update
covering in reasonable detail the status of activities with respect to the
issuance of the FDA M6-C Approval (each such report, an "Update Report"), and
(ii) upon reasonable request to Parent by the Equityholders' Representative
within thirty (30) days after receipt of any such Update Report, Parent shall
meet with the Equityholders' Representative at Parent's offices or via
telephone to provide verbal updates and respond to reasonable inquiries
regarding the status of (A) activities with respect to the issuance of the FDA
M6-C Approval and (B) the development, commercialization and other activities
of Parent Group Entities with respect to each Specified Product (as such
activities relate to the achievement of any Milestone that has not, as of the
date of such meeting, been achieved hereunder). 

 

(b)Beginning with the first fiscal quarter that ends on or after the last day
of the first Trailing Twelve Month Period, and ending once each of the First
Revenue Milestone and the Second Revenue Milestone have been achieved, or are
no longer capable of being achieved, no later than forty-five (45) days after
the end of each completed fiscal quarter, Parent shall provide the
Equityholders' Representative with a report (including reasonable supporting
information upon request) calculating Product Revenue with respect to the
Trailing Twelve Month Periods ending during such completed fiscal quarter. If
Parent determines that either or both of the First Revenue Milestone and the
Second Revenue Milestone has been achieved during any fiscal quarter, within
forty-five (45) days following the end of such fiscal quarter, Parent shall
provide notice to the Equityholders' Representative that the First Revenue
Milestone or the Second Revenue Milestone, as applicable, has been achieved.
Until the achievement of the Second Revenue Milestone (or, if the Second
Revenue Milestone is not achieved, until the Earnout Period End Date), and for
two (2) years thereafter, Parent shall keep (and shall cause its Affiliates,
including the Surviving Corporation, to keep) books and records pertaining to
Product Revenue with respect to applicable Trailing Twelve Month Periods, in
sufficient detail to permit the Equityholders' Representative to evaluate the
calculation of Product Revenue for purposes of determining whether the First
Revenue Milestone and the Second Revenue Milestone have been achieved. During
the period in which such books and records must be maintained, the
Equityholders' Representative may, upon written request, cause the Neutral
Auditor to audit the relevant records of Parent and its Affiliates (including
the Surviving Corporation) to verify calculations of Product Revenue for
applicable Trailing Twelve Month Periods. Before beginning its audit, the
Neutral Auditor shall execute a confidentiality agreement reasonably
acceptable to Parent and its Affiliates by which the Neutral Auditor agrees to
keep confidential all information received during the audit. The Neutral
Auditor shall have the right to disclose to the Equityholders' Representative
only its conclusions regarding any payments owed under this Agreement. Parent
shall make (and shall cause its Affiliates, including the Surviving
Corporation, to make) such books and records available for inspection by the
Neutral Auditor during regular business hours at such place or places where
such records are customarily kept, upon receipt of reasonable advance notice
from the Equityholders' Representative. Such audit right shall not be
exercised more than once in any calendar year and not more frequently than
once with respect to books and records covering any specific period of time.
The Neutral Auditor shall provide its audit report and its basis for any
determination to Parent at the time such report is provided to the
Equityholders' Representative. The Equityholders' Representative (on behalf of
the Equityholders)

 

17  

will bear the full cost of such audit, unless such audit discloses that the
First Revenue Milestone or the Second Revenue Milestone was achieved but not
reported by Parent, in which case, Parent shall bear the full cost of the
Neutral Auditor for such audit. The Neutral Auditor's calculation of Product
Revenue shall be final and binding on the Parties.

 

(c)In the event that Parent determines at any time during the Earnout Period
that it is no longer possible for a particular Milestone to be achieved,
Parent shall promptly notify the Equityholders' Representative in writing of
such determination (any such notice, a "Milestone Non-Achievement Notice").
The Milestone Non-Achievement Notice shall specify in reasonable detail the
rationale for such determination. Upon reasonable request to Parent by the
Equityholders' Representative within thirty (30) days after receipt of any
such Milestone Non-Achievement Notice, Parent shall make available a Parent
Representative with direct, overall responsibility for the development and
commercialization of each of the Specified Products and such other Parent
Representatives as Parent may reasonably deem appropriate at Parent's offices
or via telephone to respond to reasonable inquiries regarding such Milestone
Non-Achievement Notice.

 

(d)The Equityholders' Representative agrees to hold in strict confidence all
information received and all information learned in the course of any
procedures contemplated by clauses (a), (b) or (c) above, except to the extent
necessary to enforce its rights under this Agreement or to the extent required
to comply with any applicable Law; provided that the foregoing shall not limit
the Equityholders' Representative ability to disclose (i) to Stockholders
whether the FDA Milestone, the First Revenue Milestone, and the Second Revenue
Milestone have been achieved or whether it remains possible for any such
Milestone to be achieved, or (ii) such information on a need-to-know basis to
(A) its advisors and representatives that are subject to confidentiality
restrictions with respect to such information that are at least as restrictive
as the confidentiality restrictions applicable to the Equityholders'
Representative with respect thereto, and (B) those Equityholders that comprise
the "Advisory Committee" established under the Equityholders' Representative's
engagement letter, provided that each such Equityholder has executed a
confidentiality agreement with respect such information in form and substance
reasonably satisfactory to Parent.

 

(e)Within thirty (30) days after the delivery by Parent of written notice (or
in the case of the First Revenue Milestone and the Second Revenue Milestone,
delivery by the Neutral Auditor of an audit report containing a final
determination by the Neutral Auditor, if applicable) that any of the FDA
Milestone, the First Revenue Milestone or the Second Revenue Milestone has
been achieved, the applicable Earnout Consideration payable with respect
thereto (less the amount of any Company Transaction Expenses that become
payable as a result of such Earnout Consideration, which shall be paid by
Parent to the account or accounts specified in the Applicable Updated Payout
Schedule) shall be deposited by Parent with the Payments Administrator for
distribution, in accordance with the Applicable Updated Payout Schedule, to
(i) the Stockholders who have duly surrendered their Certificates and
delivered duly completed and validly executed Transmittal Letters and (ii) the
Optionholders, after giving effect to any required withholding Taxes. All
distributions made to Equityholders under this Section 3.10(e) shall be made
in accordance with the Applicable Updated Payout Schedule and their respective
Transmittal Letters and other Exchange Documents, or other appropriate
documentation, and shall be subject to Section 3.10(f) and Article 9.

 

(f)Subject to the express limitations and procedures set forth in Article 9
hereof, the obligation of Parent to pay any Earnout Consideration shall be
qualified by the right of Parent and the Surviving Corporation to reduce the
amount of any one or more of the First Revenue Milestone

 

18  

Consideration, Second Revenue Milestone Consideration or FDA Milestone
Consideration by (i) the amount of any Losses actually incurred or suffered by
Parent or the Surviving Corporation for which Parent or the Surviving
Corporation is entitled to indemnification pursuant to Article 9 and (ii) the
amount that would be necessary to satisfy in full any then pending and
unsatisfied or unresolved Claims for indemnification timely asserted by Parent
or any other Parent Indemnified Person in accordance with Article 9 as if such
Claims were resolved in favor of Parent or such Parent Indemnified Person. In
the event that (A) Parent sets off the amount of any Earnout Consideration by
the amount of any Losses that have not been, at the time payment of such
Earnout Consideration is made, incurred by Parent or another Parent
Indemnified Person, and it is later finally determined that the full amount of
such Losses will not be incurred by the applicable Parent Indemnified Person,
or (B) Parent sets off the amount of any Earnout Consideration by the amount
that would be necessary to satisfy in full any pending and unsatisfied or
unresolved Claim for indemnification to which the Equityholders'
Representative objects in accordance with Section 9.6(b) (such necessary
amount, "Disputed Claim Losses"), and it is later finally determined that the
applicable Parent Indemnified Person is not entitled to indemnification
pursuant to Article 9 with respect to any portion of such Disputed Claim
Losses, then, in each case of the foregoing clauses (A) and (B), promptly
after such determination, the amount of the prior reduction attributable to
such Losses that will not be incurred by the applicable Parent Indemnified
Person (in the case of the foregoing clause (A)), or attributable to the
portion of such Disputed Claim Losses for which the applicable Parent
Indemnified Person is not entitled to indemnification (in the case of the
foregoing clause (B)), shall be deposited (without interest) by Parent with
the Payments Administrator as additional Earnout Consideration for
distribution, in accordance with the Applicable Updated Payout Schedule, to
(x) the Stockholders who have duly surrendered their Certificates and
delivered duly completed and validly executed Transmittal Letters and (y) the
Optionholders, after giving effect to any required withholding Taxes. All
distributions made to Equityholders under this Section 3.10(f) shall be made
in accordance with the Applicable Updated Payout Schedule and their respective
Transmittal Letters and other Exchange Documents, or other appropriate
documentation.

 

(g)The Parties understand and agree that (i) the contingent rights to receive
any Earnout Consideration will not be represented by any form of certificate,
are not transferable, except by operation of Laws relating to descent and
distribution, divorce and community property, and do not constitute an equity
or ownership interest in Parent or the Surviving Corporation, (ii) no
Equityholder shall have any rights as a security holder of the Surviving
Corporation or Parent as a result of such Equityholder's contingent right to
receive any Earnout Consideration hereunder and (iii) no interest is payable
with respect to any Earnout Consideration.

 

(h)The Earnout Consideration provided for pursuant to this Article 3 is
provided as a result of bona fide difficulties in determining the present
value of the Company. The Earnout Consideration represents (and shall be
reported by Parent as) additional consideration for the Preferred Stock
(excluding any Redeemed Series D Shares), the Common Stock, and the Stock
Options and is not intended to be a royalty payment. Parent agrees that
Earnout Consideration paid to Stockholders will be reported by Parent as
deferred payments subject to installment sale treatment under Section 453 of
the Code (and will be reported by Parent in part as payments of interest
pursuant to Section 483 or Section 1274 of the Code).

 



 



 



 

19  

Other Payments at Closing

 

. On the Closing Date, Parent shall:

 



 

(a)on behalf of the Company, pay (or cause to be paid) to such account or
accounts as the Company specifies to Parent in the Payout Schedule, the Debt
Pay-Off Amount with respect to all Indebtedness of the Company and any of its
Subsidiaries outstanding as of 12:01 a.m. Eastern Time on the Closing Date
that is reflected in the calculation of Closing Merger Consideration, as set
forth the Payout Schedule; and

 

(b)on behalf of the Company, pay (or cause to be paid) to such account or
accounts as the Company specifies to Parent in the Payout Schedule, the
aggregate amount of all Company Transaction Expenses unpaid as of 12:01 a.m.
Eastern Time on the Closing Date that are reflected in the calculation of
Closing Merger Consideration, as set forth in the Payout Schedule (provided
that amounts payable in respect of the Company Transaction Expenses described
in clause (d) of the definition thereof shall be paid to the Surviving
Corporation for payment, in accordance with the Payout Schedule, through the
Surviving Corporation's payroll system).

 

Necessary Further Actions

 

. If, at any time after the Effective Time, any further action is necessary
or desirable to carry out the purposes of this Agreement and to vest the
Surviving Corporation with full right, title and possession to all assets,
property rights, privileges, powers and franchises of the Company and Merger
Sub, then the Company, Parent and Merger Sub shall cause their respective
directors and officers to take all such lawful and necessary action, so long
as such action is not inconsistent with this Agreement.

 



 

Article 4 
REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 



 

The Company hereby represents and warrants to Parent and Merger Sub as follows
(it being understood that each representation and warranty contained in this
Article 4 is subject to: (a) the exceptions and disclosures set forth in the
section or subsection of the Company Disclosure Schedule corresponding to the
particular section or subsection in this Article 4 in which such
representation and warranty appears; (b) any exceptions or disclosures
explicitly cross-referenced in such section or subsection of the Company
Disclosure Schedule by reference to another section or subsection of the
Company Disclosure Schedule; and (c) any exceptions or disclosures set forth
in any other section of subsection of the Company Disclosure Schedule to the
extent it is readily apparent, upon reading such exception or disclosure
without independent knowledge on the part of the reader regarding the matter
set forth in such exception or disclosure, that such exception or disclosure
should qualify such representation or warranty without the necessity of
repetitive disclosure or cross-reference):

 

Organization and Qualification

 

.

 

(a)The Company is a corporation duly organized, validly existing and in good
standing under the Laws of the State of Delaware and has all the requisite
power and authority necessary to own, manage, lease and operate its assets and
properties and to carry on its business as it is now being conducted. The
Company is in possession of all franchises, grants, authorizations, licenses,
permits, easements, consents, waivers, qualifications, certificates, Orders,
clearances and approvals (collectively, "Approvals") necessary to own, manage,
lease and operate its assets and properties and to carry on its business as it
is now being conducted, except where the failure to possess any such Approval
has not resulted and would not reasonably be expected to result, individually
or in the aggregate, in a Liability that is material to the Company and its
Subsidiaries,

 

20  

taken as a whole. The Company is duly qualified or licensed as a foreign
corporation to do business, and is in good standing, in each jurisdiction
(including any applicable non-U.S. jurisdiction) where the character of the
assets or properties owned, managed, leased or operated by it or the nature of
its activities makes such qualification or licensing necessary, except where
the failure to be so qualified or licensed has not resulted and would not
reasonably be expected to result, individually or in the aggregate, in a
Liability that is material to the Company and its Subsidiaries, taken as a
whole.

 

(b)Each Subsidiary of the Company is a legal entity, duly organized, validly
existing and in good standing under the Laws of its jurisdiction of
incorporation or organization and has all the requisite power and authority
necessary to own, manage, lease and operate its assets and properties and to
carry on its business as it is now being conducted, except where the failure
to possess any such Approval has not resulted and would not reasonably be
expected to result, individually or in the aggregate, in a Liability that is
material to the Company and its Subsidiaries, taken as a whole. Each
Subsidiary of the Company is in possession of all Approvals necessary to own,
manage, lease and operate its assets and properties and to carry on its
business as it is now being conducted. Each Subsidiary is duly qualified or
licensed to do business, and is in good standing, in each jurisdiction
(including any applicable non-U.S. jurisdiction) where the character of the
assets and properties owned, managed, leased or operated by it or the nature
of its activities makes such qualification or licensing necessary, except
where the failure to be so qualified or licensed has not resulted and would
not reasonably be expected to result, individually or in the aggregate, in a
Liability that is material to the Company and its Subsidiaries, taken as a
whole.

 

(c)Section 4.1(c) of the Company Disclosure Schedule sets forth a true and
complete list of all of the Company's directly and indirectly owned
Subsidiaries, together with the jurisdiction of incorporation or organization
of each such Subsidiary, the jurisdictions in which such Subsidiary is
qualified or licensed to do business, and the percentage of each Subsidiary's
outstanding capital stock or other equity or other interest owned by the
Company or another Subsidiary of the Company if not a wholly owned Subsidiary.
Except as set forth in Section 4.1(c) of the Company Disclosure Schedule,
neither the Company nor any of its Subsidiaries owns any equity or similar
interest in, or any interest convertible into or exchangeable or exercisable
for, directly or indirectly, any equity or similar interest in, any Person.

 

(d)Section 4.1(d) of the Company Disclosure Schedule lists (i) the directors
and officers of the Company and (ii) each person holding a comparable position
with any of the Company's Subsidiaries (including any managers or managing
directors thereof).

 

(e)Section 4.1(e) of the Company Disclosure Schedule lists, by legal entity,
every state or foreign jurisdiction in which the Company or any of its
Subsidiaries has Employees or facilities or otherwise currently conducts its
business.

 

Charter and Bylaws

 

.

 

 The Company has made available to Parent true, correct and complete copies
of the Charter and Bylaws and equivalent organizational documents of each of
the Company's Subsidiaries, in each case as modified, supplemented, amended or
restated. Such Charter and Bylaws and equivalent organizational documents of
each of the Company's Subsidiaries are in full force and effect, and no other
organizational documents are applicable to or binding upon the Company or its
Subsidiaries.

 

21  

Capitalization

 

.

 

(a)The authorized capital stock of the Company consists of 149,238,000 shares,
comprising (i) a class of 93,000,000 shares of common stock, $0.001 par value
per share ("Common Stock") and (ii) a class of 56,238,000 shares of preferred
stock, $0.001 par value per share ("Preferred Stock"), of which (A) 44,000,000
shares of Preferred Stock have been designated as Series C Preferred Stock
("Series C Preferred Stock"), (B) 7,238,000 shares of Preferred Stock have
been designated as Series C-1 Preferred Stock ("Series C-1 Preferred Stock"),
and (C) 5,000,000 shares of Preferred Stock have been designated as Series D
Preferred Stock (the "Series D Preferred Stock"). As of the date of this
Agreement, 616,073 shares of Common Stock are issued and outstanding,
35,395,332 shares of Series C Preferred Stock are issued and outstanding and
are convertible into 35,395,332 shares of Common Stock, 7,234,103 shares of
Series C-1 Preferred Stock are issued and outstanding and are convertible
(solely upon the circumstances set forth in Section 5.2(a) of the Charter)
into 7,234,103 shares of Common Stock, and 5,000,000 shares of Series D
Preferred Stock are issued and outstanding. All shares of Series C Preferred
Stock and all shares of Series C-1 Preferred Stock are convertible into shares
of Common Stock on a one-for-one basis; no shares of Series D Preferred Stock
are convertible into shares of Common Stock. As of the date of this Agreement,
8,300,851 shares of Common Stock are reserved for issuance under the Company
Equity Plans, 8,094,320 shares of which are subject to outstanding Stock
Options. As of the date of this Agreement, there are outstanding Warrants to
purchase up to 2,015,000 shares of Series C Preferred Stock, and, following
purchase thereof pursuant to such Warrants, such shares of Series C Preferred
Stock are convertible into 2,015,000 shares of Common Stock. As of the date of
this Agreement, there are outstanding Convertible Notes that are convertible
into 1,828,536 shares of Series C Preferred Stock, and, following conversion
of such Convertible Notes, such shares of Series C Preferred Stock are
convertible into 1,828,536 shares of Common Stock. The numbers of shares of
Preferred Stock and Common Stock set forth above reflect all required anti-
dilution adjustments, if any. The Company has reserved (A) a sufficient
number of shares of Series C Preferred Stock for issuance upon (I) the
exercise of all outstanding Warrants and (II) the conversion of all
outstanding Convertible Notes, and (B) a sufficient number of shares of Common
Stock for issuance upon (I) conversion of all outstanding Series C Preferred
Stock, (II) conversion of all Series C Preferred Stock issuable upon exercise
of all outstanding Warrants and upon conversion of all outstanding Convertible
Notes, and (III) exercise of all outstanding Stock Options.

 

(b)Section 4.3(b) of the Company Disclosure Schedule sets forth, as of the
date of this Agreement, a correct and complete list of each holder of
Preferred Stock, Common Stock, Stock Options, Warrants, Convertible Notes or
other equity interests in the Company, including (i) the name and address of
such holder, (ii) the number, class and series of all equity interests held by
such holder, (iii) the certificate number(s) representing such equity
interests (if applicable), (iv) the number of shares of Common Stock or Series
C Preferred Stock, as applicable, issuable in respect of any shares of
Preferred Stock, Stock Options and Warrants held by such holder (including
upon the subsequent conversion of any shares of Series C Preferred Stock for
which any Warrants are exercisable into Common Stock), (v) any accrued but
unpaid dividends and liquidation preference with respect to the shares held by
such holder, (vi) the exercise price of any Stock Options or Warrants held by
such holder, (vii) the vesting schedule, grant date and expiration date of any
Stock Options held by such holder, and (viii) whether such Stock Option is
subject to Section 422 of the Code or subject to Section 409A of the Code. No
shares of Preferred Stock or Common Stock are held in the treasury of the
Company. Except as set forth in Schedule 4.3(b) of the Company Disclosure
Schedule, no shares of voting or non-voting capital stock, other equity
interests, or other securities with voting rights of the Company are issued,
reserved for issuance or outstanding. 

 

22  

(c)All outstanding shares of Preferred Stock and Common Stock have been and
are (i) duly authorized, validly issued, fully paid and nonassessable, (ii)
issued in compliance with all applicable Laws concerning the issuance of
securities, (iii) not issued in violation of or subject to any purchase
option, call option, right of first refusal or offer, voting trust or similar
arrangement, Investor Agreement, preemptive right, subscription right or
similar right, and (iv) not subject to any Liens (other than restrictions on
transfer of securities imposed by the Charter, the Investor Agreements or by
applicable state and federal securities Laws). Except as set forth on Section
4.3(c) of the Company Disclosure Schedule, there are no bonds, debentures,
notes or other Indebtedness of the Company with voting rights (or convertible
into, or exchangeable for, securities with voting rights) on any matters.

 

(d)Section 4.3(d) of the Company Disclosure Schedule sets forth the number of
authorized and outstanding equity interests, and ownership thereof, of each of
the Company's Subsidiaries. All of the outstanding equity interests of each
of the Company's Subsidiaries have been and are duly authorized, validly
issued, fully paid and nonassessable, are not subject to, and were not issued
in violation of, any purchase option, call option, right of first refusal or
offer, preemptive right, subscription right or any similar right, and are
owned, of record and beneficially, by the Company or one of its direct or
indirect Subsidiaries, free and clear of all Liens whatsoever (other than
Permitted Liens). There are no restrictions of any kind which prevent the
payment of dividends or distributions by any of the Company's Subsidiaries,
and neither the Company nor any of its Subsidiaries is subject to any
obligation or requirement to provide funds for or to make any investment
(including in the form of a loan or capital contribution) to or in any Person.

 

(e)Except as identified in Section 4.3(e)(i) of the Company Disclosure
Schedule, there are no outstanding securities, interests, options, warrants,
calls, rights, convertible or exchangeable securities or Contracts or
obligations of any kind (contingent or otherwise) to which the Company or any
of its Subsidiaries is a party or by which any of them is bound obligating the
Company or any of its Subsidiaries to issue, deliver or sell, or cause to be
issued, delivered or sold, additional shares of capital stock or other
securities of the Company or any of its Subsidiaries or obligating the Company
or any of its Subsidiaries to issue, grant, extend or enter into any such
security, interest, option, warrant, call, right or Contract. Except as set
forth in Section 4.3(e)(ii) of the Company Disclosure Schedule, each
outstanding option was granted with an exercise price that was not less than
"fair market value" as of the grant date as determined under Section 409A of
the Code. Except as set forth in Section 4.3(e)(iii) of the Company
Disclosure Schedule, and other than as provided in Section 8 of the Charter
with respect to the outstanding shares of Series D Preferred Stock, there are
no outstanding obligations of the Company or any of its Subsidiaries
(contingent or otherwise) to repurchase, redeem or otherwise acquire any
shares of capital stock or other securities (or options or warrants to acquire
any such interests) of the Company or any of its Subsidiaries. Except as set
forth in Section 4.3(e)(iv) of the Company Disclosure Schedule, there are no
(i) outstanding or authorized stock appreciation rights, registration rights
(including piggyback rights), preemptive rights, rights of first offer, stock-
based performance units, "phantom" stock rights, restricted stock units, or
dividend equivalents, (ii) other Contracts (contingent or otherwise, but
excluding Contracts providing for performance bonuses not linked to stock
prices to service providers) pursuant to which any Person is (or is
contingently) entitled to receive any payment or other value based on the
revenues, earnings or financial performance or stock price performance of the
Company or any of its Subsidiaries or any of their respective businesses or
assets or calculated in accordance therewith, other than royalties payable
under licenses listed in Section 4.3(e)(iv) of the Company Disclosure Schedule
(the rights, units and Contracts described in the foregoing clause (i) and
this clause (ii), collectively, "Stock-Based Rights"), or (iii) rights to
cause the Company or any

 

23  

of its Subsidiaries to file a registration statement under the Securities Act
of 1933, as amended, or which otherwise relate to the registration of any
securities of the Company or any of its Subsidiaries. Except as set forth in
Section 4.3(e)(v) of the Company Disclosure Schedule, there are no voting
trusts, proxies, stockholder agreements or other Contracts of any character to
which the Company or, to the Knowledge of the Company, any of its
Equityholders (or Series D Holders) is a party or by which any of them is
bound with respect to the issuance, holding, purchase, acquisition, voting or
disposition of any shares of capital stock or similar interests of the Company
or any of its Subsidiaries.

 

Authority; Enforceability

 

.

 

 The Company has all necessary corporate power and authority to execute and
deliver this Agreement, the Escrow Agreement and each other instrument and
document required to be executed and delivered by it at or prior to the
Closing, and to perform its obligations hereunder and thereunder and, subject
to obtaining the Stockholder Approval, to consummate the Merger and the other
transactions contemplated hereby and thereby. The Company has complied with
each provision of the CCC that is applicable to the Company (pursuant to
Section 2115 of the CCC or otherwise) in connection with the Merger and the
other transactions contemplated by this Agreement (including in connection
with the execution and delivery of this Agreement). The execution and
delivery by the Company of this Agreement and the Escrow Agreement, the
performance by the Company of its obligations hereunder and thereunder, and
the consummation by the Company of the Merger and the other transactions
contemplated hereby and thereby have been approved by the Company's Board of
Directors and duly and validly authorized by all necessary action. No further
corporate or similar action is required on the part of the Company to
authorize (i) this Agreement, the Escrow Agreement or any other document
required to be executed and delivered by the Company prior to the Closing, or
(ii) the Merger or the other transactions contemplated hereby or thereby
(other than, in the case of the consummation of the Merger, obtaining the
Stockholder Approval and the filing and recordation of appropriate merger
documents as required by the DGCL). This Agreement has been duly and validly
executed and delivered by the Company, and assuming the due authorization,
execution and delivery hereof by Parent and Merger Sub, constitutes a legal,
valid and binding obligation of the Company, enforceable against the Company
in accordance with its terms, subject to the effects of (i) bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and other
similar Laws relating to or affecting creditors' rights generally, and (ii)
general equitable principles (whether considered in a proceeding in equity or
at law). The Escrow Agreement will have been duly and validly executed and
delivered by the Company as of the Closing, and, when so executed and
delivered (assuming the due authorization, execution and delivery thereof by
the other parties thereto), will constitute a legal, valid and binding
obligation of the Company, enforceable against the Company in accordance with
its terms, subject to the effects of (i) bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other similar Laws relating to or
affecting creditors' rights generally, and (ii) general equitable principles
(whether considered in a proceeding in equity or at law).

 

Required Vote

 

.

 

 The Board of Directors of the Company has, at a meeting duly called and held
prior to the execution and delivery of this Agreement, unanimously (a)
determined that this Agreement, the Escrow Agreement and the transactions
contemplated hereby and thereby, including the Merger, are fair to, advisable
and in the best interests of the Company and the Equityholders; (b) approved
and declared advisable this Agreement and the Escrow Agreement; (c) approved
the Merger and the other transactions contemplated under this Agreement and
the Escrow Agreement; (d) directed that this Agreement and the transactions
contemplated hereby, including the Merger, be submitted to the Stockholders
entitled to vote on such matters for consideration, approval and adoption by
written consent in accordance with the DGCL and, to the

 

24  

extent applicable, the CCC; and (e) resolved to recommend and recommended the
adoption of this Agreement and the approval of the transactions contemplated
hereby, including the Merger, by the Stockholders in accordance with the DGCL
and, to the extent applicable, the CCC. The affirmative vote or affirmative
action by written consent of holders of (i) at least fifty percent (50%) of
the outstanding shares of Series C Preferred Stock and Common Stock, voting
together or acting together by written consent as a single class, with (A)
each holder of shares of Common Stock entitled to one vote for each share of
Common Stock held by such holder and (B) each holder of shares of Series C
Preferred Stock entitled to the number of votes equal to the number of whole
shares of Common Stock into which the shares of Series C Preferred Stock held
by such holder could be converted at the record date for the determination of
the stockholders entitled to vote on such matters or, if no such record date
is established, the date such vote is taken or such written consent is
solicited, and (ii) at least sixty-five percent (65%) of the outstanding
shares of Preferred Stock, voting or acting by written consent on a combined
basis, with each holder of shares of Preferred Stock entitled to the number of
votes equal to the number of whole shares of Common Stock into which the
shares of Preferred Stock held by such holder are convertible (collectively,
the "Stockholder Approval"), are the only votes, approvals, consents or other
actions of the Company or the holders of any class or series of capital stock
of the Company (including any class or series of Preferred Stock or Common
Stock) necessary to authorize, approve and adopt this Agreement, the Merger
and the other transactions contemplated hereby and to consummate the Merger
and the other transactions contemplated hereby. Due execution and delivery of
the Stockholder Consent and Agreement by Stockholders holding at least the
amounts of Preferred Stock and Common Stock set forth in the immediately
preceding sentence (including by effect of the release from escrow of the
Escrowed Stockholder Consents and Agreements) shall be sufficient to
constitute the Stockholder Approval. For purposes of the Stockholder Approval
described above (including for purposes of approval by the Requisite Holders
pursuant to Section 6.1 of the Charter), no holder of shares of Series D
Preferred Stock is entitled to any votes in respect of (or by reason of) the
shares of Series D Preferred Stock held by such holder. With respect to the
approval of the Merger by the Requisite Holders pursuant to Section 6.1 of the
Charter, the record date for determining the holders of Preferred Stock that
constitute the Requisite Holders is the date on which such approval is
received. After receipt of the Stockholder Approval, no vote, approval or
other action on the part of the Company or any holder of any capital stock or
other security of the Company is required to (I) authorize, approve or adopt
this Agreement or the Escrow Agreement, (II) authorize or approve the Merger
or the other transactions contemplated by this Agreement or the Escrow
Agreement, (III) perform the Company's obligations under this Agreement or
(IV) consummate the Merger or the other transactions contemplated by this
Agreement or the Escrow Agreement. Prior to their execution of any
Stockholder Consent and Agreement, each signatory thereto shall have received
from the Company all material information necessary for such signatory to make
an informed decision with respect to the execution and delivery of such
document.

 

No Conflict; Required Filings and Consents

 

.

 

(a)None of (x) the execution or delivery by the Company or any of its
Subsidiaries of this Agreement or any other instrument or document required by
this Agreement to be executed and delivered by the Company or any of its
Subsidiaries, (y) the performance of this Agreement, the Escrow Agreement or
any other instrument or document required by this Agreement to be executed and
delivered by the Company or any of its Subsidiaries, or (z) the consummation
of the Merger or any other transaction contemplated by this Agreement, the
Escrow Agreement or any other instrument or document required by this
Agreement to be executed and delivered by the Company or any of its
Subsidiaries, in each case of the foregoing clauses (x), (y) and (z), (i)
conflict

 

25  

with or violate the Charter or Bylaws or equivalent organizational documents
of the Company or any of its Subsidiaries, (ii) conflict with or violate any
Investor Agreements, voting trusts, proxies, stockholder agreements or other
Contracts of any character to which the Company or any of its Subsidiaries or,
to the Knowledge of the Company, any of the Equityholders (or Series D
Holders) is a party or by which any of them is bound with respect to the
issuance, holding, purchase, acquisition, voting or disposition of any shares
of capital stock or similar interests of the Company, (iii) subject to the
filings and other matters referred to in Section 4.6(b), conflict with or
violate in any respect any Law or Order, in each case applicable to the
Company or any of its Subsidiaries, or by which any of their respective
properties, rights or assets is bound or affected, (iv) except as set forth in
Section 4.6(a) of the Company Disclosure Schedule, result in any breach or
violation of or constitute a default (with or without notice or lapse of time
or both) under, or impair the Company's or any of its Subsidiaries' rights or
alter the rights or obligations of any party under, or give to others any
rights of termination, amendment, acceleration or cancellation of, or result
in the termination of any Material Contract or Employee Plan or in the
creation of a Lien on any of the properties, rights or assets of the Company
or any of its Subsidiaries pursuant to any bond, indenture, Contract, permit,
franchise or other instrument or obligation to which the Company or any of its
Subsidiaries is a party or by which the Company or any of its Subsidiaries or
any of their respective properties, rights or assets is bound or affected, or
(v) impair in any material respect Parent's ability to operate the Company's
or any of its Subsidiaries' business immediately following the Closing.

 

(b)The execution and delivery by the Company of this Agreement and each other
instrument and document required by this Agreement to be executed and
delivered by the Company or any of its Subsidiaries at or prior to the Closing
do not, and the performance of this Agreement, the Escrow Agreement and any
instrument required by this Agreement to be executed and delivered by the
Company or any of its Subsidiaries at or prior to the Closing shall not,
require the Company or any of its Subsidiaries to, except as set forth in
Section 4.6(b) of the Company Disclosure Schedule, obtain any Approval of any
Person or observe any waiting period imposed by, or make any filing with or
notification to, any Governmental Authority, except for (i) compliance with
any applicable requirements of the pre-merger notification requirements of the
HSR Act and any applicable Foreign Competition Laws, (ii) the Stockholder
Approval, and (iii) the filing and effectiveness of the Certificate of Merger
in accordance with the DGCL.

 

Material Contracts

 

.

 

(a)Section 4.7(a) of the Company Disclosure Schedule sets forth (by category,
specifying the appropriate clause below) a true and complete list, and if
oral, an accurate and complete summary, of each Contract (other than Contracts
entered into after the date of this Agreement in accordance with Section 6.1)
of the type described in this Section 4.7(a) to which the Company or any of
its Subsidiaries is a party or by which the Company or any of its
Subsidiaries, or any of their respective properties, rights or assets, are
bound:

 

(i)any employment, consulting, contractor or agency Contract with any current
(or, to the extent obligations remain outstanding thereunder, former)
employee, Contract Worker or other agent of the Company or any of its
Subsidiaries (other than (A) offer letters with employees providing for "at
will" employment with the Company or any of its Subsidiaries with no
obligation to pay severance or (B) standard confidentiality agreements entered
into with employees in the ordinary course of business and on the Company's
standard form of confidentiality agreement, which standard form has been made
available to Parent);

 

26  

(ii)any severance, change in control, retention or similar Contract, including
any Contract providing for a "stay" or "sale" bonus, with any current or
former Equityholder, director, manager, managing director, officer, employee,
Contract Worker, or other agent, or any Affiliate of the Company or any of its
Subsidiaries that would result in any obligation (absolute or contingent) of
the Company or any of its Subsidiaries to make any payment to any Person
following either the consummation of the transactions contemplated hereby,
termination of employment (or the relevant relationship), or both;

 

(iii)any labor or collective bargaining Contract;

 

(iv)any promissory note, credit agreement, loan agreement, indenture, letter
of credit, evidence of Indebtedness or other instrument or Contract relating
to the borrowing or lending of money, whether as borrower, lender or
guarantor;

 

(v)any (A) interest rate swap, cap, floor or option Contract or any other
interest rate risk management arrangement or foreign exchange Contract, or (B)
other hedging, swap, derivative or similar Contract;

 

(vi)any performance or payment guarantee, keep well arrangement and other
similar credit support obligation or arrangement;

 

(vii)any Contract containing any provision limiting in any respect the freedom
of the Company or any of its Subsidiaries or their respective employees or
Affiliates (or which after the Effective Time purport to limit or would limit
the freedom of Parent, the Surviving Corporation, any of their respective
Subsidiaries or any employees or Affiliates of any of the foregoing) to engage
in any line of business, to develop, market, distribute, sell or license any
Products or services, to compete with any Person, to own any assets,
properties or rights, to operate at any location in the world or to change
sales quotas or targets under any Contracts with distributors, sales agents,
sales representatives, or other agents, including any Contract that contains
exclusivity, non-competition, non-solicitation, non-consolidation, standstill
or similar provisions;

 

(viii)any Contract containing "most favored nation" provisions or any similar
provision requiring that a third party be offered terms or concessions at
least as favorable as those offered to one or more other Persons;

 

(ix)any Contract creating or relating to any partnership, joint venture,
strategic alliance, joint development or similar agreement;

 

(x)any Contract that is primarily a guarantee, indemnification, assumption or
endorsement of, or any similar commitment with respect to, the obligations,
Liabilities or Indebtedness of any other Person;

 

(xi)any Contract providing for indemnification of any Person with respect to
Liabilities relating to any current or former business of the Company or any
of its Subsidiaries or any of their respective predecessor Persons (other than
standard Contracts with distributors, sales agents, customers or suppliers
that (A) do not primarily relate to indemnification, (B) have been entered
into in the ordinary course of business consistent with past practice and (C)
have been made available to Parent);

 

27  

(xii)any Contract with any Governmental Authority;

 

(xiii)any outstanding power of attorney empowering any Person to act on behalf
of the Company or any of its Subsidiaries;

 

(xiv)any Contract for the acquisition, directly or indirectly (by merger or
otherwise), or divestiture, of assets (whether tangible or intangible),
including any capital stock or other equity security of any Person (other than
the Company or any of its Subsidiaries), by the Company or any of its
Subsidiaries for consideration in excess of One Hundred Thousand Dollars
($100,000) individually;

 

(xv)any Lease or other Contract relating to any lease, lease guarantee,
sublease, license, easement or other use of Leased Real Property;

 

(xvi)any operating lease;

 

(xvii)any Contract relating to any capital expenditure or leasehold
improvement that has commenced but is not yet completed or that obligates the
Company or any of its Subsidiaries to incur expenditures with respect to a
project that has not yet commenced;

 

(xviii)any Contract involving the issuance or repurchase of any capital stock
or other equity interest of the Company or any of its Subsidiaries (including
newly formed Subsidiaries);

 

(xix) any Contract under which (A) the Company or any of its Subsidiaries has
granted exclusive rights with respect to Products or related services, or (B)
another party processes, produces or manufactures, or will process, produce or
manufacture, Products or has the right to do so in the future;

 

(xx)any Contract concerning Intellectual Property (other than, with respect to
software, off-the-shelf commercial or shrinkwrap software for which the
license fee is less than Ten Thousand Dollars ($10,000)), including any
Contract described in Sections 4.18(b), 4.18(i) and 4.18(k) of this Agreement;

 

(xxi)any confidentiality agreement that pertains to the receipt by the Company
or any of its Subsidiaries of the confidential information of another Person,
other than standard confidentiality terms included in customer, distributor,
sales agent or supplier Contracts listed elsewhere in Section 4.7(a) of the
Company Disclosure Schedule;

 

(xxii)any settlement agreement entered into within the last three (3) years;

 

(xxiii)any insurance brokerage Contract;

 

(xxiv)any Contract containing contingent consideration or other similar
earnout payment obligations as to which the Company or any of its Subsidiaries
has any ongoing or future Liability or obligations of any nature (contingent
or otherwise);

 

(xxv)any Contract (A) pursuant to which any third party developed or is
developing any Products, or (B) for pre-clinical or other testing or clinical
or marketing trials relating to the Products;

 

28  

(xxvi)any Contract with any physician, hospital, clinic or other health care
provider or any medical advisor;

 

(xxvii)any (A) sales agent, sales representative, resale, remarketing,
distribution or consignment Contract relating to the Company's Products or (B)
other Contract for the marketing, resale (or other sale by or through any
third party) or distribution of Products (excluding, for the avoidance of
doubt, employment agreements between the Company or any of its Subsidiaries,
on the one hand, and any employee thereof, on the other hand);

 

(xxviii)any Contract (a) with any Significant Customer or Significant
Supplier, or (b) with any other customer or supplier that provides for
payments in excess of Fifty Thousand Dollars ($50,000) individually or on an
annual basis; and

 

(xxix)any Contract not covered in clauses (i) through (xxviii) above, which is
reasonably likely to involve revenues, receipts, expenditures or Liabilities
in excess of One Hundred Thousand Dollars ($100,000) per annum or Two Hundred
Fifty Thousand Dollars ($250,000) in the aggregate, or which is otherwise
material to the business of the Company or any of its Subsidiaries.

 

All Contracts of the type described in this Section 4.7(a), whether or not
listed in Section 4.7(a) of the Company Disclosure Schedule, are collectively
referred to herein as "Material Contracts."

 



 

(b)Except as set forth in Section 4.7(b) of the Company Disclosure Schedule,
true, correct and complete copies of all Material Contracts have been made
available to Parent by the Company.

 

(c)Other than Material Contracts that have expired in accordance with their
terms, each Material Contract (i) is in full force and effect, is a valid and
binding obligation of the Company or a Subsidiary thereof and, to the
Knowledge of the Company, of each other party thereto and (ii) is enforceable
against the Company or such Subsidiary and, to the Knowledge of the Company,
against each other party thereto. Each Material Contract will continue to be
(x) valid, binding and enforceable against the Company or such Subsidiary and,
to the Knowledge of the Company, of each other party thereto, and (y) in full
force and effect immediately following the consummation of the transactions
contemplated hereby, with no alteration or acceleration or increase in fees or
Liabilities, payments, obligations or burdens. Each Contract to which the
Company or any of its Subsidiaries is a party has been entered into and
performed in accordance with applicable Law. 

 

(d)Neither the Company nor any of its Subsidiaries is or is alleged to be and,
to the Knowledge of the Company, no other party is or is alleged to be, in, or
has received notice of any, default under, or breach or violation of, any
Material Contract that has not been cured, and none of the Company or any of
its Subsidiaries has given such notice. Except as set forth in Section 4.7(d)
of the Company Disclosure Schedule, no event has occurred which, with or
without the giving of notice or passage of time or both, would reasonably be
expected to result in a default, breach or violation of any Material Contract
by the Company or any of its Subsidiaries, or give any Person the right (i) to
declare a breach and obtain any material remedy thereunder, (ii) to accelerate
the maturity, performance or payment of any obligation of the Company or any
of its Subsidiaries thereunder, (iii) to make operative any provision that
varies any of the material rights or obligations of the Company or any of its
Subsidiaries from those that would apply if the event had not occurred, or
(iv) to cancel, terminate or modify (in a manner adverse to the Company or any
of its Subsidiaries) the Material

 

29  

Contract. The Company has no reasonable basis for suspecting that any such
default, breach or violation exists or will be forthcoming. No break-up or
other similar fee is due or owing by the Company or any of its Subsidiaries in
connection with any prior negotiations, discussions or arrangements regarding
any transaction, similar to the Merger or otherwise, or other Contract. 

 

(e)Except as set forth in Section 4.7(e) of the Company Disclosure Schedule,
neither the Company nor or any of its Subsidiaries is currently involved, nor
has it been involved since January 1, 2015, in any dispute with any
counterparty to any Material Contract, and neither the Company nor or any of
its Subsidiaries has received written or, to the Knowledge of the Company,
oral notice since January 1, 2015 from any such counterparty to the effect
that such counterparty intends to terminate or otherwise alter or modify the
terms of any such Material Contract.

 

(f)Section 4.7(f) of the Company Disclosure Schedule sets forth any Material
Contract which, by its terms, will be modified or adjusted, will become
terminable by any other party thereto, or will require consent by or
notification to any other party thereto, in each case, as a result of the
execution of this Agreement or the Escrow Agreement, or the consummation of
the Merger or any other transaction contemplated hereby or thereby.

 

Compliance

 

.

 

(a)The Company is, and since January 1, 2013 the Company has been, in
compliance in all material respects with all applicable Laws (including all
Health Care Laws) and Orders. Each Subsidiary of the Company is, and since
January 1, 2013 each Subsidiary of the Company has been, in compliance in all
material respects with all applicable Laws (including all Health Care Laws)
and Orders. Neither the Company nor any of its Subsidiaries, nor any of their
respective officers, directors, managers or managing directors, has (i)
committed any act, omission or other practice, or entered into any arrangement
or engagement, for which a Governmental Authority could have a reasonable
basis for criminal prosecution or civil or administrative enforcement or
sanction under any applicable Law (including any Health Care Law) or (ii)
received any written or other notice of, been charged with, or received any
inquiry concerning, the possible violation of any applicable Law (including
any Health Care Law). To the Knowledge of the Company, (A) neither the
Company nor any of its Subsidiaries, nor any of their respective officers,
directors, managers or managing directors, is under Governmental Investigation
with respect to the violation of any applicable Law (including any Health Care
Law), Approval or Order, (B) there are no facts or circumstances that could
reasonably be expected to form the basis for any such violation, and (C)
neither the Company nor any of its Subsidiaries, nor any of their respective
officers, directors, managers or managing directors, has been charged with,
threatened to be charged with or received notice of any revocation or
modification of any Approval or any Law or Order applicable to the Company or
any of its Subsidiaries. Since January 1, 2013, neither the Company nor any
of its Subsidiaries, nor any of their respective officers, directors, managers
or managing directors, has made, or been ordered to make, any payment in
respect of any Governmental Damages, and there are no current or outstanding
reimbursement audits, recoupment efforts, or appeals by any Governmental
Authority pending.

 

(b)The Company and each of its Subsidiaries is in compliance with, and is not
in default or violation of (i) the Charter, (ii) the Bylaws, (iii) the
organizational documents of the Company's Subsidiaries, (iv) the Investor
Agreements, and (v) the terms of all bonds, indentures, Contracts, permits,
franchises and other instruments or obligations to which the Company or any of
its Subsidiaries is a party or by which the Company or any of its
Subsidiaries, or any of their

 

30  

respective properties, rights or assets, are bound or affected, except in the
case of the foregoing clause (v) for immaterial noncompliance, defaults or
violations.

 

(c)Section 4.8(c) of the Company Disclosure Schedule sets forth a complete and
accurate list of all Approvals of Governmental Authorities issued to or held
by the Company or any of its Subsidiaries. Such Approvals are the only
Approvals of Governmental Authorities that are required for the Company or any
of its Subsidiaries to conduct their respective businesses, activities and
operations as presently conducted. Each such Approval is in full force and
effect. The Company and each of its Subsidiaries have been and are in
material compliance with the terms of each such Approvals. To the Knowledge
of the Company, no revocation, suspension, cancellation or material adverse
modification of any such Approval is threatened. To the Knowledge of the
Company, all applications required to have been filed for the renewal of the
Approvals have been duly filed with the appropriate Governmental Authority,
and all other filings required to have been made with respect to the Approvals
and applicable Laws have been duly made on a timely basis with the appropriate
Governmental Authority. Each such Approval will continue in full force and
effect immediately following the Effective Time.

 

Financial Statements

 

.

 

(a)Section 4.9(a) of the Company Disclosure Schedule contains true, correct
and complete copies of the following (collectively, the "Financial
Statements"): (i) the audited consolidated balance sheet of the Company and
its Subsidiaries as of December 31, 2016, December 31, 2015 and December 31,
2014, and the related audited consolidated statements of operations and
comprehensive income, stockholders' equity and cash flows of the Company and
its Subsidiaries for the fiscal years then ended, together with all related
notes and schedules thereto, accompanied by the reports thereon of the
Company's accountants, (ii) the unaudited consolidated balance sheet of the
Company as of December 31, 2017, and the related consolidated statements of
operations and comprehensive income, stockholders' equity and cash flows of
the Company and its Subsidiaries for the fiscal year then ended, together with
any related notes and schedules thereto, and (iii) the unaudited consolidated
balance sheet of the Company as of January 31, 2018 (the "Company Balance
Sheet Date"), and the related consolidated statements of operations and
comprehensive income, stockholders' equity and cash flows of the Company and
its Subsidiaries for the one-month period then ended, together with any
related notes and schedules thereto. Except as set forth in Section 4.9(a) of
the Company Disclosure Schedule, the Financial Statements (A) were prepared in
accordance with the books of account and other financial records of the
Company and its Subsidiaries, (B) present fairly in all material respects the
consolidated financial condition, results of operations, changes in
stockholders' equity and cash flows of the Company and its Subsidiaries as of
the dates thereof or for the periods covered thereby, subject, in the case of
the unaudited Financial Statements, to the absence of footnotes, (C) have been
prepared in accordance with GAAP applied on a basis consistent with the past
practices of the Company and its Subsidiaries and (D) include all adjustments
(consisting only of normal recurring accruals) that are necessary to present
fairly in all material respects the consolidated financial condition, results
of operations, changes in stockholders' equity and cash flows of the Company
and its Subsidiaries as of the dates thereof or for the periods covered
thereby.

 

(b)Except as set forth in Section 4.9(b) of the Company Disclosure Schedule,
the Company maintains a standard system of accounting established and
administered in accordance with GAAP. Except as set forth in Section 4.9(b)
of the Company Disclosure Schedule, the Company and its Subsidiaries maintain
a system of internal accounting controls sufficient to provide

 

31  

reasonable assurance that (i) transactions are executed in accordance with
management's general or specific authorizations, (ii) transactions are
recorded as necessary to permit preparation of financial statements in
conformity with GAAP and to maintain asset accountability, (iii) access to
assets is permitted only in accordance with management's general or specific
authorization, and (iv) the recorded accountability for assets is compared
with the existing assets at reasonable intervals and appropriate action is
taken with respect to any differences. Section 4.9(b) of the Company
Disclosure Schedule lists, and the Company has made available to Parent true,
correct and complete copies of, all written policies, manuals and other
documents promulgating such internal accounting controls.

 

(c)To the Knowledge of the Company, no employee of the Company or any of its
Subsidiaries has provided or is providing information to any law enforcement
agency regarding the commission or possible commission of any crime or the
violation or possible violation of any applicable Law by the Company, any of
its Subsidiaries, or any of their respective directors, managers, managing
directors, officers, employees, Contract Workers, agents, contractors or
subcontractors. Neither the Company nor any of its Subsidiaries, nor any of
their respective officers or employees or, to the Knowledge of the Company,
any contractor, subcontractor or agent of the Company or any of its
Subsidiaries, has discharged, demoted, suspended, threatened, harassed or in
any other manner discriminated against any employee of the Company or any of
its Subsidiaries in the terms and conditions of employment because of any act
of such employee described in 18 U.S.C.  1514A(a).

 

Absence of Certain Changes or Events

 

.

 

(a)Except as described in Section 4.10(a) of the Company Disclosure Schedule,
since December 31, 2016, (i) the Company and its Subsidiaries have conducted
their businesses only in the ordinary course of business consistent with past
practice and in compliance with applicable Laws, (ii) there has not been any
Material Adverse Effect, and (iii) there has not been any damage, destruction
or loss (whether or not covered by insurance) in an amount greater than Twenty
Five Thousand Dollars ($25,000) with respect to any rights, assets or
properties of the Company or any of its Subsidiaries.

 

(b)Except as described in Section 4.10(b) of the Company Disclosure Schedule,
since December 31, 2017, neither the Company nor any of its Subsidiaries has
taken any action that, if taken after the date hereof, would require Parent's
consent under Section 6.1.

 

No Undisclosed Liabilities

 

.

 

 Except as described in Section 4.11 of the Company Disclosure Schedule,
neither the Company nor any of its Subsidiaries has any material Liabilities,
and, to the Knowledge of the Company, there is no existing fact, condition or
circumstance which would reasonably be expected to result in such Liabilities,
except Liabilities (a) disclosed in the consolidated balance sheet of the
Company and its Subsidiaries as of the Company Balance Sheet Date, (b)
incurred since the Company Balance Sheet Date in the ordinary course of
business consistent with past practice and which are ordinary in nature and
amount and do not rise out of any charge, complaint, proceeding or demand or
relate to any breach of Contract, tort or infringement, or (c) which are
expressly contemplated by, and incurred in compliance with, this Agreement.

 

Absence of Litigation

 

.

 

 Except as described in Section 4.12 of the Company Disclosure Schedule,
there is no (a) Claim pending on behalf of, against or involving, or, to the

 

32  

Knowledge of the Company, threatened on behalf of or against, the Company, any
of its Subsidiaries, any of their respective properties, rights or assets, or
any of their respective officers, directors, managers or managing directors
(in their capacities as such) (including cease and desist letters or requests
for a license), (b) Order outstanding to which the Company, any of its
Subsidiaries, any of their respective properties, rights or assets, or any of
their respective officers, directors, managers or managing directors (in their
capacities as such) is subject or (c) Claim that questions or challenges (i)
the validity of this Agreement or (ii) any action taken or to be taken by or
on behalf of the Company or any of its Subsidiaries pursuant to this Agreement
or in connection with the transactions contemplated hereby. No director,
manager, managing director, officer, employee, Contract Worker or agent of the
Company or any of its Subsidiaries has asserted a Claim or demand for payment
or, to the Knowledge of the Company, has a basis for a Claim or demand for
payment against the Company or any of its Subsidiaries in respect of the
period prior to and including the Effective Time (other than for accrued and
unpaid compensation earned in the ordinary course of business).

 

Employee Benefit Plans

 

.

 

(a)Section 4.13(a) of the Company Disclosure Schedule lists and, in the case
of employee benefit plans not reduced to writing, describes all employee
benefit plans, including "employee benefit plans" as defined in Section 3(3)
of the Employee Retirement Income Security Act of 1974, as amended ("ERISA")
(whether subject to ERISA or not), bonus, commission, retention or other cash
incentive, equity or equity-based incentive, deferred compensation, pension,
savings, profit sharing, retirement or supplemental retirement, severance,
termination, change of control or other transaction-based incentive, golden
parachute, health and welfare, vacation, cafeteria, dependent care, medical
care, employee assistance, education or tuition assistance, insurance and
other similar fringe or employee benefit plans, programs or arrangements,
whether written or oral, and any employment or executive compensation or
severance Contracts, written or otherwise, for the benefit of, or relating to,
any current or former employee, director, manager, managing director, or
Contract Worker of the Company or any of its Subsidiaries, (i) which is or has
been entered into, contributed to, established by, participated in or
maintained by the Company or any trade or business (whether or not
incorporated) which is a member of a controlled group or which is under common
control (within the meaning of Section 414 of the Code) with the Company or
any of its Subsidiaries (an "ERISA Affiliate"), or (ii) under which the
Company, its Subsidiaries or any of their ERISA Affiliates has or may have any
Liability whether or not such plan is terminated (together, the "Employee
Plans"), except for (x) Contracts that provide for employment that is
terminable "at will" and that are terminable without severance, change of
control pay or benefits, or other Liabilities, in which case only forms of
such contracts are listed in Section 4.13(a) of the Company Disclosure
Schedule, (y) individual Stock Option or other Stock-Based Right agreements,
in which case only forms of such individual agreements are listed in Section
4.13(a) of the Company Disclosure Schedule, unless such individual agreements
provide acceleration of vesting of awards in a manner not provided for under
the applicable form(s) or that otherwise materially differ from such forms or
(z) consulting Contracts that are terminable without penalty on less than
thirty (30) days' notice, in which case only forms of such contracts are
listed in Section 4.13(a) of the Company Disclosure Schedule. Section 4.13(a)
of the Company Disclosure Schedule separately identifies the Employee Plans
that cover any current or former employee, director, manager, managing
director, or Contract Worker of the Company or any of its Subsidiaries that is
or was employed or providing services outside of the United States
(collectively, the "Foreign Plans"). With respect to each Employee Plan
(other than Employee Plans that provide a de minimis level of benefits), the
Company has made available to Parent true, correct and complete copies of
(where applicable) (A) all plan documents and amendments thereto, including
all adoption and participation agreements, summary

 

33  

plan descriptions, summaries of material modifications, and resolutions,
related to such Employee Plan, (B) the most recent determination letters or
opinion letters received from the IRS for such Employee Plan, (C) the three
most recent IRS Form 5500 Annual Reports for such Employee Plan (and all
schedules and attachments thereto), (D) the most recent audited financial
statement and actuarial valuation report for such Employee Plan, (E) the most
recent discrimination and compliance testing results for such Employee Plan,
(F) all related agreements (including trust agreements), insurance Contracts
and other Contracts which implement such Employee Plan, and (G) all material
correspondence with, rulings by or opinions by the IRS, the U.S. Department of
Labor or any other Governmental Authority for such Employee Plan for the past
three years. Neither the Company nor any of its Subsidiaries has any formal
plan or commitment to create any additional Employee Plan or to modify,
change, or terminate any existing Employee Plan. There are no restrictions on
the ability of the sponsor of each Employee Plan (which is currently the
Company or a Subsidiary of the Company) to amend or terminate any Employee
Plan, and each Employee Plan may be transferred to or assumed by Parent,
Merger Sub or, after the Effective Time, the Surviving Corporation, as the
case may be.

 

(b)(i) There has been no "prohibited transaction," as such term is defined in
Section 406 of ERISA and Section 4975 of the Code, with respect to any
Employee Plan (and which is not otherwise exempt); (ii) there has been no
breach of fiduciary obligations imposed under Title I of ERISA with respect to
any Employee Plan; (iii) there are no Claims pending (other than routine
claims for benefits) or, to the Knowledge of the Company, threatened against
any Employee Plan, against the assets of any Employee Plan or any fiduciary
thereof with respect to their duties to the Employee Plan; (iv) all Employee
Plans conform to, and in their operation and administration are in all
material respects in compliance with, the terms thereof and requirements
prescribed by any and all statutes (including ERISA and the Code), Orders and
governmental Regulations currently in effect with respect thereto and any
other applicable Laws; (v) the Company and each of its Subsidiaries and their
ERISA Affiliates have performed in all material respects all obligations
required to be performed by them under each Employee Plan and are not in
default under or in violation of, and the Company has no Knowledge of any
default or violation by any other Person with respect to, any of the Employee
Plans; (vi) each Employee Plan intended to qualify under Section 401(a) of the
Code is so qualified (and each corresponding trust is exempt under Section 501
of the Code), and has received or is the subject of a favorable determination
or opinion letter from the IRS, and nothing has occurred which may reasonably
be expected to cause the loss of such qualification (or exemption); and (vii)
each Employee Plan that is a "nonqualified deferred compensation plan" (as
such term is defined in Section 409A(d)(1) of the Code) has been administered
in material compliance with its terms and the operational and documentary
requirements of Section 409A of the Code and the regulations thereunder.

 

(c)No Employee Plan is subject to Title IV of ERISA or a "multiemployer plan"
(within the meaning of Section 3(37) of ERISA), and neither the Company, any
of its Subsidiaries nor any of their ERISA Affiliates has or has ever had an
obligation to contribute, or incurred any Liability in respect of a
contribution, to any such plan. Neither the Company nor any of its
Subsidiaries has any Liability as a result of being an ERISA Affiliate of any
other Person, nor do any circumstances exist that could reasonably be expected
to result in any such Liability becoming a Liability of Parent or any of its
Affiliates (including, as of the Closing, the Surviving Corporation and its
Subsidiaries).

 

(d)Except as set forth in Section 4.13(d) of the Company Disclosure Schedule,
no Employee Plan is (i) a "voluntary employees' beneficiary association"
(within the meaning of

 

34  

Section 501(c)(9) of the Code), (ii) an "employee stock ownership plan"
(within the meaning of Section 4975(e)(7) of the Code) or otherwise invests in
"employer securities" (within the meaning of Section 409(l) of the Code),
(iii) a "multiple employer plan," as described in Section 413(c) of the Code
or Sections 4063 or 4064 of ERISA, or (iv) a "multiple employer welfare
arrangement" as defined in Section 3(40)(A) of ERISA (a "MEWA"). If any
Employee Plan is a MEWA, the benefits thereunder are fully insured.

 

(e)Each Employee Plan that is a "group health plan" (within the meaning of
Code Section 5000(b)(1)) has been operated in compliance in all material
respects with the group health plan continuation coverage requirements of
Section 4980B of the Code and Sections 601 through 608 of ERISA ("COBRA
Coverage") and similar state laws, Section 4980D of the Code and Sections 701
through 713 of ERISA, The Public Health Service Act and the provisions of the
Social Security Act, as amended, to the extent such requirements are
applicable. Except as set forth in Section 4.13(e) of the Company Disclosure
Schedule, no Employee Plan or other written or oral agreement exists which
obligates the Company or any of its Subsidiaries to provide post-employment
health or welfare benefits (whether or not insured) to any current or former
employee, director, manager, managing director or Contract Worker of the
Company or any of its Subsidiaries or any of their dependents following such
current or former employee's, director's, manager's, managing director's or
Contract Worker's termination of employment, service or consultancy with the
Company or any of its Subsidiaries, other than COBRA Coverage or similar state
law coverage at such individual's sole cost.

 

(f)Except as set forth in Section 4.13(f) of the Company Disclosure Schedule,
no Employee Plan exists that, as a result of the execution and delivery of
this Agreement, the Stockholder Approval, the Merger or the other transactions
contemplated by this Agreement (whether alone or in connection with any
subsequent event(s)), will result in (i) severance pay or any increase in
severance pay upon any termination of employment after the date of this
Agreement, or (ii) acceleration of the time of payment or vesting or result in
any payment or funding (through a grantor trust or otherwise) of compensation
or benefits under, increase the amount payable or result in any other material
obligation pursuant to, any of the Employee Plans.

 

(g)All contributions and payments with respect to each Employee Plan that are
required to be made by the Company or any of its Subsidiaries with respect to
periods ending on or prior to the Closing Date have been, or will be, made or
accrued before the Closing Date in accordance with the terms of the applicable
Employee Plan and applicable Law.

 

(h)Without limiting the foregoing, each Foreign Plan (i) that is required or
intended to be registered or approved by a foreign Governmental Authority has
been registered with, or approved by, and has been maintained in all material
respects in good standing with such Governmental Authority, (ii) that is
intended to qualify for favorable tax benefits under the laws of any non-
United States jurisdiction is so qualified, and nothing has occurred which
could reasonably be expected to adversely affect such qualification, and (iii)
that is required to be funded or book reserved is fully funded and/or book
reserved, as appropriate, based upon reasonable actuarial assumptions.

 

Employment and Labor Matters

 

.

 

(a)Section 4.14(a) of the Company Disclosure Schedule identifies (i) all
current directors and officers of the Company and all Persons currently
holding a comparable position with

 

35  

any of the Company's Subsidiaries (including any and all current managers and
managing directors thereof) and (ii) all current employees and Contract
Workers employed or engaged by the Company or any of its Subsidiaries and, for
each individual identified in clauses (i) or (ii), sets forth each such
individual's rate of pay or annual compensation, job title, location, date of
hire or engagement, incentive compensation opportunity, leave of absence
status, classification under applicable wage and hour laws as either exempt or
not exempt for overtime pay, full-time, part-time, temporary or seasonal
employee status, and employee or Contract Worker/non-employee classification.
As of the date hereof, no employee or Contract Worker has disclosed to the
Company or any of its Subsidiaries any plans to terminate his or her
employment or consultant relationship or has given written notice to the
Company or any of its Subsidiaries that any such employee or Contract Worker
intends to terminate his or her employment or relationship with the Company or
any of its Subsidiaries. To the Knowledge of the Company, no employee or
Contract Worker is in violation of any term of any employment Contract,
Contract Worker Contract, non-disclosure agreement or non-competition
agreement in any material respect. Neither the Company nor any of its
Subsidiaries is party to, bound by, or currently negotiating any collective
bargaining agreement, Contract or other agreement or understanding with any
labor union or labor organization. None of the Company's or its Subsidiaries'
employees or Contract Workers are represented by a labor union or labor
organization and no union or organizing activities involving such employees or
Contract Workers are pending or, to the Knowledge of the Company, threatened.
Neither the Company nor any of its Subsidiaries has a duty to recognize or
bargain with any labor union or labor organization or other Person purporting
to act as the exclusive bargaining representative of any employees or Contract
Workers of the Company or any of its Subsidiaries with respect to wages, hours
or other terms and conditions or to engage in effects bargaining or other
bargaining relating to or in connection with, or to provide advance notice of,
any prior or contemplated transactions. Neither the Company nor any of its
Subsidiaries has failed to make or is otherwise delinquent in payments to any
of its employees or Contract Workers for any wages, salaries, overtime pay,
commissions, bonuses, benefits or other compensation for any services or
otherwise arising under any policy, practice, Contract, plan, program or Law.
Except as set forth in Section 4.14(a) of the Company Disclosure Schedule,
none of the Company's or any of its Subsidiaries' employment policies or
practices is currently being audited or investigated by any Governmental
Authority. Except as set forth in Section 4.14(a) of the Company Disclosure
Schedule, there is no pending or, to the Knowledge of the Company, threatened
Claim, unfair labor practice charge, or other charge or inquiry against the
Company or any of its Subsidiaries with respect to employment practices
brought by or before any Governmental Authority.

 

(b)Except as set forth in Section 4.14(b) of the Company Disclosure Schedule,
there are no, and within the past six years there have been no, (i) Claims or
controversies with respect to Employment Law matters (including relating to or
asserting allegations of employment discrimination, harassment, retaliation,
misclassification, wage or hour violations or unfair labor practices)
existing, pending or, to the Knowledge of the Company, threatened against or
involving the Company or any of its Subsidiaries in any judicial, regulatory
or administrative forum, under any private dispute resolution procedure or
internally by any of their respective current or former employees or Contract
Workers, or (ii) strikes, slowdowns, work stoppages, lockouts, or concerted
interference with normal operations existing, pending, or threatened against
or involving the Company or any of its Subsidiaries by or with respect to any
employees of the Company or any of its Subsidiaries. Neither the Company nor
any of its Subsidiaries is a party to, or otherwise bound by, any consent
decree with, or citation or other Order by, any Governmental Authority
relating to employees or employment practices. The Company and each of its
Subsidiaries are in compliance in all material respects with all applicable
Laws, Contracts and policies relating to employment, employment practices,
wages, hours and terms and conditions of employment, Tax withholding,

 

36  

prohibited discrimination, harassment or retaliation, disability rights and
benefits, reasonable accommodation, meal and rest break obligations, equal
employment, fair employment practices, immigration status, hiring and
termination of employees, data protection and employee privacy, leaves of
absence, workers compensation, pension and unemployment insurance and
employment related Taxes, employee safety and health, plant closures and
layoffs (including the obligations of the Worker Adjustment and Retraining
Notification Act of 1988, as amended (the "WARN Act"), and similar Laws), and
all other notification and bargaining obligations arising by Law or otherwise.
With respect to each current and former employee of the Company or any of its
Subsidiaries, the Company and each of its Subsidiaries: (A) has withheld and
reported all amounts required by Law or by agreement to be withheld and
reported with respect to wages, salaries and other payments to such employee;
(B) is not liable for any arrears of wages, severance pay or other amounts due
to such employees, including pursuant to any Contract, policy, practice or
applicable Law; and (C) is not liable for any payment to any trust or other
fund governed by or maintained by or on behalf of any Governmental Authority,
with respect to unemployment compensation benefits, social security or other
benefits or obligations for such employee (other than routine payments to be
made in the normal course of business and consistent with past practice).
Neither the Company nor any of its Subsidiaries has effectuated a "plant
closing," "termination," "relocation" or "mass layoff" as those terms are
defined in the WARN Act and similar Laws, affecting in whole or in part any
site of employment, facility, operating unit or employee of the Company or any
of its Subsidiaries, without complying with all provisions of the WARN Act (or
similar Laws) or implemented any early retirement, separation or window
program within the past five (5) years, nor has the Company or any of its
Subsidiaries planned or announced any such action or program for the future.
Except as would not, individually or in the aggregate, give rise to a material
Liability of the Company or any of its Subsidiaries, each individual that
renders services to the Company or any of its Subsidiaries that is classified
as (x) a Contract Worker or other non-employee status or (y) an exempt or non-
exempt employee, in each case is properly characterized as such for all
purposes (including (I) taxation and Tax reporting, (II) Fair Labor Standards
Act purposes and (III) applicable Laws governing the payment of wages,
including overtime), and the Company and its Subsidiaries have properly
classified and treated them in accordance with all applicable Laws and for
purposes of all applicable Employee Plans. Neither the Company nor any of its
Subsidiaries has any Liability for any misclassification of any employee as an
independent contractor or any non-exempt employee as an exempt employee.

 

Title to Assets; Sufficiency of Assets; Leases

 

.

 

(a)Except as described in Section 4.15(a) of the Company Disclosure Schedule,
the Company and each of its Subsidiaries has good and marketable title to all
of their real or personal properties (whether owned or leased), rights and
assets, free and clear of all Liens (other than Permitted Liens). Except as
set forth in Section 4.15(a) of the Company Disclosure Schedule, (A) the real
and personal assets, properties and rights owned, licensed or leased by the
Company and its Subsidiaries constitute all of the real and personal assets,
properties and rights that are required for or currently used in connection
with the conduct of the respective businesses, activities and operations of
the Company and each of its Subsidiaries as they are currently conducted and
as they are currently planned to be conducted, and (B) following the Closing,
none of the Equityholders (or Series D Holders) or any of their respective
Affiliates will own, lease or license any real or personal assets, properties
or rights that are required for or currently used in connection with the
conduct of the respective businesses, activities and operations of the Company
and each of its Subsidiaries as they are currently conducted and as they are
currently planned to be conducted.

 

37  

(b)Neither the Company nor any of its Subsidiaries owns any real property or
has ever owned any real property.

 

(c)Section 4.15(c)(i) of the Company Disclosure Schedule sets forth a true and
complete list of all leases and subleases of real property to which the
Company or any of its Subsidiaries is a party or by which any of them holds a
leasehold interest or is otherwise obligated (the "Leased Real Property").
The Company has made available to Parent true, correct and complete copies of
all such leases and subleases for the Leased Real Property (each, a "Lease"),
including all amendments and modifications thereto and related consents and
other documents. Except as set forth in Section 4.15(c)(ii) of the Company
Disclosure Schedule, the Company or one of its Subsidiaries has, and following
the Closing will continue to have, a good and valid leasehold interest in the
Leased Real Property. To the Knowledge of the Company, the Company or a
Subsidiary of the Company has the right to use and occupy the Leased Real
Property for the full term of the Lease relating thereto. Each such Lease is a
legal, valid and binding obligation, enforceable in accordance with its terms,
of the Company or a Subsidiary of the Company and, to the Knowledge of the
Company, the other parties thereto, is in full force and effect in accordance
with its terms, and all rents and additional rents due to date from the
Company or any of its Subsidiaries pursuant to each Lease have been paid.
Neither the Company nor any of its Subsidiaries has assigned or licensed any
or all of its interest under any Lease or subleased or sublet any part of the
Leased Real Property or permitted any other Person to occupy the Leased Real
Property (whether pursuant to a formal or informal arrangement, and whether or
not for consideration), and neither the Company nor any of its Subsidiaries
has received notice of any default (with or without notice or lapse of time or
both) with respect to any Lease. There exists no material default by the
Company or any of its Subsidiaries or, to the Knowledge of the Company, by any
other party under any Lease. Except as set forth in Section 4.15(c)(iii) of
the Company Disclosure Schedule, there are no leases, subleases, licenses,
concessions or any other Contracts to which the Company or any of its
Subsidiaries is a party granting to any Person other than the Company or any
of its Subsidiaries any right to possession, use, occupancy or enjoyment of
any of the Leased Real Property or any portion thereof and none of the Company
or any of its Subsidiaries is obligated under or bound by any option, right of
first refusal, purchase contract, or other Contract to sell or otherwise
dispose of any interest in any Leased Real Property. Except as set forth on
Section 4.15(c)(iv) of the Company Disclosure Schedule, (x) no landlord under
any Lease is holding any security deposit and (y) neither the Company nor any
Subsidiary of the Company is required to remove any improvements at the end of
term of (or upon the earlier termination of) any Lease.

 

(d)Section 4.15(d) of the Company Disclosure Schedule contains a true and
complete list of all leases of all property, rights or assets (other than
Intellectual Property licenses listed in Section 4.18(b) of the Company
Disclosure Schedule and Leases) to which the Company or any of its
Subsidiaries is a party or by which any of them holds a leasehold interest.

 

(e)The use and operation of the Leased Real Property is (i) permitted by and
in compliance with all applicable zoning regulations and has received all
required zoning approvals, (ii) not in violation of any recorded or other
encumbrance and (iii) permitted by the terms of the applicable Lease.

 

(f)Neither the Company nor any Subsidiary of the Company has received any
notice within the past twenty-four (24) months of any pending or threatened
condemnations, planned public improvements, annexation, special assessments,
zoning or subdivision changes, or other adverse claims affecting the Leased
Real Property.

 

38  

(g)The Leased Real Property and the operation thereof by the Company and its
Subsidiaries comply in all material respects with all applicable Laws and any
restrictive covenants applicable to the Leased Real Property. Neither the
Company nor any of its Subsidiaries has received any written notice from any
Governmental Authority of any violations of any Law affecting any portion of
the Leased Real Property.

 

(h)The improvements included in the Leased Real Property are (i) fit for their
intended purposes, (ii) in good working order and condition (wear and tear
excepted), and (iii) in compliance in all material respects with all
applicable Laws.

 

(i)The Leased Real Property has adequate rights of way and access to public
ways and is served by public utilities and services in the surrounding
community, including water, sewer, sanitary sewer and storm drain facilities,
police and fire protection, public transportation, refuse removal, public
education, and enforcement of safety codes which are adequate in relation to
the premises and location on which the Leased Real Property is located. All
liquid and solid waste disposal, septic and sewer systems located at the
Leased Real Property are in good and safe condition and repair and in
compliance in all material respects with all applicable Laws.

 

(j)All improvements, equipment, machinery and fixtures located within the
demised premises constituting the Leased Real Property are in good operating
condition and repair, have been maintained in accordance with commercially
reasonable standards and are adequate and suitable in all material respects
for the present and continued use and operation thereof as currently used or
operated and as currently planned to be used or operated, ordinary wear and
tear excepted.

 

(k)To the Knowledge of the Company, (i) there are no violations of Law with
respect to Leased Real Property; (ii) there are no violations of any covenant,
restriction or easement affecting the Leased Real Property or any part of it,
or with respect to the use or occupancy of the Leased Real Property or any
part of it; and (iii) there have been no work orders, deficiency notices or
other similar notices of noncompliance issued by any Governmental Authority
or otherwise with respect to the Leased Real Property that are outstanding or
that require or recommend (or otherwise identify as necessary or desirable)
work or repairs in connection with the Leased Real Property or any part
thereof.

 

Taxes

 

.

 



 

(a)Except as set forth in Section 4.16(a) of the Company Disclosure Schedule:

 

(i)All income and other material Tax Returns required to be filed by or on
behalf of the Company, each of its Subsidiaries and each affiliated, combined,
consolidated or unitary group of which the Company or any of its Subsidiaries
is or was at any time a member have been timely filed (taking into account any
applicable extensions), and all such Tax Returns are true, complete and
correct in all material respects.

 

(ii)All income and other material Taxes payable by or with respect to the
Company and each of its Subsidiaries (whether or not shown on any Tax Return)
have been timely paid, and adequate reserves in accordance with GAAP are
provided on the most recent Company balance sheet included in the Financial
Statements for any Taxes not yet due. All assessments for Taxes due and owing
by or with respect to the Company and each of its Subsidiaries with respect to
completed and settled examinations or concluded litigation have been paid.
Neither the Company

 

39  

nor any of its Subsidiaries has incurred a Tax Liability from the date of the
most recent balance sheet included in the Financial Statements other than a
Tax Liability in the ordinary course of business consistent with past
practice. There are no Tax Liens on any assets, properties or rights of the
Company or any of its Subsidiaries except Liens for current Taxes not yet due
and payable.

 

(iii)No written Claim has been made and, to the Knowledge of the Company, no
audit has commenced and no written notice has been given that such audit or
other proceeding is pending or threatened with respect to the Company or any
of its Subsidiaries or any group of entities of which the Company or any of
its Subsidiaries is or has been a member (an "Affiliated Group") in respect of
any Taxes. No Tax deficiency or claim for additional Taxes has been asserted
in writing or, to the Knowledge of the Company, threatened to be asserted
against the Company or any of its Subsidiaries or any Affiliated Group by any
Taxing authority. 

 

(iv)No written Claim has ever been made by a Taxing authority in any
jurisdiction in which the Company or any of its Subsidiaries does not file Tax
Returns that the Company or such Subsidiary is or may be subject to taxation
by that jurisdiction. Neither the Company nor any of its Subsidiaries has a
permanent establishment in any country other than the country under the laws
of which it is organized.

 

(v)Neither the Company nor any of its Subsidiaries has requested or been
granted any waiver of any federal, state, local or foreign statute of
limitations with respect to, or any extension of a period for the assessment
of, any Tax. No extension or waiver of time within which to file any Tax
Return of, or applicable to, the Company or any of its Subsidiaries has been
granted or requested which has not since expired (other than any automatic
extension for which approval of a Taxing authority is not required).

 

(vi)Neither the Company nor any of its Subsidiaries is or has ever been (nor
does the Company or any of its Subsidiaries have any Liability for unpaid
Taxes because it once was) a member of an affiliated, consolidated, combined
or unitary group (other than a group the common parent of which was the
Company). Neither the Company nor any of its Subsidiaries is a party to any
Tax allocation, Tax indemnity or Tax sharing agreement (in each case, other
than any commercial agreement entered into in the ordinary course of business,
the primary purpose of which is not Tax related), is or has ever been a member
of an affiliated group of corporations filing a consolidated federal income
Tax Return, or is liable for the Taxes of any other person under Treasury
Regulations 1.1502-6 (or any similar provision of state, local or foreign
law), as transferee or successor, by Contract, or otherwise. Neither the
Company nor any of its Subsidiaries is or has ever been a partner in a
partnership or a participant in an arrangement or the owner of an entity that,
to the Knowledge of the Company, is or may be treated as a partnership for
federal income Tax purposes.

 

(vii)The Company and each of its Subsidiaries have complied in all material
respects with all applicable Laws relating to the payment and withholding of
Taxes (including withholding of Taxes pursuant to Sections 1441, 1442, 1445,
1471, 1472 and 3406 of the Code or similar provisions under any foreign Laws)
and have, within the time and in the manner required by Law, withheld from
payments to employees, Contract Workers and other persons and paid over to the
proper Governmental Authorities all amounts required to be so withheld and
paid over under all applicable Laws.

 

(viii)None of the Company or any of its Subsidiaries will be required to
include any item of income in, or exclude any item of deduction from, taxable
income for any taxable

 

40  

period or portion thereof ending after the Closing Date as a result of any (i)
change in the method of accounting for a taxable period or portion thereof
ending on or prior to the Closing Date, (ii) intercompany transaction
(including any intercompany transaction subject to Section 367 or 482 of the
Code) entered into on or prior to the Closing Date, (iii) prepaid amount
received on or prior to the Closing Date, (iv) installment sale or open
transaction disposition made on or prior to the Closing Date, (v) pursuant to
Section 108(i) of the Code, or (vi) use of any improper method of accounting
for a taxable period ending on or prior to the Closing Date.

 

(ix)The Company and each of its Subsidiaries has collected all sales, use and
value added Taxes required to be collected, and has remitted on a timely basis
to the appropriate taxing authorities all sales, use and value added Taxes and
all customs and duties required to be paid, or has been furnished properly
completed exemption certificates, if applicable.

 

(x)There are no closing agreements, gain recognition agreements or similar
Contracts with any Taxing authority with regard to the determination of the
Tax liability of the Company or any of its Subsidiaries that would have
continuing effect on Tax periods ending on or after the Closing Date. No Tax
rulings have been applied for or received by the Company or any of its
Subsidiaries.

 

(xi)No power of attorney has been executed with respect to any matter relating
to Taxes of the Company or any of its Subsidiaries, which is currently in
force.

 

(xii)Neither the Company nor any of its Subsidiaries has been a party to any
distribution occurring during the last two (2) years in which the parties to
such distribution treated the distribution as one to which Section 355 or
Section 361 of the Code is applicable; nor has the Company or any of its
Subsidiaries been a party to any distribution that could constitute part of a
"plan" or "series of related transactions" (within the meaning of Section
355(e) of the Code) in conjunction with the transactions contemplated by this
Agreement.

 

(xiii)Neither the Company nor any of its Subsidiaries has entered into any
transactions that are or would be part of any "reportable transaction" under
Sections 6011, 6111 or 6112 of the Code (or any similar provision under any
state or local Law).

 

(xiv)Neither the Company nor any of its Subsidiaries has participated in or
cooperated with an international boycott, within the meaning of Section 999 of
the Code, nor has the Company or any of its Subsidiaries had operations that
are or may hereafter become reportable under Section 999 of the Code.

 

(xv)Any and all transactions between or among any of the Company, its
Subsidiaries, the Equityholders, the Series D Holders and Affiliates of the
Company or of any of its Subsidiaries have occurred on arm's length terms, and
the Company and its Subsidiaries have complied with any and all tax-related
requirements that the arm's-length nature of the terms of such transactions be
documented.

 

(xvi)Neither the Company nor any of its Subsidiaries is a United States real
property holding corporation within the meaning of Section 897(c)(4) of the
Code and neither the Company nor any of its Subsidiaries has been a United
States real property holding corporation at any time during the applicable
period specified in Section 897(c)(1)(A)(ii) of the Code.

 

41  

(xvii)Neither the Company nor any of its Subsidiaries has any deferred
compensation plan or arrangement that is described in Section 409A(a)(1)(A)(i)
of the Code.

 

(xviii)There is no agreement, plan, arrangement or other Contract covering any
current or former employee, director, manager, managing director, or
independent contractor of the Company or any of its Subsidiaries to which the
Company is a party or by which the Company is bound that, considered
individually or considered collectively with any other such agreements, plans,
arrangements or other Contracts, will, or could reasonably be expected to, as
a result of the transactions and agreements contemplated by this Agreement
(whether alone or upon the occurrence of any additional or subsequent events),
give rise directly or indirectly to the payment of any amount that could
reasonably be expected to be characterized as a "parachute payment" within the
meaning of Section 280G of the Code (or any corresponding or similar provision
of state, local or foreign Tax law). Neither the Company nor any of its
Subsidiaries has made any payments, is obligated to make any payments, or is a
party to any agreements that under any circumstances could obligate it to make
any payments that reimburse or otherwise "gross-up" any Person for any Taxes
as a result of Sections 280G, 409A, or 4999 of the Code.

 

(xix)The Company has made available to Parent correct and complete copies of
all income and franchise Tax Returns and other material Tax Returns of the
Company and each of its Subsidiaries for the six (6) taxable periods ended
prior to the date of this Agreement.

 

(xx)None of the Company's Subsidiaries is a "deferred foreign income
corporation" within the meaning of Section 965 of the Code.

 

(b)Section 4.16(b) of the Company Disclosure Schedule sets forth the
classification (as a corporation, partnership or disregarded entity) for
federal income Tax purposes of each Subsidiary. The classification of each
Subsidiary has remained the same at all times that such Subsidiary has been
owned, directly or indirectly and in whole or in part, by the Company.

 

(c)Section 4.16(c) of the Company Disclosure Schedule sets forth, to the
Knowledge of the Company, as of December 31, 2017, the amount of net operating
losses of the Company and its Subsidiaries and their respective expiration
dates. None of the net operating losses of the Company and its Subsidiaries
is a "dual consolidated loss" within the meaning of Section 1503 of the Code.

 

(d)The Cayman Subsidiary is solvent for purposes of Section 332 of the Code
and the rules and regulations promulgated thereunder (including for purposes
of Section 1.332-2(b) of the Treasury Regulations as it would apply in
connection with any election to classify the Cayman Subsidiary as a
disregarded entity for U.S. federal income tax purposes).

 

Environmental Matters

 

.

 



 

(a)Except as set forth in Section 4.17(a) of the Company Disclosure Schedule,
the Company and its Subsidiaries are in compliance with and have complied with
all applicable Environmental Laws.

 

(b)Except as set forth in Section 4.17(b)(i) of the Company Disclosure
Schedule, the Company and its Subsidiaries have obtained all Environmental
Permits necessary for the operation of their respective businesses or the use
and operation of any Leased Real Property, and all

 

42  

such Environmental Permits are in full force and effect. All such
Environmental Permits are listed in Section 4.17(b)(ii) of the Company
Disclosure Schedule. Except as set forth in Section 4.17(b)(iii) of the
Company Disclosure Schedule, there is no action or proceeding pending, alleged
or threatened against the Company or any of its Subsidiaries to revoke or
modify such Environmental Permits. Except as set forth in Section 4.17(b)(iv)
of the Company Disclosure Schedule, all of the Environmental Permits are
transferable and none require consent, notification, or other action to remain
in full force and effect following consummation of the transactions
contemplated hereby.

 

(c)Except as set forth in Section 4.17(c) of the Company Disclosure Schedule,
neither the Company nor any of its Subsidiaries has any material Liability
under Environmental Law or with respect to Hazardous Materials, and neither
the Company nor any of its Subsidiaries has received any written notice,
demand, directive, Order or claim or is subject to any judicial or
administrative proceeding concerning (i) any non-compliance or alleged non-
compliance with any Environmental Law, or (ii) any alleged or threatened
Liability under any Environmental Law or with respect to Hazardous Materials.

 

(d)Except as set forth in Section 4.17(d) of the Company Disclosure Schedule,
there is not now, nor to the Knowledge of the Company, has there ever been,
on, in or about any Leased Real Property: (i) any asbestos-containing or
asbestos-related materials; (ii) any underground storage tank, above ground
storage tank, wetlands, landfill or other area used for waste disposal; (iii)
any polychlorinated biphenyls (PCBs); (iv) any radioactive substances or (v)
any toxic mold.

 

(e)The Company has made available to Parent true, correct and complete copies
of all audits, studies, reports, analyses, results of investigations or other
material documents in the possession or control of the Company or any of its
Subsidiaries with respect to the environmental condition of any real property
currently or formerly owned, operated or leased by the Company or any of its
Subsidiaries or with respect to the Company's, or any of its Subsidiaries'
compliance with Environmental Laws.

 

(f)Except as set forth in Section 4.17(f)(i) of the Company Disclosure
Schedule, there has been no Release of any Hazardous Materials at any real
property owned, operated or leased by the Company or any of its Subsidiaries
as to which Company or any of its Subsidiaries has been or could be liable
under Environmental Law. Except as set forth in Section 4.17(f)(ii) of the
Company Disclosure Schedule, neither the Company nor any of its Subsidiaries
has arranged, by contract, agreement, or otherwise, for the transportation,
disposal or treatment of Hazardous Materials at any location such that it is
or could be liable for Remediation of such location pursuant to Environmental
Laws.

 

(g)Except as set forth in Section 4.17(g) of the Company Disclosure Schedule,
no authorization, notification, recording, filing, consent, waiting period,
Remediation, or approval is required under any Environmental Law in order to
consummate the transaction contemplated hereby.

 

Intellectual Property

 

.

 



 

(a)The Company and its Subsidiaries own all right, title and interest in, or
are validly licensed to use in the manner used and contemplated to be used by
the Company or any of its Subsidiaries, all Intellectual Property used in or
necessary for the respective businesses, Products or services of the Company
and its Subsidiaries.

 

43  

(b)Section 4.18(b) of the Company Disclosure Schedule lists all: (i) patents,
provisional and non-provisional patent applications, registered trademarks,
trade names, service marks and copyrights, applications to register
trademarks, trade names, service marks and copyrights, domain names and other
registrations or pending applications to register Intellectual Property owned
by the Company or any of its Subsidiaries ("Scheduled Company Intellectual
Property"), including where applicable the registration, issuance, and
application numbers, and the jurisdictions, both domestic and foreign, in
which each such item of Intellectual Property has been issued or registered or
in which any application for such issuance and registration has been filed
(and, with respect to domain names, the domain name registrar); (ii) licenses,
sublicenses and other Contracts to which the Company or any of its
Subsidiaries is a party and pursuant to which any Person is authorized to use
any Scheduled Company Intellectual Property or any other Intellectual Property
owned by the Company or any of its Subsidiaries (other than, with respect to
such Intellectual Property, for any use that is authorized solely for the
purpose of conducting work for the Company or any of its Subsidiaries); (iii)
licenses, sublicenses, and other Contracts to which the Company or any of its
Subsidiaries is a party and pursuant to which the Company or any of its
Subsidiaries is authorized to use any Intellectual Property of any third
party, including patents, trademarks, and copyrights, and applications
therefor, and software (other than, with respect to such software, off-the-
shelf commercial or shrinkwrap software for which the license fee is less than
Ten Thousand Dollars ($10,000)) ("Third Party Intellectual Property"); and
(iv) all Contracts to which the Company or any of its Subsidiaries is a party
that provide for an optional or contingent license, sublicense, or other
agreement as described in clauses (ii) or (iii) above in this paragraph. All
issued patents and registered trademarks included in the Scheduled Company
Intellectual Property are valid, enforceable, have been duly maintained, are
in full force and effect, and have not been cancelled, expired, withdrawn,
lapsed, invalidated, or abandoned. Neither the Company nor any of its
Subsidiaries is obligated to pay any royalties or fees to any third party
under any patent, trademark, copyright, or other Intellectual Property
license, other than as set forth in Section 4.18(b)(iii) of the Company
Disclosure Schedule.

 

(c)The Company has taken all action necessary in its reasonable discretion to
obtain or maintain the enforceability and registration of all Scheduled
Company Intellectual Property.

 

(d)Except as set forth in Section 4.18(d) of the Company Disclosure Schedule,
neither the Company nor any of its Subsidiaries has sent to any third party or
otherwise communicated to another Person in the six (6) years preceding the
date of this Agreement, any charge, complaint, Claim, demand or notice
asserting that such Person has infringed, misappropriated, or acted in
conflict with any of the Scheduled Company Intellectual Property or any other
Intellectual Property owned by the Company or any of its Subsidiaries or that
any Claim, demand, or notice asserting any such other Person has conducted any
acts of unfair competition against the Company or any of its Subsidiaries,
nor, to the Knowledge of the Company, is any such infringement,
misappropriation, conflict or act of unfair competition occurring or
threatened.

 

(e)Except as set forth in Section 4.18(e) of the Company Disclosure Schedule,
the Company has not received and does not have Knowledge of any allegations,
assertions, or suggestions of, or facts that would support, any Claim, demand
or notice that the Company or any of its Subsidiaries has infringed,
misappropriated, or acted in conflict with any Intellectual Property owned by
any third party, that the Company or any of its Subsidiaries has conducted any
acts of unfair competition or other legal wrong against any third party or
that the Scheduled Company Intellectual Property and the Material Company
Trade Secrets are invalid, unenforceable, not owned by the Company or its
Subsidiaries or otherwise defective, inoperable, unregisterable, or

 

44  

unpatentable, except for communications from patent offices received in the
normal course of patent prosecution, and neither the Company nor any of its
Subsidiaries has received any offer to take a license for any patents,
trademarks, copyrights, or other Intellectual Property of any third party.
Without limiting the foregoing, neither the Company nor any of its
Subsidiaries has received notice of any inventorship challenge, opposition,
cancellation, re-examination, interference, invalidity, unenforceability or
other action or proceeding (other than in the ordinary course of patent
prosecution) relating to any Scheduled Company Intellectual Property.

 

(f)(i) Except as set forth in Section 4.18(d) of the Company Disclosure
Schedule, to the Knowledge of the Company, there is no unauthorized use,
disclosure, infringement or misappropriation of any rights of the Company or
any of its Subsidiaries in the Scheduled Company Intellectual Property or any
Third Party Intellectual Property licensed to the Company or any of its
Subsidiaries, by any third party, including any employee or former employee of
the Company, and (ii) except as set forth in Section 4.18(b)(iii) or Section
4.18(f) of the Company Disclosure Schedule, there are no royalties, fees, or
other payments or compensation payable by any third party to, or to any third
party by, the Company or any of its Subsidiaries by reason of the Company's or
any of its Subsidiaries' ownership, use, sale, or disposition of Intellectual
Property.

 

(g)Except as set forth in Section 4.18(g) of the Company Disclosure Schedule,
the Company is not, none of its Subsidiaries is, nor will the Company or any
of its Subsidiaries be, as a result of the execution and delivery of this
Agreement, or the performance of its obligations hereunder, in breach of any
license, sublicense, or Material Contract involving Intellectual Property, or
in violation of any Third Party Intellectual Property thereby.

 

(h)The respective businesses of the Company or any of its Subsidiaries
(including its Products and services) as previously and presently conducted in
the United States and in any jurisdiction foreign to the United States,
including Europe and Australia, have not and do not interfere with, conflict
with, infringe upon, misappropriate, or otherwise violate any Intellectual
Property of any third party, and no action or Claim is pending or, to the
Knowledge of the Company, threatened alleging that the Products or services of
the Company and its Subsidiaries or the operation of their respective
businesses interfere with, conflict with, infringe upon, misappropriate, or
otherwise violate the Intellectual Property rights of any third party and, to
the Knowledge of the Company, there is no basis therefor.

 

(i)Each current and former officer, employee, and Contract Worker of the
Company or any of its Subsidiaries has executed and provided to the Company or
such Subsidiary a written, enforceable, and valid agreement providing that the
Company or such Subsidiary is the owner (including through assignment) of any
Intellectual Property such current or former officer, employee, or Contract
Worker of the Company or such Subsidiary created or creates within the scope
of his or her employment, or, in the case of a non-employee, from the services
such non-employee of the Company or such Subsidiary performed or performs for
the Company or any of its Subsidiaries.

 

(j)No Equityholder (or Series D Holder) or former equityholder, partner,
director, manager, managing director, officer or employee of the Company or
any of its Subsidiaries (or any of their respective predecessors in interest)
has or will have, after giving effect to the transactions contemplated by this
Agreement, any legal or equitable right, title, or interest in or to, or any
right to use, directly or indirectly, in whole or in part, any Scheduled
Company Intellectual Property or any other Intellectual Property of the
Company or any of its Subsidiaries.

 

45  

(k)The Company or its Subsidiaries have entered into written, enforceable, and
valid confidentiality agreements with all employees and third parties to whom
the Company or any of its Subsidiaries has disclosed material Company-owned
confidential Intellectual Property, including Trade Secrets owned by the
Company or any of its Subsidiaries that are used in and material to the
business or Products of the Company or any of its Subsidiaries ("Material
Company Trade Secrets").

 

(l)The Company and its Subsidiaries have taken commercially reasonable
measures to protect the confidentiality of their Trade Secrets, including
requiring their former and current officers, employees, Contract Workers, and
all other Persons having access thereto to execute written, enforceable, and
valid non-disclosure agreements. No Material Company Trade Secret has been
disclosed or authorized to be disclosed by the Company or any of its
Subsidiaries to any third party other than pursuant to a written, enforceable,
and valid non-disclosure agreement that adequately protects the Company's and
the applicable Subsidiary's proprietary interests in and to such Trade Secret.
To the Knowledge of the Company, no party to any non-disclosure agreement with
the Company or any of its Subsidiaries is in breach or default thereof or has
threatened breach or default thereof.

 

(m)[intentionally left blank].

 

(n)To the Knowledge of the Company, neither the Company nor any of its
Subsidiaries has misrepresented, or failed to disclose, any facts or
information in any application for any of the Company's or any of its
Subsidiaries' patents or patent applications that would reasonably be expected
to constitute fraud, misrepresentation or other inequitable conduct.

 

(o)Section 4.18(o) of the Company Disclosure Schedule sets forth a complete
and accurate list of each item of open source, free, shared, or public library
software ("Open Source Software"), in each case that is contained in or
distributed with any Products of the Company or any of its Subsidiaries.
Neither the Company nor any of its Subsidiaries uses, develops or maintains,
or has used, developed or maintained, any proprietary software for use in or
with, or contemplated to be used in or with, its respective Products, (i)
which uses any Open Source Software or is subject to any open source licensing
agreement and (ii) which thereby requires the Company or any of its
Subsidiaries to disclose the source code of such proprietary software. The
use of any Open Source Software in conjunction with any of the Company's or
any of its Subsidiaries' Products does not impose (x) a requirement or
condition that any such Product or part thereof (A) be disclosed or
distributed in source code form, (B) be licensed for the purpose of making
modifications or derivative works, (C) be licensed under the same license as
third-party software, or (D) be redistributable at no charge, or (y) any other
material limitation, restriction, or condition on the right or ability of the
Company or any of its Subsidiaries to use or distribute any of the Company's
or any of its Subsidiaries' Intellectual Property.

 

Information Technology

 

.

 

(a)The information technology and data processing systems, facilities,
services, websites, and infrastructure used or currently planned to be used in
the conduct of the respective businesses of the Company and its Subsidiaries
and the development, manufacturing, processing, packaging, sale, and
distribution of the Products, including all software, hardware, firmware,
equipment, networks, interfaces, platforms, and related systems (collectively,
"Systems") are, to the Knowledge of the Company, reasonably sufficient for the
needs of the respective businesses of the

 

46  

Company and its Subsidiaries as intended to be operated by the Company and
such Subsidiaries in the next twelve (12) months, including as to capacity,
scalability, and ability to process current and anticipated peak volumes in a
timely manner. The Systems (i) function in material accordance with all
applicable documentation and specifications and are in good working condition
to effectively perform all computing, information technology, and data
processing operations reasonably necessary for the operation of the respective
businesses of the Company and its Subsidiaries and the development,
manufacturing, processing, packaging, sale, and distribution of the Products
as currently conducted and (ii) are maintained and supported in accordance
with customary industry practice. Except as set forth on Section 4.19(a) of
the Company Disclosure Schedule, in the twelve (12) month period prior to the
date of this Agreement, there has been no failure, breakdown, or continued
substandard performance of any Systems that has caused a material disruption
or interruption in or to the Systems or the operation of the business of the
Company or any of its Subsidiaries, including the development, manufacturing,
processing, packaging, sale, and distribution of the Products.

 

(b)Except as set forth on Section 4.19(b) of the Company Disclosure Schedule,
all Systems, other than Systems duly and validly licensed to the Company or
any of its Subsidiaries or used by or provided to the Company or any of its
Subsidiaries pursuant to a Contract listed in Section 4.18(b) of the Company
Disclosure Schedule and other than off-the-shelf commercial or shrinkwrap
software available on non-negotiated terms and for which the license fee is
less than Ten Thousand Dollars ($10,000), are owned and operated by and are
under the control of the Company or any of its Subsidiaries and are not wholly
or partly dependent on any systems, facilities, or services which are not
under the ownership, operation, and control of the Company or any of its
Subsidiaries.

 

(c)The Company and each of its Subsidiaries has taken commercially reasonable
steps to provide for the remote-site back-up of data and information critical
to the conduct of the business of the Company or any of its Subsidiaries in a
commercially reasonable attempt to avoid material disruption to, or material
interruption in, the conduct of the business of the Company or any of its
Subsidiaries and the development, manufacturing, processing, packaging, sale,
and distribution of the Products. The Company and each of its Subsidiaries
has in place industry standard (and, in any event, not less than commercially
reasonable) disaster recovery and business continuity plans, procedures, and
facilities.

 

(d)To the Knowledge of the Company, all Systems are free of any material
defects, bugs, and errors in accordance with generally-accepted industry
standards, and the Systems do not contain or make available any disabling
codes or instructions, spyware, Trojan horses, worms, viruses, or other
software routines that permit or cause unauthorized access to, or disruption,
impairment, disablement, or destruction.

 

Insurance

 

.

 

(a)Section 4.20(a) of the Company Disclosure Schedule sets forth a true and
complete list of all insurance policies and fidelity bonds covering the
assets, business, equipment, properties, rights, operations, employees,
Contract Workers, officer, directors, managers or managing directors of the
Company and its Subsidiaries, as well as a summary of the terms thereof and
the retention amounts with respect thereto. The Company has made available to
Parent true, correct and complete copies of all such policies and bonds. As of
the date of this Agreement, Section 4.20(a) of the Company Disclosure Schedule
also contains a list of all claims (including any pending claims subject to a
reservation of rights) made since January 1, 2017 for which coverage was
denied by any

 

47  

insurer, and, to the Knowledge of the Company, the estimated amounts of such
claims as listed in Section 4.20(a) of the Company Disclosure Schedule as have
been reasonably determined. 

 

(b)Each insurance policy listed in Section 4.20(a) of the Company Disclosure
Schedule that was renewed on or after January 1, 2017 was renewed on
substantially the same terms and conditions as the corresponding expiring
policy. There is no Claim by, on behalf of or against the Company or any of
its Subsidiaries pending under any of such policies or bonds as to which
coverage has been questioned, denied or disputed by the underwriters of such
policies or bonds or which exceeds coverage limitations. No reservation of
rights or denial of coverage has been issued by the underwriters of such
policies or bonds with respect to any Claim pending against the Company or any
of its Subsidiaries. All premiums payable under all such policies and bonds
have been paid in full and the Company and its Subsidiaries are otherwise in
full compliance with the terms of such policies and bonds (or other policies
and bonds providing substantially similar insurance coverage). Neither the
Company nor any of its Subsidiaries has taken any action or failed to take any
action which, with notice or the lapse of time or both, would constitute a
breach or default, or permit termination or modification, of any of such
insurance policies or bonds. 

 

(c)The Company and its Subsidiaries maintain insurance for their respective
businesses and operations in amounts and on such terms as are (i) in
compliance with applicable Law and any Contract(s) to which the Company or
any of its Subsidiaries is a party and (ii) reasonable and customary for
businesses of the type conducted by the Company or any of its Subsidiaries and
covering risks which are normally insured by companies possessing similar
assets and carrying on businesses of the type conducted by the Company and its
Subsidiaries. No insurer under any such policy or bond has cancelled or
generally disclaimed liability under any such policy or bond or, to the
Knowledge of the Company, indicated any intent to do so or to materially
increase the premiums payable under or not renew any such policy. To the
Knowledge of the Company, there is not any threatened termination of, notice
of cancellation of, notice of non-renewal of or material premium increase with
respect to any of such policies or bonds. With respect to incidents Known to
the Company that occurred prior to the Closing Date and which would reasonably
result in a claim after the Closing Date, the Company has provided the
relevant underwriters of such policies or bonds with notice of such incidents
or will do so prior to the Closing Date. The Company and its Subsidiaries
have complied in all material respects with all applicable requirements
(including contractual, statutory and regulatory requirements) governing the
purchase of insurance (including the requirements to provide or retain
evidence of such insurance).

 

Takeover Statutes

 

.

 

 The Board of Directors of the Company has taken all necessary actions such
that the restrictions on business combinations set forth in Section 203 of the
DGCL and any other "fair price," "moratorium," "control share acquisition" or
other similar anti-takeover Law enacted under state or federal Laws in the
United States applicable to the Company (each, a "Takeover Statute") will not
be applicable to Parent, Merger Sub or any other Subsidiary of Parent in
connection with this Agreement, the Merger or the other transactions
contemplated by this Agreement, including the Stockholder Consents and
Agreements, and no such Takeover Statute is applicable to this Agreement, the
Merger or the other transactions contemplated hereby. The Company does not
have any shareholder rights plan, "poison pill" or similar plan or arrangement
in effect.

 

Brokers

 

.

 

 Except as set forth in Section 4.22 of the Company Disclosure Schedule, no
broker, financial advisor, finder or investment banker or other Person is
entitled to any broker's, financial advisor's, finder's or other fee or
commission in connection with the transactions

 

48  

contemplated by this Agreement based upon arrangements made by or on behalf of
the Company. True and complete copies of all engagement letters or other
Contracts with any broker, financial advisor, finder, investment banker or
other Person listed in Section 4.22 of the Company Disclosure Schedule have
been made available to Parent.

 

Corporate Records

 

.

 

 Except as set forth in Section 4.23(a) of the Company Disclosure Schedule,
(i) the minute books and other similar records of the Company contain accurate
and complete records, in all material respects, of actions taken at any
meeting of the Board of Directors of the Company or any committee thereof and
of written consents executed in lieu of the holding of any such meeting and
(ii) the minute books and other similar records of the Company's Subsidiaries
contain accurate and complete records, in all material respects, of actions
taken at any meeting of the Board of Directors (or equivalent body) of such
Subsidiary or any committee thereof and of written consents executed in lieu
of the holding of any such meeting. Section 4.23(b) of the Company Disclosure
Schedule contains a true and complete list of all bank accounts and safe
deposit boxes of the Company and its Subsidiaries and the names of Persons
having signature authority with respect thereto or access thereto. The books
and records of the Company and its Subsidiaries are true and complete and have
been maintained in accordance with sound business practices, and reflect, in
reasonable detail, all material transactions involving the Company and its
Subsidiaries and their respective businesses.

 

Interested Party Transactions

 

.

 

 Except as set forth in Section 4.24 of the Company Disclosure Schedule,
there are no existing, and since December 31, 2016 there have been no,
Contracts, transactions, Indebtedness or other arrangements, or any related
series thereof, between the Company or any of its Subsidiaries, on the one
hand, and any of the directors, managers, managing directors, officers,
Equityholders, Series D Holders or other Affiliates of the Company or any of
its Subsidiaries, or any of their respective Affiliates or family members, on
the other hand (except for (i) indemnification agreements on the standard form
made available to the Parent that were entered into with the officers or
directors of the Company or its Subsidiaries in the ordinary course of
business consistent with past practice, (ii) at-will employment and invention
assignment agreements on the standard forms made available to Parent that were
entered into with employees of the Company or its Subsidiaries in the ordinary
course of business consistent with past practice, (iii) amounts due as
salaries and bonuses to employees of the Company or its Subsidiaries in the
ordinary course of business consistent with past practice for services
rendered to the Company or its Subsidiaries, (iv) amounts paid to employees of
the Company pursuant to, and in accordance with the terms of, Employee Plans
listed in Section 4.13(a) of the Company Disclosure Schedule in the ordinary
course of business consistent with past practice or (v) reimbursements of
ordinary expenses in the ordinary course of business consistent with past
practice). There is no Indebtedness owed to the Company or any of its
Subsidiaries by any employee, Contract Worker, officer, director, manager,
managing director, Equityholder, Series D Holder, sales representative,
distributor or agent of the Company or any of its Subsidiaries, other than
salary advances or travel expenses in the ordinary course of business
consistent with past practice. To the Knowledge of the Company, no officer,
director, manager or managing director of the Company or any of its
Subsidiaries (or any member of the immediate family of any such officer,
director, manager or managing director) has any direct or indirect ownership
interest in any firm or corporation with which the Company or any of its
Subsidiaries has a business relationship, or any firm or corporation that
competes with the Company or any of its Subsidiaries, except that officers,
directors, managers or managing directors of the Company or any of its
Subsidiaries (and members of their immediate families) may own a de minimis
portion of the publicly-traded stock of (but not exceeding two percent (2%) of
the outstanding capital stock of) companies that may compete with the Company
or any of its

 

49  

Subsidiaries. No member of the immediate family of any officer, director,
manager or managing director of the Company or any of its Subsidiaries is
directly or indirectly interested in any Material Contract.

 

Accounts Receivable and Accounts Payable

 

.

 

(a)Subject to any reserves set forth in the Financial Statements, the accounts
receivable shown on the Financial Statements represent bona fide claims
against debtors for sales and other charges from arm's-length transactions
between unrelated parties in the ordinary course of business, consistent with
GAAP and the Company's past practices, requiring no further act (other than
preparing and mailing bills to customers with respect to unbilled accounts
receivable) under any circumstances on the part of the Company or any of its
Subsidiaries to cause such accounts receivable to be due and payable by the
account debtor with respect thereto. The amount carried for doubtful accounts
and allowances disclosed in the Financial Statements was calculated in
accordance with GAAP and in a manner consistent with prior periods.

 

(b)Except as set forth in Section 4.25(b) of the Company Disclosure Schedule,
all accounts payable of the Company and its Subsidiaries reflected in the
Financial Statements or arising thereafter are the result of bona fide
transactions in the ordinary course of business, consistent with past
practice, and have been paid or are not yet due or payable.

 

Existing Indebtedness.

 

 Section 4.26 of the Company Disclosure Schedule sets forth a true and
complete list as of the date of this Agreement of all Indebtedness of the
Company and its Subsidiaries (collectively, the "Existing Indebtedness"), and
provides (a) the names of the original lender and current holder (to the
extent that the Company or any of its Subsidiaries has received a written
notice of the assignment thereof); (b) outstanding principal balances and all
accrued and unpaid interest as of March 15, 2018; and (c) a list of all Liens
(if any) that secure such Existing Indebtedness. The information contained in
Section 4.26 of the Company Disclosure Schedule is complete and accurate in
all respects. True, correct and complete copies of all instruments (including
all amendments, supplements, waivers and consents) evidencing, providing
security for and relating to the Existing Indebtedness have been made
available to Parent. As of the Closing, assuming that Parent complies with
its obligations under Section 3.11(a), neither the Company nor any of its
Subsidiaries will have any outstanding Indebtedness.

 

Section 4.27Compliance with Privacy Laws.

 

(a)The Company, each of its Subsidiaries or any of the Employee Plans that
meet the definition of a "group health plan" under HIPAA (each, a "Group
Health Plan") are, and have been at all times, in compliance in all material
respects with all Laws governing the collection, maintenance, use, processing,
disclosure, privacy, protection or security of, and standard transactions
related to, Personal Data and the protection of consumers, including the
Gramm-Leach-Bliley Act and its implementing regulations ("GLBA"), HIPAA, the
Federal Trade Commission Act, the Genetic Information Nondiscrimination Act of
2008 (GINA) and its implementing Regulations (29 C.F.R.  1635), state health
information privacy laws, state data breach notification laws and all
applicable international privacy and data security laws, each as amended from
time to time, and any Regulations implemented pursuant to any of the foregoing
(collectively, "Applicable Privacy Laws"). Neither the Company nor any of its
Subsidiaries or Group Health Plans has received any written or other notice
of, or been charged with, the violation of any Applicable Privacy Laws, and
there are no pending investigations of the Company or any of its Subsidiaries
by any Governmental

 

50  

Authority relating to Applicable Privacy Laws, or civil actions against the
Company or any of its Subsidiaries alleging any violation of Applicable
Privacy Laws.

 

(b)To the Knowledge of the Company, there are no facts, circumstances or
conditions that would reasonably be expected to form the basis for any Claim
against or affecting the Company or any of its Subsidiaries relating to or
arising under Applicable Privacy Laws. All Personal Data that the Company or
any of its Subsidiaries has shared, or will share, with Parent or its any of
its Affiliates, or that will be transferred to Parent or any of its Affiliates
pursuant to the terms of this Agreement (including indirectly by virtue of the
Merger), has been collected, maintained and used at all times in compliance in
all material respects with (i) the requirements of the Applicable Privacy
Laws, (ii) the requirements of Contracts to which the Company or any of its
Subsidiaries is a party, and (iii) any consents or authorizations received
from Persons about whom the Personal Data relates ("Data Subject Consents").
Without limitation to the foregoing, the Company and each of its Subsidiaries
has received and maintained all Data Subject Consents that are necessary in
order for the Company and each of its Subsidiaries to use and disclose
Personal Data in the manner in which it has used and disclosed that Personal
Data. None of (A) the Company's or its Subsidiaries' sharing of Personal
Data with Parent or any of its Affiliates, (B) the Company's or its
Subsidiaries' transfer of Personal Data to Parent or any its Affiliates
pursuant to the terms of this Agreement (including indirectly by virtue of the
Merger) or (C) use of that Personal Data in a manner consistent with the
manner in which the Company and its Subsidiaries have used that Personal Data,
will breach any of the Company's or its Subsidiaries' obligations under
Applicable Privacy Laws, Contracts to which the Company or such Subsidiary is
a party, or Data Subject Consents.

 

(c)When required by Applicable Privacy Laws, the Company, each of its
Subsidiaries and each Group Health Plan has entered into a Contract that
addresses the provisions for "business associate contracts" required by 45
C.F.R.  164.504(e) or  164.314(a), as amended, with the applicable third
party in each instance where (i) the Company, its Subsidiary or a Group Health
Plan acts as a business associate (as defined in 45 C.F.R.  160.103) to that
third party, (ii) the Company, its Subsidiary or a Group Health Plan provides
protected health information (as defined in 45 C.F.R.  160.103) to that third
party, or (iii) that third party otherwise acts as a business associate to the
Company, its Subsidiary or a Group Health Plan, in each case as required by,
and in conformity with, Applicable Privacy Laws and the applicable Contracts
to which the Company, its Subsidiary or any Group Health Plan is a party.

 

(d)The Company and each of its Subsidiaries have implemented reasonable
administrative, physical, and technical safeguards to protect the
confidentiality, integrity and security of all Personal Data and all computer
systems, including software, hardware, databases, firmware, middleware and
platforms, interfaces, systems, networks, information technology equipment,
facilities, websites, infrastructure, workstations, switches, data
communications lines and associated documentation used or held for use by or
on behalf of the Company or any of its Subsidiaries in connection with the
conduct of their businesses ("IT Assets") against any unauthorized control,
use, access, interruption, modification or corruption in material conformance
with all Applicable Privacy Laws.

 

(e)To the Knowledge of the Company, there has been no data security breach or
unauthorized access, control, use, modification or destruction of any IT
Asset, or unauthorized access, use, acquisition or disclosure of any Personal
Data owned, used, stored, received, or controlled by or on behalf of the
Company, including any unauthorized access, use or disclosure of Personal Data
that would constitute a breach for which notification to individuals or
governmental

 

51  

authorities is required under any Applicable Privacy Laws or Contracts to
which the Company, any of its Subsidiaries or any Group Health Plan is a
party.

 

(f)The Company and each of its Subsidiaries transfer personal data from
countries in the European Economic Area to recipients in third countries that
do not provide an equivalent level of data protection only on the basis of and
in compliance with the Applicable Privacy Laws.

 

Section 4.28Medical Device Regulatory and Related Matters.

 

(a)The Company and its Subsidiaries are, and have been within the last 5
years, in material compliance with (i) the Federal Food, Drug, and Cosmetic
Act (the "FDandC Act"), 21 U.S.C.  301 et. seq., (ii) applicable EU Medical
Device Directives and any related national legislation of individual EU Member
States implementing the provisions of the EU Medical Device Directives into
their national laws and (iii) applicable equivalent Laws, including those
relating to investigational devices, clinical studies, premarket clearance or
approval, medical device registration and listing, facility registration, good
manufacturing practices, informed consent, good clinical practices, good
laboratory practices, labeling, promotion, export, recalls, record keeping and
filing of reports (the legislation, directives, regulations and other Laws
described in the foregoing clauses (i), (ii) and (iii), collectively, "FDA Law
and Regulation").

 

(b)Except as set forth in Section 4.28(b) of the Company Disclosure Schedule,
none of the Company's facilities have been inspected by the FDA or a
comparable foreign Governmental Authority within the past five (5) years.

 

(c)Except as set forth in Section 4.28(c) of the Company Disclosure Schedule,
neither the Company nor any of its Subsidiaries has received any written
notice or written communication from the FDA or comparable foreign
Governmental Authority alleging noncompliance with any applicable FDA Law and
Regulation. Neither the Company nor any of its Subsidiaries is subject to any
enforcement proceedings by the FDA or comparable foreign Governmental
Authority and, to the Knowledge of the Company, no such proceedings have been
threatened. There is no Claim, warning letter, untitled letter, Governmental
Investigation or enforcement action pending against the Company or any of its
Subsidiaries. To the Knowledge of the Company, there is no act, omission,
event, or circumstance that could reasonably give rise to or lead to, any such
Claim, warning letter or untitled letter or any similar Liability. To the
Knowledge of the Company, no director, manager, managing director, officer,
employee, Contract Worker or agent of the Company or any of its Subsidiaries:
(i) has made any untrue statement of material fact or fraudulent statement to
the FDA or any other Governmental Authority; (ii) has failed to disclose a
material fact required to be disclosed to the FDA or any other Governmental
Authority; (iii) has committed an act, made a statement, or failed to make a
statement that would reasonably be expected to provide the basis for the FDA
or any other Governmental Authority to invoke its policy respecting "Fraud,
Untrue Statements of Material Facts, Bribery, and Illegal Gratuities," as set
forth in 56 Fed.Reg. 46191 (September 10, 1991); (iv) has been convicted of
any crime or engaged in any conduct for which debarment is mandated or
permitted by 21 U.S.C.  335a; or (v) has been convicted of any crime or
engaged in any conduct for which such Person or entity could be excluded from
participating in the federal health care programs under Section 1128 of the
Social Security Act, as amended, or any similar law or regulation. The
Company and its Subsidiaries have never been and are not now subject to FDA's
Application Integrity Policy or comparable Law enacted by a comparable foreign
Governmental Authority. No current director, manager, managing director,

 

52  

officer, employee, Contract Worker or agent of the Company or any of its
Subsidiaries, and, to the Knowledge of the Company, no former director,
manager, managing director or officer of the Company or any of its
Subsidiaries, is listed on an "Exclusion List," meaning the current (A)
HHS/OIG List of Excluded Individuals/Entities (available through the Internet
at http://www.oig.hhs.gov), (B) General Services Administration's System for
Award Management (available through the Internet at http://www.sam.gov) and
(C) FDA Debarment List (available through the Internet at
http://www.fda.gov/ora/compliance_ref/debar/).

 

(d)Neither the Company nor any of its Subsidiaries has introduced in
commercial distribution or exported outside the U.S. within the past five (5)
years any Products that were upon their shipment by the Company or any of its
Subsidiaries adulterated or misbranded in violation of 21 U.S.C.  331 or
comparable foreign Law.

 

(e)Premarket Approval Application, P170036, for the M6-C Disc was submitted to
FDA on or about October 31, 2017 and has since been accepted for filing, and
is currently under review by FDA. The submitted indicated use in P170036 is
"for replacement of the disc following single level discectomy in skeletally
mature patients with intractable degenerative cervical radiculopathy with or
without spinal cord compression (Nurick's Classification  2) at one level
from C3 - C7. The disease state is defined as discogenic neck and/or arm pain
and is demonstrated by signs and/or symptoms (e.g., numbness, weakness,
pathologic reflexes, mild gait disturbances, etc.) of disc herniation and/or
osteophyte formation and is confirmed by patient history and radiographic
studies. Surgery is recommended when all of the following are present:
cervical root compression visualized on MRI, concordant symptoms and signs of
cervical root-related dysfunction, pain or both; and persistence of pain
despite conservative management for at least 6 weeks. The M6-C is implanted
via an open anterior approach."

 

(f)All pre-clinical testing and clinical trials funded or conducted by, or on
behalf of, the Company or its Subsidiaries were conducted in material
compliance with experimental protocols, procedures and controls, accepted
professional scientific standards and applicable Laws. Neither the Company
nor any of its Subsidiaries has received any notices, correspondence or other
communication from the FDA, the FDA's Center for Devices and Radiological
Health, or any other Governmental Authority requiring the termination or
suspension of any clinical trials conducted by, or on behalf of, the Company
or any of its Subsidiaries.

 

(g)Except as set forth on Schedule 4.28(g) of the Company Disclosure Schedule,
the Company and the Company's Subsidiaries and, to the Company's Knowledge,
their respective suppliers are, and have been for the past five (5) calendar
years, in compliance with, and each Product regulated as a medical device in
current commercial distribution is, to the extent applicable, designed,
manufactured, prepared, assembled, packaged, labeled, stored, installed,
serviced, exported, distributed, and processed in compliance with, the Quality
System Regulation set forth in 21 C.F.R. Part 820 (as may be amended from time
to time), or, as applicable, a quality management system that is accepted by a
comparable foreign Governmental Authority, including ISO 13485 and ISO 9000
series.

 

(h)Section 4.28(h) of the Company Disclosure Schedule sets forth a true and
complete list of all permits, licenses, registrations, certificates, orders,
clearances or other Approvals issued under the FDandC Act or foreign equivalent
Law (collectively, the "Regulatory Permits") and held exclusively by the
Company or any of its Subsidiaries. Such listed Regulatory Permits are the
only permits (including licenses, registrations, certificates, orders,
clearances or approvals) issued

 

53  

under the FDandC Act and foreign equivalent Law that are required for the
Company and its Subsidiaries to conduct their respective businesses as
currently conducted. The Company and its Subsidiaries have been and are in
material compliance with the terms of each such Regulatory Permit. To the
Knowledge of the Company, no revocation, suspension, cancellation or material
adverse modification of any such Regulatory Permit is threatened and there is
no basis for believing that such Regulatory Permit will not be renewable upon
expiration. To the Knowledge of the Company, all material applications
required to have been filed for the renewal of the Regulatory Permits have
been duly filed with the appropriate Governmental Authority, and all other
material filings required to have been made with respect to the Regulatory
Permits and applicable Laws have been duly made on a timely basis with the
appropriate Governmental Authority. Each such Regulatory Permit is currently
in full force and effect and will continue in full force and effect
immediately following the Effective Time.

 

(i)Each of the Company's and the Company's Subsidiaries' facilities are
registered with the FDA and each Product is listed with the FDA under the
applicable FDA registration and listing regulations for medical devices.

 

(j)Neither the Company nor any of its Subsidiaries has initiated, participated
in or experienced, either voluntarily or at the request of any Governmental
Authority, any withdrawal, removal, recall, field safety corrective action,
suspension of a clinical trial or clinical hold as a result of the design,
manufacture, ownership, possession, clinical development, clinical
investigation, clinical evaluation, distribution, marketing promotion, sale,
provision, implanting or other use of any Products or any services performed,
nor are there any pending or, to the Knowledge of the Company, threatened
withdrawals, removals, recalls, field safety corrective actions, suspensions
of clinical trials, clinical holds or claims with respect to any Products or
any services performed for which the Company or any its Subsidiaries has or
may have a continuing Liability. No seizures have been made and no adverse
regulatory actions have been taken, and there are no pending or, to the
Knowledge of the Company, threatened seizures or regulatory actions, by the
FDA or any other Governmental Authority with respect to any of the Products,
including with respect to any facilities where any of the Products are
manufactured, processed, packaged or stored. Except as set forth in Section
4.28(j) of the Company Disclosure Schedule, to the Knowledge of the Company,
there are no facts that would reasonably be expected to cause the Company or
any of its Subsidiaries to withdraw, remove, recall, correct or suspend any
Products from the market, to issue a field safety notice, to suspend any
clinical trial or to change the marketing classification of any Products.

 

Section 4.29Health Care Regulatory and Related Matters.

 

(a)The Company and its Subsidiaries are currently and, for the five (5) year
period prior to the date of this Agreement have been, operating in compliance
with all applicable Health Care Laws (except for such non-compliance as would
not, individually or in the aggregate, impair or result in the impairment of
the business or operations of, or otherwise give rise to a material Liability
of, the Company or any of its Subsidiaries) and no officer, director, manager
or managing director of the Company or any Subsidiary of the Company, or, to
the Knowledge of the Company, any other Person, has engaged in any act on
behalf of the Company or any of its Subsidiaries that violates any Health Care
Law. "Health Care Laws" shall mean all Laws relating to the production,
preparation, propagation, pricing, marketing, promotion, sale, distribution,
coverage or reimbursement of a drug, device, biological or other medical item,
supply or service, including (i) the Federal Health Care Program Anti-Kickback
Statute, 42 U.S.C.  1320a-7b(b); the Federal civil False Claims Act, 31
U.S.C.  3729-3733; the criminal provisions under HIPAA; the Program

 

54  

Fraud Civil Remedies Act, 31 U.S.C.  3801-3812; the criminal False Claims
Law, 42 U.S.C.  1320a-7b(a), the Civil Monetary Penalties Law, 42 U.S.C. 
1320a-7a; the exclusion authorities, 42 U.S.C.  1320a-7; the Physician
Payment Sunshine Act, 42 U.S.C.  1320a-7h; Medicare and Medicaid coverage and
reimbursement provisions (Titles XVIII and XIX of the Social Security Act);
and the applicable requirements of Medicare, Medicaid and other health care
programs of other Governmental Authorities, including the Veterans Health
Administration and U.S. Department of Defense health care and contracting
programs, each as amended, and any regulations promulgated thereunder; and
(ii) any comparable foreign, local, state or federal health care Laws,
including  299, 299a/b and 331 et seq. of the German Criminal Code
(Strafgesetzbuch), the German Act on Advertising in the Health Care Sector
(Heilmittelwerbegesetz), the German Act against Unfair Competition (Gesetz
gegen den unlauteren Wettbewerb), and  128 of the German Social Code V
(Sozialgesetzbuch V), each as amended, and the applicable regulations
promulgated thereunder.

 

(b)All Contracts, participations in the Company or its Subsidiaries and joint
ventures and other business relationships with potential customers,
prescribers or other sources of orders or referrals, including consulting,
speaker, development, sponsorship, grant and royalty agreements with, and
training events for, physicians, other health care professionals or providers,
governmental representatives or health care organizations, comply in all
material respects with all Health Care Laws.

 

(c)Except as set forth in Section 4.29(c) of the Company Disclosure Schedule,
currently and for the five (5) year period prior to the date of this
Agreement, none of the Company, any Subsidiary of the Company, or any of their
respective employees, officers, directors, managers or managing directors has
received any notice or other communication from a Governmental Authority,
vendee or other Person that alleges that the Company or any of its
Subsidiaries (or such employee, officer, director, manager or managing
director) is in violation of, or is otherwise not in compliance with, any
Health Care Law, and, to the Knowledge of the Company, there are no facts,
circumstances or conditions that would reasonably be expected to give rise to
such an allegation.

 

(d)Except as set forth in Section 4.29(d) of the Company Disclosure Schedule,
currently and for the five (5) year period prior to the date of this
Agreement, neither the Company nor any of its Subsidiaries has received any
subpoena, civil investigative demand or formal or informal request for
information or documents, or, to the Knowledge of the Company, been the
subject of a Governmental Investigation, in connection with any violation of,
or any suspected or alleged violation of, any Health Care Law. To the
knowledge of the Company, no Governmental Investigation with respect to the
Company or any Subsidiary is pending or threatened.

 

(e)None of the Company, any Subsidiary of the Company or any of their
respective officers, directors, managers, managing directors or employees is
excluded from any federal health care program as that term is defined by 42
U.S.C.  1320a-7b(f) or is debarred, restricted or prohibited from
participation in any health care, procurement or nonprocurement program or
reimbursement system authorized, funded, administered or sponsored by any
Governmental Authority. None of the Company, any Subsidiary of the Company,
or any of their respective officers, directors, managers, managing directors
or employees (i) has engaged in, been charged with or been investigated for
any conduct that would reasonably be expected to result in exclusion from any
federal health care program or debarment or any other sanction under similar
foreign, state, or local applicable Law, or (ii) has otherwise engaged in any
activities that would reasonably be expected to provide cause for civil,
criminal or administrative penalties or sanctions or mandatory or permissive
exclusion under any Health Care Laws.

 

55  

(f)There have not been and currently are no actions (including enforcement,
criminal, regulatory or administrative proceedings), audits or recoupment by
or before any Governmental Authority alleging a violation of Health Care Laws
by the Company, any of its Subsidiaries, or any of their respective employees,
officers, directors, managers or managing directors. Neither Company nor any
Subsidiary of the Company is a party to any corporate integrity agreement,
monitoring agreement, consent decree, settlement order, deferred prosecution
agreement, non-prosecution agreement or similar agreement with or imposed by
any Governmental Authority.

 

(g)All material documents, reports and notices required to be maintained or
filed with any Governmental Authority by the Company or any of its
Subsidiaries with respect Health Care Laws have been so maintained or filed on
a timely basis, and were complete and accurate in all material respects as of
the date of filing. No such filing with any Governmental Authority contains
any statement or information that, as of the date such filing was made, was
(expressly or due to omission of material information) materially false or
misleading.

 

Section 4.30Trade Compliance Matters.

 

(a)At all times during the past five (5) years, the Company and each of its
Subsidiaries have been in compliance with all applicable export control and
economic sanctions laws and regulations of the United States and other
countries (collectively, the "Trade Control Laws"), including the U.S. Export
Administration Regulations ("EAR") (15 C.F.R. Part 730 et seq.), the EAR's
rules on Restrictive Trade Practices or Boycotts (15 C.F.R. Part 760, the so-
called "Anti-Boycott Regulations"), the Arms Export Control Act and the
International Traffic in Arms Regulations (22 C.F.R. Part 120 et seq.), all
laws and regulations related to import and customs requirements, and the
economic sanctions laws and regulations implemented under statutory authority
or Presidential Executive Orders and administered by the U.S. Department of
the Treasury's Office of Foreign Assets Control (31 C.F.R. Part 500 et seq.;
collectively, the "OFAC Regulations") or implemented by the European Union, EU
member states, and other relevant governmental authorities.

 

(b)At all times during the past five (5) years, the Company and each of its
Subsidiaries have obtained from the relevant government agencies all required
licenses, license exceptions, and other material consents, notices, waivers,
approvals, orders, authorizations, registrations, declarations,
classifications, and filings required for the sale, supply, export, transfer
and import of hardware, software, technology and services in accordance with
applicable Trade Control Laws.

 

(c)Neither the Company nor any of its Subsidiaries, nor, to the knowledge of
the Company, any of their respective officers, directors, managers, managing
directors, employees or agents, appear on, or is owned or controlled by any
Person that appears on, restricted party lists maintained by any relevant
government authority, including the Specially Designated Nationals and Blocked
Persons List, Denied Persons List, Unverified List, Entity List and Debarred
Parties List maintained by the Bureau of Industry and Security of the U.S.
Department of Commerce or the Debarred Parties List maintained by the
Directorate of Defense Trade Controls of the U.S. Department of State
(collectively, "Restricted Parties").

 

(d)Neither the Company nor any of its Subsidiaries (i) have, or in the past
five (5) years have had, any transactions with, accounts receivable from or
accounts payable to, (ii) are, or in the past five (5) years have been, a
party to or a beneficiary under any Contract with, or (iii) are, or

 

56  

in the past five (5) year have, engaged in any other activities directly or
indirectly with or involving, in each case of the foregoing clauses (i), (ii)
and (iii), Cuba, Iran, North Korea, Sudan, Syria, Crimea, or any Restricted
Party. 

 

(e)At no time during the past five (5) years has the Company or any its
Subsidiaries (i) been cited or fined for failure to comply with Trade Control
Laws, and no charge, proceeding or, to the Knowledge of the Company,
investigation, complaint, or inquiry by any Governmental Authority with
respect to any alleged non-compliance with Trade Control Laws by the Company
or any of its Subsidiaries is pending or, to the Knowledge of the Company, has
been asserted or threatened with respect to the Company or any of its
Subsidiaries; or (ii) made any disclosures (voluntary or otherwise) to any
relevant governmental agency with respect to any potential violation or
liability of the Company or any of its Subsidiaries arising under or relating
to any Trade Control Laws.

 

(f)The Company and each of its Subsidiaries are in compliance in all material
respects with all applicable U.S. and non-U.S. customs Laws and Regulations,
including any export or import declaration filing, payment of customs duties,
compliance with import quotas, import registration or any other similar
requirements related to the exportation or importation of goods or services by
the Company or any of its Subsidiaries. As of the date of this Agreement,
Section 4.30(f) of the Company Disclosure Schedule lists each special import
or export program in which the Company participates, including any temporary
importation, bonded warehouse, expedited customs clearance or processing,
drawback or similar program entitling the Company or any of its Subsidiaries
to customs or Tax benefits related to the importation or exportation of its
goods or services. The Company and its Subsidiaries are in compliance in all
material respects with all requirements imposed under any such programs.
There is no charge, proceeding or, to the Knowledge of the Company,
investigation by any Governmental Authority with respect to a material
violation of any applicable U.S. or non-U.S. customs Laws or Regulations that
is now pending or, to the Knowledge of the Company, threatened with respect to
the Company or any of its Subsidiaries.

 

Anti-Money Laundering.

 

 The operations of the Company and its Subsidiaries are and have been
conducted at all times in compliance in all material respects with all anti-
money laundering Laws and all applicable financial record keeping and
reporting requirements, rules, regulations applicable to the Company and its
Subsidiaries (collectively, "Money Laundering Laws") and no Claim by or before
any Governmental Authority involving the Company or any of its Subsidiaries
with respect to Money Laundering Laws is pending and, to the Knowledge of the
Company, no such Claims are threatened or contemplated.

 

Ethical Practices.

 



 

(a)Neither the Company nor any Subsidiary of the Company, nor any of their
respective directors, managers, managing directors, officers, employees,
agents, Contract Workers or representatives, nor any other Person acting for
or on behalf of (or, to the Knowledge of the Company, purporting to act for or
on behalf of) the Company or any Subsidiary of the Company, directly or
indirectly, has:

 

(i)violated or is in violation of any provision of any Improper Payment Law;

 

57  

(ii)(A) made, given, undertaken, caused to be made or given, offered to make
or give, promised to make or give, or authorized, ratified or facilitated the
making or giving of any bribe, rebate, payoff, influence payment, facilitation
payment, kickback or other payment or gift of money or any other thing of
value to any Person, or (B) given, caused to be given, offered to give,
promised to give, or authorized, ratified or facilitated the giving of any
political contribution or charitable contribution, or any advantage, to any
Person, in each case of the foregoing clauses (A) and (B), (x) in violation
of, or that is prohibited under, any Improper Payment Law, or (y) otherwise
for the purpose of influencing any act or decision of such payee in his
official capacity, inducing such payee to do or omit to do any act in
violation of his lawful duty, securing any improper advantage, inducing such
payee to use his influence with a government or instrumentality thereof to
affect or influence any act or decision of such government or instrumentality
or to secure any improper advantage, or inducing such payee to enter into a
commercial arrangement in violation of applicable Law;

 

(iii)requested or received any payment, gift, political contribution,
charitable contribution or other thing of value or advantage in violation of,
or that is prohibited under, any Improper Payment Law;

 

(iv)(A) been subject to, or received notice with respect to, any actual,
pending or, to the Knowledge of the Company, threatened or reasonably
anticipated civil, criminal or administrative Claim with respect to any matter
or conduct of the type described in the foregoing clause (i), (ii) or (iii);
(B) been subject to, or received notice of, any allegation of (x) any
violation of, or conduct violative of, any Improper Payment Law or (y) any
matter or conduct of the type described in the foregoing clause (i), (ii) or
(iii); or (C) made any voluntary disclosure to any Governmental Authority with
respect to any matter or conduct of the type described in the foregoing clause
(i), (ii) or (iii); or

 

(v)established or maintained a secret or unrecorded fund (or made any promise
or undertaking in such regard).

 

(b)There have been no false or fictitious entries made in the books or records
of the Company or any of its Subsidiaries relating to (i) any secret or
unrecorded fund or (ii) any unlawful payment, gift, political contribution,
charitable contribution or other thing of value or advantage (including any
payment, gift, political contribution, charitable contribution or other thing
of value or advantage of the type described in Section 4.32(a)(ii) or Section
4.32(a)(iii))

 

(c)For the avoidance of doubt, any reference to "other thing of value" in this
Section 4.32 includes meals, entertainment, travel and lodging, and any
reference to "representatives" of the Company or any of its Subsidiaries in
this Section 4.32 includes distributors, sales agents, third-party
representatives, commercial intermediaries, partners and joint venturers.

 

Inventory.

 

 All items included in the inventories of the Company and its Subsidiaries
consist of items of a quality usable or saleable in the ordinary course of
business consistent with past practice (except for an immaterial number of
obsolete or damaged items that have been written off or for which adequate
reserves have been established in the Financial Statements) and are in
quantities sufficient for the normal operation of the business in accordance
with past practice. The inventories of the Company and its Subsidiaries set
forth on the Financial Statements were properly stated therein at the lesser
of cost or fair market value determined in accordance with GAAP. Inventories
now on hand that were purchased after December 31, 2016

 

58  

were purchased in the ordinary course of business at a cost not exceeding
market prices prevailing at the time of purchase. All of the inventories are
owned by the Company or one of its Subsidiaries free and clear of all Liens
(other than Permitted Liens). 

 

Customers, Suppliers and Distributors.

 

 Section 4.34 of the Company Disclosure Schedule lists (a) the names of the
twenty (20) most significant customers of the Company and its Subsidiaries
(measured by dollar volume of sales by the Company or any Subsidiary of the
Company to such customers) for the period from January 1, 2017 through
December 31, 2017 ("Significant Customers"); (b) the ten (10) most significant
suppliers from which the Company or any Subsidiary of the Company purchased
materials, supplies, services or other goods (measured by dollar volume of
purchases by the Company or any Subsidiary of the Company from such suppliers)
for the period from January 1, 2017 through December 31, 2017; (c) each sole
source supplier of the Company or any Subsidiary of the Company (such
suppliers in clauses (b) and (c) are collectively referred to as "Significant
Suppliers"), and the amount for which each such Significant Supplier invoiced
the Company or any Subsidiary of the Company during such period; and (d) lists
the names of all distributors (including distributors, sales agents,
manufacturer's representatives, commission agents, third party sales
organizations, lead finders or any Person who acts or acted on behalf of the
Company or any of its Subsidiaries or represents or represented the Company or
any of its Subsidiaries in dealing with the customers of the Company or its
Subsidiaries) of the Company or any of its Subsidiaries for the period from
January 1, 2017 through the date of this Agreement ("Company Distributors").
Neither the Company nor any of its Subsidiaries has received any written or,
to the Knowledge of the Company, oral notice that (i) any Significant Customer
has ceased or will cease to purchase or use the Products, equipment, goods or
services of the Company or any of its Subsidiaries or has substantially
reduced or will substantially reduce the purchase or use of such Products,
equipment, goods or services, (ii) that any Significant Supplier has ceased or
will cease to supply materials, supplies, services or other goods to the
Company or any of its Subsidiaries after the date hereof on terms and
conditions similar in all material respects to those imposed on current sales
to the Company and its Subsidiaries, or (iii) that any Company Distributor has
ceased or will cease to purchase, sell or use the Products, equipment, goods
or services of the Company or any of its Subsidiaries or has substantially
reduced or will substantially reduce the purchase, sale or use of such
Products, equipment, goods or services.

 



 

Product Liability; Product Warranty.

 

 Section 4.35 of the Company Disclosure Schedule sets forth a description of
the standard warranties still in effect or currently offered by the Company or
any of its Subsidiaries. Except as set forth in Section 4.35 of the Company
Disclosure Schedule, all Products and services sold, provided or delivered
within the last five years by the Company or any of its Subsidiaries were
designed, manufactured, prepared, assembled, packaged, labeled, sterilized,
stored, serviced and processed in compliance, in all material respects, with
applicable Law, applicable contractual commitments, express and implied
warranties, Product and service specifications and quality standards, and, to
the Knowledge of the Company, other than as reserved for in the ordinary
course of business, neither the Company nor any of its Subsidiaries has any
Liability for replacement or repair thereof or other damages in connection
therewith. Except as set forth in Section 4.35 of the Company Disclosure
Schedule, no Product or service sold, provided or delivered by the Company or
any of its Subsidiaries to customers on or prior to the Closing is subject to
any guaranty, warranty (other than warranties imposed by law) or other
indemnity beyond the applicable standard terms and conditions of sale. Except
as set forth in Section 4.35 of the Company Disclosure Schedule, neither the
Company nor any of its Subsidiaries has any Liability arising out of any
injury to a Person or property as a result of the ownership, design,
manufacture, possession, provision, clinical development, distribution,
marketing, promotion, sale,

 

59  

implanting, or other use of any equipment, Product or service sold, provided
or delivered by the Company or any of its Subsidiaries on or prior to the
Closing. All Claims (including those relating to clinical trials) against or
involving or, to the Knowledge of the Company, threatened against the Company
or any of its Subsidiaries that are pending or were asserted within the last
five years and that relate in any way to one or more Products, whether covered
by insurance or not and whether litigation has resulted or not, are listed and
summarized in Section 4.35 of the Company Disclosure Schedule. Except as set
forth in Section 4.35 of the Company Disclosure Schedule, within the last five
years, no allegation has been asserted that any of the Products contains a
design defect or a manufacturing defect.

 

Article 5 
REPRESENTATIONS AND WARRANTIES OF PARENT AND MERGER SUB

 



 

Parent and Merger Sub hereby, jointly and severally, represent and warrant to
the Company as follows:

 

Organization and Qualification.

 

 Parent is a corporation duly incorporated, validly existing and in good
standing under the Laws of the State of Massachusetts. Merger Sub is a
corporation duly incorporated, validly existing and in good standing under the
Laws of the State of Delaware. Merger Sub is a newly formed entity that has
been formed solely for the purposes of the Merger and does not carry on any
business or engage in any activities other than those reasonably related to
the Merger and the other transactions contemplated by this Agreement.

 

Authority; Enforceability.

 

 Each of Parent and Merger Sub has all necessary corporate power and
authority to execute and deliver this Agreement and, in the case of Parent,
the Escrow Agreement, to perform their respective obligations hereunder and
thereunder and to consummate the transactions contemplated hereby and thereby
(including, in the case of Merger Sub, the Merger). The execution and
delivery by each of Parent and Merger Sub of this Agreement and by Parent of
the Escrow Agreement, the performance of their respective obligations
hereunder and thereunder, and the consummation by Parent and Merger Sub of the
transactions contemplated hereby and thereby (including, in the case of Merger
Sub, the Merger) have been duly and validly authorized by the Board of
Directors of Parent and Merger Sub and (in the case of this Agreement and the
transactions contemplated thereby, including the Merger) by Parent as the sole
stockholder of Merger Sub. No further corporate action is required on the
part of Parent or Merger Sub to authorize (a) this Agreement or the Escrow
Agreement or (b) the Merger or the other transactions contemplated hereby
(other than, in the case of the consummation of the Merger, the filing and
recordation of appropriate merger documents as required by the DGCL). This
Agreement has been duly and validly executed and delivered by each of Parent
and Merger Sub, and assuming the due authorization, execution and delivery
hereof by the Company and the Equityholders' Representative, constitutes a
legal, valid and binding obligation of each of Parent and Merger Sub,
enforceable against each of Parent and Merger Sub in accordance with its
terms, subject to the effects of (i) bankruptcy, insolvency, fraudulent
conveyance, reorganization, moratorium and other similar Laws relating to or
affecting creditors' rights generally, and (ii) general equitable principles
(whether considered in a proceeding in equity or at law). The Escrow
Agreement will have been duly and validly executed and delivered by Parent as
of the Closing, and, when so executed and delivered (assuming the due
authorization, execution and delivery thereof by the other parties thereto),
will constitute a legal, valid and binding obligation of Parent, enforceable
against it in accordance with its terms, subject to the effects of (i)
bankruptcy, insolvency, fraudulent conveyance, reorganization, moratorium and

 

60  

other similar Laws relating to or affecting creditors' rights generally, and
(ii) general equitable principles (whether considered in a proceeding in
equity or at law).

 

Section 5.3No Conflict; Required Filings and Consents.

 

(a)None of (x) the execution or delivery by Parent and Merger Sub of this
Agreement or by Parent of the Escrow Agreement, (y) the performance by Parent
and Merger Sub of this Agreement or by Parent of the Escrow Agreement, or (z)
the consummation of the Merger or any other transactions contemplated by this
Agreement or the Escrow Agreement, in each case of the foregoing clauses (x),
(y) and (z), (i) conflict with or violate any certificate of incorporation or
bylaws of Parent or Merger Sub, or (ii) subject to the filings and other
matters referred to in Section 5.3(b), conflict with or violate in any
material respect any Law or Order in each case applicable to Parent or Merger
Sub, or by which they or any of their respective properties, rights or assets
are bound or affected.

 

(b)The execution and delivery by Parent and Merger Sub of this Agreement and
by Parent of the Escrow Agreement do not, and the performance by Parent and
Merger Sub of this Agreement and by Parent of the Escrow Agreement shall not,
require Parent or Merger Sub to obtain any Approval of any Person or observe
any waiting period imposed by, or make any filing with or notification to, any
Governmental Authority, except for (i) compliance with any applicable
requirements of the pre-merger notification requirements of the HSR Act and
applicable Foreign Competition Laws, (ii) the filing and effectiveness of the
Certificate of Merger in accordance with the DGCL, and (iii) Approvals,
waiting periods, filings or notifications that would not reasonably be
expected to, individually or in the aggregate, materially impair or delay the
ability of Parent or Merger Sub to perform their respective obligations
hereunder, including the consummation of the Merger.

 

Available Funds.

 

 Parent has as of the date of this Agreement, and will have on the Closing
Date, a sufficient amount of cash or borrowing capacity under existing
committed credit facilities or loan agreements to satisfy Parent's payment
obligations pursuant to Sections 3.4, 3.9 and 9.4(a).

 

Article 6 
COVENANTS

 



 

Conduct of Business by the Company Pending the Merger

 

. The Company covenants and agrees that, between the date of this Agreement
and the earlier to occur of the Effective Time and the termination of this
Agreement pursuant to its terms, unless Parent shall otherwise specifically
consent in writing in advance (provided that such consent shall only be
requested and provided if consistent with applicable Law, and such consent
shall not be unreasonably withheld, conditioned or delayed), or unless
otherwise expressly required by this Agreement, the Company shall, and shall
cause each of its Subsidiaries to, conduct its business (i) in the ordinary
course of business and in a manner consistent with past practice and (ii) in
compliance with all applicable Laws and Orders. Without limiting the
generality of the foregoing, the Company shall use its commercially reasonable
efforts to, and shall cause each of its Subsidiaries to use its commercially
reasonable efforts to, (A) preserve intact its business organization and its
rights, assets and properties, including Intellectual Property, (B) keep
available the services of its officers, employees, Contract Workers, sales
representatives, distributors and sales agents (other than terminations for
cause in the ordinary course of business consistent with past practice), (C)
maintain

 

61  

in effect Material Contracts (other than those Material Contracts that expire
in accordance with their terms or terminations expressly provided for by this
Agreement), (D) pay Indebtedness for borrowed money and Taxes of the Company
or any of its Subsidiaries when due (subject to the right of Parent to review
and comment on any Tax Returns filed on or prior to the Closing Date) and (E)
preserve its relationships with customers, licensees, suppliers and other
Persons with which the Company or any of its Subsidiaries has business
relationships. In addition to and not in limitation of the foregoing, the
Company shall not, and shall cause its Subsidiaries not to, between the date
of this Agreement and the earlier to occur of the Effective Time and the
termination of this Agreement pursuant to its terms, directly or indirectly
do, or propose to do, any of the following without the prior written consent
of Parent (provided that such consent shall only be requested and provided if
consistent with applicable Law), unless otherwise expressly permitted by this
Agreement, required by applicable Law or otherwise expressly set forth in
Section 6.1 of the Company Disclosure Schedule:

 

(a)amend, propose to amend or otherwise change the Charter, the Bylaws or any
organizational documents of the Company's Subsidiaries, alter (through merger,
liquidation, reorganization, reclassification, recapitalization, restructuring
or in any other fashion) the corporate or capital structure or ownership of
the Company or any of its Subsidiaries, or commence any voluntary liquidation,
dissolution or winding up of the Company or any of its Subsidiaries, in each
case, except otherwise expressly provided in Section 6.19;

 

(b)issue, grant, sell, transfer, deliver, pledge, promise, dispose of or
encumber, or authorize the issuance, grant, sale, transfer, deliverance,
pledge, promise, disposition or encumbrance of, or alter, amend or modify the
terms of or rights or obligations under, (i) any shares of capital stock of
any class or series of the Company or any of its Subsidiaries, (ii) any other
ownership interests or Stock-Based Rights of the Company or any of its
Subsidiaries, (iii) any (A) securities or other instruments (including notes
or other evidences of Indebtedness or Stock-Based Rights) convertible into or
exchangeable for, (B) subscription rights, options or warrants to acquire, or
(C) other agreements or commitments of any character obligating it to issue,
in each case of the foregoing clauses (A), (B), and (C), any such shares,
interests or Stock-Based Rights (or any convertible or exchangeable
instruments or securities) or (iv) any other securities (including convertible
or exchangeable securities) or convertible or exchangeable instruments of the
Company or any of its Subsidiaries; provided, however, the Company may issue
shares of Common Stock or Series C Preferred Stock upon (x) the valid exercise
of Stock Options or Warrants outstanding as of the date of this Agreement
(excluding any early exercise of Stock Options), (y) the valid conversion of
Convertible Notes, Series C Preferred Stock or Series C-1 Preferred Stock
outstanding as of the date of this Agreement or issued pursuant to the
foregoing clauses (x);

 

(c)establish, amend or accelerate the vesting or rights under any stock option
plan, stock appreciation rights plan, stock purchase plan, phantom stock plan
or other equity incentive plan;

 

(d)adopt, ratify or effectuate a stockholders' rights plan or agreement or
similar plan or Contract;

 

(e)(i) declare, set aside or pay any dividend or other distribution (whether
in cash, stock or property or any combination thereof) in respect of any of
its capital stock (except that (A) a wholly owned Subsidiary of the Company
may declare and pay a dividend to its parent and (B) to the extent dividends
have accrued with respect to outstanding shares of Series D Preferred Stock
pursuant to Section 2.1 of the Charter, the Company may declare and pay such
accrued dividends

 

62  

with respect to such outstanding shares of Series D Preferred Stock in
accordance with Section 2.1 of the Charter), (ii) split, combine or reclassify
any of its capital stock, (iii) effect a recapitalization, (iv) issue or
authorize the issuance of any other securities in respect of, in lieu of or in
substitution for, shares of its capital stock, or (v) redeem, purchase (or
repurchase) or otherwise acquire, directly or indirectly, any of the capital
stock or other securities of the Company or any of its Subsidiaries (except
that the Company may redeem outstanding shares of Series D Preferred Stock as
provided in Section 3.2(a) or otherwise in accordance with Section 8 of the
Charter);

 

(f)sell, transfer, assign, deliver, lease, sublease, license, sublicense,
mortgage, pledge, encumber, impair or otherwise dispose of (in whole or in
part), or create, incur or assume any Lien (other than a Permitted Lien) on,
or otherwise cause to be subjected to any Lien (other than a Permitted Lien),
any of the material assets, material properties or securities of the Company
or any of its Subsidiaries (including any Intellectual Property or accounts
receivable), except for the sale of inventory in the ordinary course of
business consistent with past practice;

 

(g)(i) acquire any equity interests in, or otherwise acquire or form, any
entity or other Person, (ii) acquire any real property, or (iii) acquire any
rights, assets or properties other than in the ordinary course of business
consistent with past practice and in compliance with applicable Law;

 

(h)(i) incur or modify any Indebtedness or issue any debt securities or any
warrants or rights to acquire any debt security, (ii) assume, guarantee or
endorse, or otherwise become responsible for, the obligations of any other
Person, (iii) enter into any off-balance sheet financing arrangement or any
accounts receivable or payable financing arrangement, (iv) make any loans,
advances or enter into any other financial commitments (except for advances of
reasonable business expenses in the ordinary course of business consistent
with past practice and in compliance with applicable Law);

 

(i)authorize or make any capital expenditures outside of the ordinary course
of business consistent with past practice, or in excess of Fifty Thousand
Dollars ($50,000);

 

(j)(i) increase, accelerate or provide for additional compensation or benefits
(fringe or otherwise) to, or grant, agree to grant, pay or otherwise make
payable any incentive, bonus or similar compensation or rights to, any current
or former director, manager, managing director, officer, employee, Contract
Worker or agent of the Company or any of its Subsidiaries, (ii) grant, pay or
otherwise make payable any change in control, transaction-based, severance,
retention, continuation or termination pay to any current or former director,
manager, managing director, officer, employee, Contract Worker or agent of the
Company or any of its Subsidiaries, other than as required pursuant to
Employee Plans in existence as of the date of this Agreement and listed on
Section 4.13(a) of the Company Disclosure Schedule, (iii) loan or advance (or
forgive any such loan or advance of) any money or other property to any
current or former director, manager, managing director, officer, employee,
Contract Worker or agent of the Company or any of its Subsidiaries (except for
advances of business expenses in the ordinary course of business consistent
with past practice), (iv) establish, adopt, enter into, amend, or terminate
(including termination of participation in) (A) any Employee Plan or any other
plan, agreement, program, policy, trust, fund or other arrangement that would
be an Employee Plan if it were in existence as of the date of this Agreement
(except as may otherwise be required pursuant to applicable Law and except for
immaterial amendments in the ordinary course of business consistent with past
practice that would not result in an increase in Liability to the Company or
any of its Subsidiaries, or, after the Closing, to Parent, the

 

63  

Surviving Corporation, or any of their respective Affiliates), or (B)
collective bargaining agreement or other labor agreement, or (v) terminate any
employee, other than termination for cause in the ordinary course of business
consistent with past practice, or encourage any employee to resign from the
Company or any of its Subsidiaries;

 

(k)fail to timely file or cause to be timely filed all reports and returns
required to be filed by the Company or any of its Subsidiaries with any
Governmental Authority;

 

(l)(i) change any accounting or cash management policies, procedures or
practices used by the Company or management of working capital (including with
respect to reserves, revenue recognition, timing for payments of accounts
payable and collection of accounts receivable) unless required by a change in
Law or GAAP or (ii) revalue any asset, including writing down the value of
inventory or writing off notes or accounts receivable;

 

(m) (i) enter into any Contract of the type listed in Section 4.7(a) (which
shall constitute a Material Contract for purposes of this Agreement), (ii)
modify, amend, extend or supplement in any material respect, transfer or
terminate any Material Contract or waive, release or assign any rights or
Claims thereto or thereunder, (iii) enter into, extend or amend any lease or
sublease with respect to Leased Real Property with any third party, or (iv)
modify, amend or transfer in any way or terminate any license agreement,
standstill or confidentiality agreement with any third party, or waive,
release or assign any rights or Claims thereto or thereunder;

 

(n)(i) transfer or license to any Person any rights to any Intellectual
Property or enter into any agreement with respect to any Intellectual Property
with any Person, (ii) buy or license any Third Party Intellectual Property or
enter into any agreement with respect to the Third Party Intellectual Property
of any Person (other than non-exclusive end user license agreements entered
into in the ordinary course of business consistent with past practice), (iii)
enter into any agreement with respect to the development of any Intellectual
Property with a third party, or (iv) terminate, fail to renew, abandon,
cancel, let lapse, or fail to continue to prosecute or defend any Intellectual
Property;

 

(o)make or change any Tax election or change any method of tax accounting
other than an election in the ordinary course of business consistent with the
past practices of the Company and its Subsidiaries, settle or compromise any
federal, state, local or foreign Tax Liability, file any amended income or
other material Tax Return, enter into any closing agreement relating to any
Tax, agree to an extension or waiver of any limitation period applicable to
any claim or assessment in respect of Taxes, or surrender any right to claim a
Tax refund;

 

(p)fail to promptly pay or cause to be paid when due all Taxes, assessments
and governmental charges or fees, including interest and penalties levied or
assessed, unless diligently contested in good faith by appropriate
proceedings;

 

(q)modify or change, or fail to maintain in full force and effect, any
material permits, licenses, registrations, certificates, orders, clearances or
approvals held by the Company or any of its Subsidiaries, except as required
by Law;

 

(r)pay, discharge, satisfy or settle any Claim, except if such payment,
discharge, satisfaction or settlement (i) would not impose or otherwise result
in any injunctive or similar Order on the Company or any of its Subsidiaries,
(ii) would not restrict in any way, or otherwise result in

 

64  

any restriction on, the business of the Company (or the Surviving Corporation
after the Effective Time), and (iii) would not exceed Twenty-Five Thousand
Dollars ($25,000) in cost, Liability or value to the Company or any of its
Subsidiaries;

 

(s)(i) waive, assign, release or otherwise relinquish any material rights or
claims, or (ii) commence any suit, action or proceeding, or threaten to
commence any suit, action or proceeding, against any Person (other than Parent
or Merger Sub);

 

(t)engage in any transactions with, or enter into or modify or amend in any
material respect any Contract or other arrangement with, any of the directors,
managers, managing directors, officers, employees, Contract Workers, agents,
Equityholders, Series D Holders or other Affiliates of the Company or any of
its Subsidiaries, or any of their respective Affiliates or family members,
other than offer letters and other standard documents, in the Company's
standard forms that have been made available to Parent (and not providing any
rights to severance or similar payments), with any new employees or Contract
Workers hired or retained after the date of this Agreement;

 

(u)fail to maintain in full force and effect all insurance currently in
effect, except that existing policies may be replaced by new or successor
policies of substantially similar coverage and at a substantially similar
cost; or

 

(v)authorize any of the foregoing, or agree or enter into or amend any
Contract or commitment to do any of the foregoing.

 

No Solicitation of Other Proposals

 

. 

 

(a)From the date hereof until the earlier to occur of the Effective Time and
the termination of this Agreement pursuant to its terms, the Company shall
not, nor shall the Company permit any of its Affiliates or Subsidiaries to,
nor shall the Company authorize, direct or permit any of its or their
respective Equityholders, Series D Holders, directors, managers, managing
directors, officers, employees, Contract Workers, advisors, representatives or
agents (collectively, with Affiliates of the Company, the "Company
Representatives") to, directly or indirectly, (i) solicit, facilitate,
initiate or knowingly encourage, or take any action to solicit, facilitate,
initiate or knowingly encourage, any inquiries or communications regarding, or
the making, submission or announcement of, any proposal or offer that
constitutes or would reasonably be expected to constitute an Acquisition
Proposal, (ii) participate or engage in any discussions or negotiations with,
provide any information to, or take any other action with the intent to
facilitate the efforts of, any Person concerning any possible Acquisition
Proposal or any inquiry or communication which would reasonably be expected to
result in an Acquisition Proposal, or (iii) consider, entertain or accept any
proposal or offer from any Person relating to a possible Acquisition Proposal.
The Company shall immediately cease and cause to be terminated, and shall
cause its Subsidiaries and all Company Representatives to immediately cease
and cause to be terminated, all existing discussions or negotiations with any
Persons conducted heretofore with respect to, or that would reasonably be
expected to lead to, an Acquisition Proposal, and the Company shall promptly
issue (or, as the case may be, cause such Subsidiaries or Company
Representatives to issue) instructions to return or destroy all confidential
information provided to any Person (other than Parent or its Affiliates) in
connection with such existing discussions or negotiations. The Company shall
take, and cause all of its Subsidiaries to take, all reasonable actions to
ensure that each Company Representative complies with the provisions of this
Section 6.2(a). Without limiting the foregoing, any action or conduct by

 

65  

any Company Representative that would be a violation of this Section 6.2(a) if
taken by the Company, whether or not such Person is purporting to act on
behalf of the Company, shall be deemed to be a breach of this Section 6.2(a)
by the Company.

 

(b)During the period from the date of this Agreement until the earlier to
occur of the Effective Time and the termination of this Agreement, the Company
shall notify Parent as promptly as practicable upon receipt (and in no event
later than twenty-four (24) hours following such receipt) by the Company, any
of its Affiliates or any Company Representatives of any (i) Acquisition
Proposal or amendment or modification to an Acquisition Proposal, (ii) request
for non-public information relating to the Company other than requests for
information in the ordinary course of business and unrelated to an Acquisition
Proposal, or (iii) inquiry, contact or request for discussions or negotiations
regarding or reasonably likely to lead to any Acquisition Proposal. As
promptly as practicable (and in no event later than twenty-four (24) hours
after receipt of such Acquisition Proposal, amendment, modification, request,
inquiry or contact), the Company shall provide to Parent a copy of such
Acquisition Proposal, amendment, modification, inquiry or request (or, where
no such copy is available, a description of such Acquisition Proposal,
amendment, modification, inquiry or request, including the identity of the
Person making such Acquisition Proposal, amendment, modification, inquiry or
request and the material terms and conditions thereof).

 

Access to Information; Confidentiality

 

. 

 

(a)From the date hereof until the earlier to occur of the Effective Time and
the termination of this Agreement pursuant to its terms, consistent with
applicable Law (including applicable Antitrust Laws), the Company shall (and
shall cause each of its Subsidiaries to):

 

(i)upon reasonable notice, afford to the officers, employees, accountants,
counsel, advisors and other representatives and agents of Parent and its
Affiliates (collectively, the "Parent Representatives") full access (with
reasonable prior notice, and during regular business hours) to all of its
properties (including for the purpose of performing non-intrusive and
intrusive environmental, health, safety and compliance investigations),
premises, records, databases, source code, books, Contracts, commitments,
reports of examination, documents and other information (however stored)
(including materials filed or furnished by the Company or any of its
Subsidiaries with any Governmental Authority with respect to compliance with
applicable Law), and the Company shall furnish, and shall cause each of its
Subsidiaries to furnish, promptly to Parent all such information as Parent may
reasonably request, to, among other things, (A) enable Parent to review the
Company's and its Subsidiaries' material compliance with Laws, (B) complete
Parent's legal, compliance and financial due diligence of the Company and its
Subsidiaries, (C) verify the accuracy of the representations and warranties
contained in this Agreement, and (D) verify that the covenants contained in
this Agreement have been complied with and the conditions to this Agreement
have been satisfied;

 

(ii)reasonably cooperate with such investigations of the Company, its
Subsidiaries and any distributors, sub-distributors, sales representatives,
sales agents or other contractors or agents of the Company or any of its
Subsidiaries as Parent deems reasonably necessary or advisable in connection
with the consummation of the transactions contemplated hereby (including with
respect to compliance or other legal matters, employee matters, information
technology, finance and sales), which reasonable cooperation shall include the
use of commercially reasonable efforts to arrange and facilitate such
interviews of distributors, sub-distributors, sales

 

66  

representatives, sales agents or other contractors or agents of the Company
and its Subsidiaries as Parent deems reasonably necessary in connection with
such investigations;

 

(iii) make available to Parent and the Parent Representatives the appropriate
individuals for discussion of its business, properties and personnel as Parent
or the Parent Representatives may reasonably request; and

 

(iv)without limiting the foregoing, provide all financial and operating data
and other information concerning the Company and its Subsidiaries as may be
reasonably requested by Parent or the Parent Representatives and cause the
Company's and its Subsidiaries' accountants to furnish to Parent and Parent's
accountants access to all work papers relating to the Company and its
Subsidiaries for any periods covered by the Financial Statements.

 

(b)Without limiting the foregoing clause (a), the Company shall (i) deliver to
Parent (A) as soon as practicable (but in any event no later than forty-five
(45) days) after the end of any fiscal quarter of the Company, consolidated
financial statements of the Company and its Subsidiaries for such fiscal
quarter, and (B) as soon as practicable (but in any event no later than twenty
(20) days) after the end of each calendar month, consolidated financial
statements of the Company and its Subsidiaries for such calendar month, and
(ii) use its reasonable best efforts to deliver to Parent the 2017 Audited
Financial Statements, together with an unqualified opinion of Ernst and Young
LLP thereon, as soon as reasonably practicable after the date hereof (but in
any event no later than May 1, 2018).

 

(c)Parent shall keep all non-public information obtained pursuant to Section
6.3(a) confidential in accordance with the terms of the Confidentiality
Agreement. The Confidentiality Agreement shall continue in full force and
effect prior to the Effective Time and after any termination of this
Agreement. Anything contained in the Confidentiality Agreement to the
contrary notwithstanding, the Company and Parent hereby agree that each such
Party may issue press release(s) or make other public announcements regarding
the transactions contemplated in this Agreement only in accordance with
Section 6.8.

 

Regulatory and Other Approvals

 

. From the date hereof until the earlier to occur of the Effective Time and
the termination of this Agreement pursuant to its terms:

 

(a)The Parties (other than the Equityholders' Representative) will, in order
to consummate the Merger and the other transactions contemplated hereby, (i)
proceed diligently and in good faith and use commercially reasonable efforts,
as promptly as practicable, to obtain all Approvals required to be obtained in
connection with the Merger and the other transactions contemplated hereby in
form and substance reasonably satisfactory to Parent and the Company, and to
make all required filings with, and to give all required notices to,
applicable Governmental Authorities or other third parties, and (ii) cooperate
in good faith with such Governmental Authorities and provide promptly such
other information and communications to such Governmental Authorities or other
Persons as such Governmental Authorities or other Persons may reasonably
request in connection therewith.

 

(b)The Company shall promptly notify Parent, and Parent shall promptly notify
the Company, of any material communication such Party or any of its Affiliates
receives from any Governmental Authority relating to the matters that are the
subject of this Agreement, and each Party

 

67  

shall permit the other Parties and their advisors to review in advance any
proposed communication to any Governmental Authority relating to the matters
that are the subject of this Agreement.

 

(c)In furtherance of the foregoing covenants:

 

(i)Each Party (other than the Equityholders' Representative, to which this
Section 6.4(c)(i) shall not apply) shall prepare, or shall cause its
Affiliates or ultimate parent entities (as such term is defined under the HSR
Act) to prepare, as soon as practicable following the execution of this
Agreement, all necessary filings in connection with the transactions
contemplated by this Agreement that may be required under the HSR Act, any
Foreign Competition Laws or any other Laws. The Parties shall request
expedited treatment of any such filings. The Parties shall promptly make any
appropriate or necessary subsequent or supplemental filings, and shall
cooperate with each other in the preparation of such filings in such manner as
is reasonably necessary and appropriate. The Parties shall consult with each
and shall agree in good faith upon the timing of such filings.

 

(ii)Subject to applicable confidentiality restrictions or restrictions
required by Law, each of Parent and the Company will notify the other promptly
upon the receipt of (A) any comments or questions from any officials of any
Governmental Authority in connection with any filings made pursuant to this
Section 6.4 or the transactions contemplated by this Agreement and (B) any
request by any officials of any Governmental Authority for (I) amendments or
supplements to any filings made pursuant to this Section 6.4 or (II) answers
to any questions, or the production of any documents, relating to an
investigation of the transactions contemplated by this Agreement by any
Governmental Authority. Whenever Parent or the Company becomes aware of the
occurrence of any event that is required to be set forth in an amendment or
supplement to any filing made pursuant to this Section 6.4, such Party will
promptly inform the other of such occurrence and cooperate in filing promptly
with the applicable Governmental Authority such amendment or supplement.
Without limiting the generality of the foregoing, each of Parent and the
Company shall provide to the other (or the other's respective advisors) upon
request copies of all correspondence between such Party and any Governmental
Authority relating to the transactions contemplated by this Agreement. The
Parties may, as they deem advisable and necessary, designate any competitively
sensitive materials provided to the other under this Section 6.4 as "outside
counsel only." Such materials and the information contained therein shall be
given only to outside counsel of the recipient and will not be disclosed by
such outside counsel to employees, officers or directors of the recipient
without the prior written consent of the Party providing such materials. In
addition, to the extent reasonably practicable, all discussions, telephone
calls, and meetings with a Governmental Authority regarding the transactions
contemplated by this Agreement shall include representatives of Parent and the
Company. Subject to applicable Law, the Parties will consult and cooperate
with each other in connection with any analyses, appearances, presentations,
memoranda, briefs, arguments, and proposals made or submitted to any
Governmental Authority regarding the transactions contemplated by this
Agreement by or on behalf of any Party.

 

Employee Benefits

 

.

 

(a)Parent shall give, or shall cause the Surviving Corporation or one of its
Affiliates to give, each current employee of the Company and its Subsidiaries,
determined as of the Closing Date (collectively, the "Employees"), full credit
for purposes of eligibility to participate in and vesting under the employee
benefit plans or arrangements maintained by Parent or its U.S. Affiliates in
which such Employee participates following the Closing Date for such
Employee's

 

68  

service with the Company and its Subsidiaries, to the same extent recognized
by comparable Employee Plans immediately prior to the Closing Date, provided
that no such credit shall result in duplication of benefits or retroactive
application. Notwithstanding the foregoing, with respect to any welfare
benefit plans maintained by Parent or its U.S. Affiliates for the benefit of
Employees on and after the Closing Date, Parent shall use commercially
reasonable efforts to (i) cause there to be waived any eligibility
requirements or pre-existing condition limitations, to the same extent waived
under comparable Employee Plans immediately prior to the Closing Date and (ii)
give effect, in determining any deductible and maximum out-of-pocket
limitations, to amounts paid by such Employee in the year of the Closing Date
with respect to similar Employee Plans, in each case of (i) and (ii) except to
the extent otherwise required by an insurance policy providing such welfare
benefits.

 

(b)For a period of twelve (12) months following the Closing Date (or until an
Employee's earlier termination of employment), Parent shall, or shall cause
the Surviving Corporation or one of its Affiliates to, provide each Employee
with substantially comparable types and levels of compensation and employee
benefits, in the aggregate, as those provided to similarly situated employees
of Parent; provided that, for this purpose, the employee benefits generally
provided to Employees as of immediately prior to the Effective Time shall be
deemed to be substantially comparable in the aggregate to those provided to
similarly situated employees of Parent, it being understood that the Employees
may commence participation in the employee benefit plans maintained by Parent
or any of its Affiliates at such times as are determined by Parent.

 

(c)At the written request of Parent provided no later than five (5) days prior
to Closing, the Company shall take all action necessary to cease contributions
to and terminate each plan qualified under Section 401(k) of the Code (the
"Company 401(k) Plan"), and to adopt written resolutions, the form and
substance of which shall be subject to Parent's prior review and approval, to
terminate such Company 401(k) Plan and to one hundred percent (100%) vest all
participants under the Company 401(k) Plan, such termination and vesting to be
effective no later than the Business Day preceding the Closing; provided,
however, that such Company 401(k) Plan termination may be made contingent upon
the consummation of the transactions contemplated by this Agreement. Parent
reserves the right to suspend the distribution of benefits from the Company
401(k) Plan until the later of the receipt of a favorable determination letter
from the IRS with respect to the termination of (or termination of
participation in) such plan and the completion of final testing and record
keeping for such plan. The expenses incurred in connection with the
termination of the Company 401(k) Plan shall constitute Company Transaction
Expenses for purposes of this Agreement.

 

(d)Nothing contained in this Agreement shall (i) constitute or be deemed to be
an amendment to any Employee Plan or any other compensation or benefit plan,
program or arrangement of the Company, Parent, any of their respective
Subsidiaries or Affiliates, (ii) prevent the amendment or termination of any
Employee Plan or interfere with the right or obligation of Parent or the
Surviving Corporation to make such changes as are necessary to conform with
applicable Law, or (iii) otherwise operate to require Parent to duplicate any
payments or benefits payable pursuant to any Employee Plan or other
compensation or benefits plan, policy, program, agreement or other arrangement
of the Surviving Corporation.

 

(e)The Parties acknowledge and agree that all provisions contained in this
Section 6.5 are included for the sole benefit of the Parties, and that nothing
in this Agreement, whether express or implied, shall create any third party
beneficiary or other rights (i) in any other

 

69  

Person, including any employees or former employees of the Company or its
Subsidiaries, or (ii) to continued employment or service following the Closing
Date.

 

Notification of Certain Matters

 

. 

 

(a)The Company shall give prompt notice to Parent of the occurrence or non-
occurrence of any fact, condition or event of which the Company has Knowledge,
the occurrence or non-occurrence of which would reasonably be expected to (i)
result in any representation or warranty of the Company contained in this
Agreement being untrue or inaccurate in any material respect (or, in the case
of any representation or warranty qualified by its terms by materiality
(including the words "material" or "Material Adverse Effect"), untrue or
inaccurate in any respect) had such representation or warranty been made as of
the time of occurrence, non-occurrence or discovery of such fact, condition or
event or (ii) result in or constitute a failure of the Company to comply with
or satisfy in any material respect any covenant, condition or agreement to be
complied with or satisfied by it hereunder; provided, however, that the
delivery of any notice pursuant to this Section 6.6(a) shall not limit or
otherwise affect the remedies available hereunder to Parent or any Parent
Indemnified Person, including the right to or scope of indemnification.

 

(b)Each of the Company and Parent shall give prompt notice to the other of (i)
any notice or other communication from any Person alleging that the Approval
of such Person is or may be required in connection with this Agreement or the
transactions contemplated hereby, including the Merger, (ii) subject to
Section 6.4(c)(iii), as applicable, any notice, document, request, court
papers or other communication from any Governmental Authority or other third
party in connection with this Agreement or the transactions contemplated
hereby, including the Merger, (iii) any Claim relating to or involving or
otherwise affecting such Party that relates to this Agreement or the
transactions contemplated hereby, including the Merger, or (iv) any fact,
event, change, development, circumstance, condition or effect that such Party
has determined has delayed or impeded, or would reasonably be expected to
delay or impede, the ability of such Party to consummate the transactions
contemplated by this Agreement or to fulfill its obligations set forth herein.

 

(c)The Company shall promptly notify Parent of (i) any Claim that is
threatened, brought, asserted or commenced against the Company or any of its
Subsidiaries that would have been required to be listed in Section 4.12 of the
Company Disclosure Schedule or would have otherwise resulted in a breach or
inaccuracy of the representations and warranties in Section 4.12 if such Claim
had arisen prior to the date hereof, (ii) any actual, suspected or potential
Material Compliance Violation, (iii) any Material Adverse Effect, or (iv) any
event that would have been required to be listed in Section 4.7(d) of the
Company Disclosure Schedule or would have otherwise resulted in a breach or
inaccuracy of the representations and warranties in Section 4.7(d) if such
event had occurred prior to the date hereof, in each case of the foregoing of
clauses (i) through (iv), of which the Company has Knowledge; provided,
however, that the delivery of any notice pursuant to this Section 6.6(c) shall
not limit or otherwise affect the remedies available hereunder to Parent or
any Parent Indemnified Person, including the right to or scope of
indemnification.

 

(d)In the event an actual, suspected, or potential Material Compliance
Violation occurs or is discovered prior to the Closing Date, the Company shall
agree, at the request of Parent, jointly, cooperatively and transparently to
take reasonable and customary steps to investigate with Parent the facts and
circumstances giving rise to such actual, suspected, or potential Material
Compliance Violation, and shall in connection with any such investigation
afford to Parent and the

 

70  

Parent Representatives reasonable access to all information reasonably
necessary to complete such investigation to the reasonable satisfaction of
Parent. 

 

Stockholder Approval; General Release of Claims

 

.

 

(a)Immediately following the execution of this Agreement and the release, by
virtue thereof, of the Escrowed Stockholder Consents and Agreements, the
Company shall deliver to Parent copies of the duly executed Escrowed
Stockholder Consents and Agreements, together with any other duly executed
Stockholder Consents and Agreements obtained by the Company, which
collectively evidence the receipt of Stockholder Approval, together with a
certificate of the Secretary of the Company certifying that the Stockholder
Approval has been obtained in accordance with the Charter, the DGCL and, to
the extent applicable, the CCC; provided, that in the event that any of the
Escrowed Stockholder Consents and Agreements are revoked prior to their
release from escrow such that the remaining Escrowed Stockholder Consents and
Agreements, upon their release from escrow immediately following the execution
of this Agreement, together with any other duly executed Stockholder Consents
and Agreements obtained by the Company, would not be sufficient to obtain the
Stockholder Approval, the Company (unless otherwise directed by Parent) shall
use its best efforts to (i) obtain duly executed Stockholder Consents and
Agreements evidencing the Stockholder Approval, and (ii) deliver to Parent
copies of such duly executed Stockholder Consents and Agreements, together
with a certificate of the Secretary of the Company certifying that the
Stockholder Approval has been obtained in accordance with the Charter and the
DGCL, in each case (i) and (ii), as soon as practicable and in no event later
than 12:00 noon Eastern Time on the first (1st) Business Day following the
date of this Agreement (the "Written Consent First Deadline").

 

(b)If the Company fails to (i) obtain duly executed Stockholder Consents and
Agreements evidencing the receipt of the Stockholder Approval or (ii) deliver
to Parent copies of such duly executed Stockholder Consents and Agreements,
together with a certificate of the Secretary of the Company certifying that
the Stockholder Approval has been obtained in accordance with the Charter, the
DGCL and, to the extent applicable, the CCC, in each case (i) and (ii), by
12:00 noon Eastern Time on the third (3rd) Business Day after the date of this
Agreement (the "Written Consent Second Deadline"), the Company, acting through
the Board of Directors of the Company, shall, in accordance with and subject
to the requirements of the DGCL and, to the extent applicable, the CCC:

 

(i)duly set a record date for, call and give notice of a special meeting of
Stockholders (the "Special Meeting"), which notice shall include a description
of the Appraisal Rights and, if applicable, Dissenters' Rights of the
Company's stockholders available under the Appraisal Rights Statutes, for the
purpose of considering and taking action upon this Agreement and the
transactions contemplated hereby, including the Merger (with the meeting date
being no later than thirty (30) days after the Written Consent Second
Deadline) (the "Special Meeting Date Deadline"), and convene and hold the
Special Meeting no later than the Special Meeting Date Deadline; and

 

(ii)use its reasonable best efforts to (A) solicit from the Stockholders
irrevocable proxies in favor of the adoption of this Agreement and approval of
the transactions contemplated hereby, including the Merger and (B) secure any
approval of the Stockholders that is required by the DGCL, the CCC and any
other applicable Law to effect the Merger;

 

71  

provided, that the Company may cancel the Special Meeting if prior to the
commencement of the Special Meeting the Company shall have obtained executed
Stockholder Consents and Agreements evidencing the receipt of the Stockholder
Approval.

 



 

(c)Within ten (10) days following the date of receipt of the Stockholder
Approval, the Company shall distribute notice thereof (and of the availability
of Appraisal Rights and, if applicable, Dissenters' Rights) to all
Stockholders who did not execute and deliver a Stockholder Consent and
Agreement pursuant to and in accordance with Applicable Law (including
Sections 228(e) and 262(d)(2) of the DGCL and, if applicable, Sections 603 and
1301 of the CCC), together with (i) a description of the Appraisal Rights and,
if applicable, Dissenters' Rights of the Company's stockholders available
under the Appraisal Rights Statutes, and (ii) such other information as is
required by Section 262(d)(2) of the DGCL and, if applicable, Chapter 13 of
the CCC. Without limiting the rights and remedies of Parent or any of the
Parent Indemnified Persons, such notice, description and other information
shall be subject to prior review and approval by Parent.

 

Public Announcements

 

. On or prior to the Closing, no Party or any of its respective Subsidiaries
or Affiliates will make any press release, public statement or public
announcement with respect to this Agreement, the Escrow Agreement or any of
the transactions contemplated hereby or thereby without the prior written
consent of Parent or the Company, as the case may be; provided, that Parent
may make any press release, public statement or public announcement which
Parent determines is required by applicable Law, stock listing requirements or
rating agency arrangements, in which case Parent shall use commercially
reasonable efforts to consult with the Company regarding the contents thereof
prior to issuing any such press release or making any such public statement or
public announcement. 

 

Takeover Statutes

 

. If any Takeover Statute or other anti-takeover Law, Charter provision or
Contract is or shall become applicable to the Merger or the transactions
contemplated by this Agreement, the Company and the Board of Directors of the
Company shall grant such Approvals and take such actions as are necessary
under any such Law, provision or Contract so that the Merger and the other
transactions contemplated hereby may be consummated as promptly as practicable
on the terms contemplated hereby without adverse effect under, and otherwise
act to eliminate or minimize the effects of, such Law, provision or Contract.

 

Equityholders and Other Claims

 

. Prior to the Effective Time, the Company shall not settle or compromise any
Claim brought in connection with the Merger or other transactions contemplated
by this Agreement by any present, former or purported holder of any securities
of the Company, or other present, former or purported counterparty to a
Contract with the Company or any of its Subsidiaries, in each case without the
prior written consent of Parent; provided that such consent shall not be
unreasonably withheld, conditioned or delayed.

 

Company Transaction Expenses.

 

 By no later than 10:00 a.m. Central Time on the last Business Day prior to
the scheduled Closing Date, the Company shall submit to Parent invoices or
other documentation reasonably satisfactory to Parent with respect to all
Company Transaction Expenses that are reflected in the calculation of Closing
Merger Consideration, which invoices or other documentation shall (i) have
been issued by the recipients of such Company Transaction Expenses, and (ii)
reflect the identity of each recipient, dollar amounts, wire instructions and
any other information necessary to effect the final payment in full of such
Company Transaction Expenses. If Parent, any Affiliate of Parent, the
Surviving Corporation or any of their respective

 

72  

Subsidiaries has any liability to pay any Company Transaction Expenses that
are not paid as of the Effective Time or reflected as a reduction of the
Closing Merger Consideration, Parent shall be entitled to be indemnified
pursuant to Article 9 for any amounts necessary to satisfy such liability and
any related Losses.

 

Escrow Agreement.

 

 At or before the Closing, Parent and the Equityholders' Representative will
execute and deliver, and will use commercially reasonable efforts to cause the
Escrow Agent to execute and deliver, the Escrow Agreement contemplated by
Article 9 in substantially the form attached hereto as Exhibit K (the "Escrow
Agreement").

 

Delivery of Corporate Records.

 

 At or before the Closing, the Company shall deliver to Parent or its
designee true, correct and complete copies of (a) all minute books of all
meetings of (i) the Equityholders (or Series D Holders), the Board of
Directors of the Company, and any committees thereof, and (ii) the
shareholders (or other equity interest holders) of, and the Board of Directors
(or comparable governing body) of, any Subsidiary of the Company (and any
committees of such Board of Directors or comparable governing body), (b) all
unanimous or other consents of (i) any Equityholder, any Series D Holder, the
Board of Directors of the Company, and any committees thereof, and (ii) any
shareholder (or other equity interest holder) of, and the Board of Directors
(or comparable governing body) of, any Subsidiary of the Company (and any
committees of such Board of Directors or comparable governing body), (c) all
stock ledgers of the Company and each Subsidiary of the Company, (d) the
Charter and Bylaws (and similar organizational documents of each Subsidiary of
the Company, including all stock certificates or similar evidence of ownership
of the common stock or other equity interests held by the Company, directly or
indirectly, of all of its Subsidiaries), and (e) other similar records and
items reasonably requested by Parent from the Company.

 

Equityholder Agreements.

 

 The Company shall cause the Investor Agreements and all other stockholder
agreements, investor rights agreements, registration rights agreements or
other similar Contracts between the Company and any Equityholder (or any
Series D Holder), including any such Contract granting any Person investor
rights, rights of first refusal, registration rights, director designation
rights or similar rights, to be terminated prior to the Effective Time,
without any Liability being imposed on the part of Parent or the Surviving
Corporation.

 

Payout Schedule.

 



 

(a)No less than two (2) Business Days prior to the scheduled Closing Date, the
Company shall deliver to Parent a schedule and reasonable supporting
documentation (collectively, the "Payout Schedule"), which shall set forth:

 

(i)a calculation of the portion of the Merger Consideration payable to each
Equityholder under Article 3 (as determined in accordance with the Charter and
the Company Equity Plans in effect immediately prior to the Effective Time),
including:

 

(A)the information required to be set forth on Section 4.3(b) of the Company
Disclosure Schedule, as of the Effective Time;

 

(B)the total amount of the Closing Merger Consideration (including the amounts
for each of the elements of the Closing Merger Consideration,

 

73  

such as the Estimated Working Capital, the Estimated Debt Pay-Off Amount, the
Estimated Company Transaction Expenses and the Estimated Cash);

 

(C)by Equityholder, an amount equal to the portion of the Closing Merger
Consideration that such Equityholder is entitled to receive (as determined in
accordance with the Charter and the Company Equity Plans in effect immediately
prior to the Effective Time), in the aggregate and in respect of each type of
security (e.g., Preferred Stock, Common Stock, Stock Options) held by such
Equityholder;

 

(D)by Equityholder, an amount to be withheld from the portion of the Closing
Merger Consideration payable to such Equityholder due to applicable payroll,
income tax or other withholding Taxes as of the Closing Date; and

 

(E)by Equityholder, for any Contingent Consideration that might become payable
pursuant to Article 3 or Section 9.4 (other than the Equityholders Final
Closing Adjustment Consideration), the portion of such Contingent
Consideration that such Equityholder would be entitled to receive (as
determined in accordance with the Charter and the Company Equity Plans in
effect immediately prior to the Effective Time), both as a dollar amount and
as a percentage (assuming, for purposes of calculating such amount and
percentage, that (I) the Final Closing Adjustment Amount would be Zero Dollars
($0), (II) there are no Claims made against, or other reductions of, the
Escrow Fund or the Expense Fund, and (III) neither Parent nor the Surviving
Corporation exercise any right of set off pursuant to Section 3.10(f));

 

(ii)the information required to be set forth on Section 4.26 of the Company
Disclosure Schedule, as of the Effective Time;

 

(iii)the amount (including any interest accrued thereon and any prepayment or
similar penalties, expenses or reimbursements) and payee of, and wire
instructions with respect to, any Indebtedness of the Company or any of its
Subsidiaries outstanding as of 12:01 a.m. Eastern Time on the Closing Date
that is reflected in the calculation of Closing Merger Consideration;

 

(iv)the amount and payee of, and wire instructions with respect to, any
Company Transaction Expenses unpaid as of 12:01 a.m. Eastern Time on the
Closing Date that are reflected in the calculation of the Closing Merger
Consideration; and

 

(v)the amounts of any Company Transaction Expenses that become payable as a
result of any Earnout Consideration that is paid, if any, pursuant to Section
3.10 and the payees to whom such amounts are owed.

 

(b)Together with the Payout Schedule, the Company shall deliver to Parent a
certificate of the Chief Executive Officer of the Company certifying that the
Payout Schedule is true, correct and complete in all respects and complies
with the Charter and Company Equity Plans (as in effect immediately prior to
the Effective Time). The Company shall also provide Parent with such
information as Parent may reasonably request to verify the calculations and
other information reflected in the Payout Schedule.

 

74  

(c)The Payout Schedule, and each Updated Payout Schedule, shall be in the form
attached hereto as Exhibit F.

 

(d)From and after the Closing, no less than two (2) Business Days prior to the
date by which any payment must be made to, any deposit must be made with, or
any amount must be delivered to the Payments Administrator for distribution to
the Equityholders, including any payment or deposit of Earnout Consideration
or other Contingent Consideration or any delivery of any amount remaining in
the Escrow Fund or the Expense Fund, the Equityholders' Representative shall
deliver to Parent and the Payments Administrator an updated Payout Schedule
(an "Updated Payout Schedule"), which Updated Payout Schedule shall set forth:

 

(i)by Equityholder, an amount equal to the portion of such payment, deposit or
remaining amount that such Equityholder is entitled to receive (as determined
in accordance with the Charter and the Company Equity Plans in effect
immediately prior to the Effective Time), in the aggregate and in respect of
each type of security (e.g., Preferred Stock, Common Stock, Stock Options)
held by such Equityholder;

 

(ii)in the case of any payment or deposit of Contingent Consideration, the
amount and payee of any Company Transaction Expenses that become payable as a
result of such Contingent Consideration; and

 

(iii)the items described in clauses (i) through (v) of Section 6.15(a)
(excluding Section 6.15(a)(i)(D)); provided that the information required by
clause (i)(E) of Section 6.15(a) shall be updated to reflect (A) any
Contingent Consideration that has become payable or has previously been paid
(including, to the extent paid or payable to the Equityholders pursuant to
Section 3.8(d), any Equityholders Final Closing Adjustment Consideration) or
that otherwise can no longer become payable, (B) any reduction in the Escrow
Fund or Expense Fund due to distributions or disbursements thereof or
otherwise, and (C) any reduction in any Earnout Consideration as a result of
the exercise of any right of set off pursuant to Section 3.10(f).

 

(e)The Equityholders' Representative and Parent shall cooperate with each
other to the extent reasonably requested in connection with the preparation of
each Updated Payout Schedule by the Equityholders' Representative. The
Equityholders' Representative shall also provide Parent and the Payments
Administrator with such information as Parent and the Payments Administrator
may reasonably request to verify the calculations and other information
reflected in any Updated Payout Schedule; provided that, for the avoidance of
doubt, the foregoing shall not be construed to mean that any Updated Payout
Schedule is subject to Parent's or the Payment Administrator's approval (or
that the Equityholders' Representative is required to furnish a draft of any
Updated Payout Schedule to Parent or the Payment Administrator for review in
advance of delivery of such Updated Payout Schedule pursuant to Section
6.15(d)).

 

(f)Notwithstanding anything to the contrary in this Agreement, no delay by
Parent, the Surviving Corporation or the Payments Administrator in
distributing, paying, releasing or otherwise delivering any funds to any
Equityholders pursuant to this Agreement shall constitute a breach of this
Agreement to the extent such delay results from the failure of the
Equityholders' Representative to timely deliver an Updated Payout Schedule in
accordance with Section 6.15(d) (or from the omission of required information,
or inclusion of erroneous information, in the Payout Schedule or any Updated
Payout Schedule).

 

75  

Treatment of Series D Preferred Stock, Stock Options, Warrants and Convertible
Notes.

 



 

(a)As soon as reasonably practicable following the date of this Agreement, the
Company shall provide notice of the Merger and other transactions contemplated
by this Agreement to all holders of Series D Preferred Stock, Stock Options,
Warrants and Convertible Notes. The Company shall provide to Parent as
promptly as practicable copies of all notices or other correspondence to or
from holders of Series D Preferred Stock, Stock Options, Warrants or
Convertible Notes in connection with the Merger and other transactions
contemplated hereunder (including any notice delivered pursuant to this
Section 6.16) and, in the case of notices or other correspondence to holders
of Series D Preferred Stock, Stock Options, Warrants or Convertible Notes,
shall provide Parent with a reasonable opportunity to review and comment upon
all such documentation prior to its dissemination to holders of Series D
Preferred Stock, Stock Options, Warrants or Convertible Notes. 

 

(b)Any exercise of Stock Options between the date hereof and immediately prior
to the Effective Time may be made subject to and conditioned on the Closing
and effectiveness of the Merger at the Effective Time.

 

Section 6.17Indemnification of Directors and Officers.

 

(a)For a period of six (6) years from and after the Effective Time, subject to
Section 6.17(b), the Surviving Corporation agrees to honor provisions
regarding indemnification of, and advancement of expenses to, Covered Persons
that are no less favorable to the Covered Persons than the provisions
contained (i) in the Charter and Bylaws or in the equivalent organizational
documents of each Subsidiary of the Company listed on Section 4.1(c) of the
Company Disclosure Schedule, as applicable, in each case as in effect on the
date hereof, and (ii) in any indemnification agreement between such Covered
Person and the Company (or any Subsidiary thereof) that is listed in Section
6.17 of the Company Disclosure Schedule and has been made available to Parent
prior to the date hereof, as in effect on the date hereof (without giving
effect to any amendments or modifications thereto, unless such amendments or
modifications are specifically referenced in Section 6.17 of the Company
Disclosure Schedule and were made available to Parent prior to the date
hereof). For purposes of this Section 6.17, "Covered Person" shall mean any
person who is serving (as of immediately prior to the Effective Time) or has
previously served as a director, manager, managing director or officer of the
Company or any Subsidiary of the Company listed on Section 4.1(c) of the
Company Disclosure Schedule.

 

(b)At or before the Effective Time, the Company shall purchase for the benefit
of the Covered Persons a directors' and officers' liability insurance and
fiduciary liability insurance "tail" or "run-off" policy of at least the same
coverage and amounts as, and containing terms and conditions that are, in the
aggregate, no less advantageous to the insured than, the Company's current
policies of directors' and officers' liability insurance, with respect to
claims arising from facts or events that occurred on or before the Effective
Time and which covers a period of six (6) years from and after the Effective
Time. 

 

(c)Notwithstanding anything to the contrary in this Agreement, for purposes of
the calculation of the Closing Merger Consideration, the aggregate amount of
the premium paid to purchase the above-referenced "tail" or "run-off" policy
shall be the responsibility of the Company (and treated as a Company
Transaction Expense hereunder). For the avoidance of doubt, nothing

 

76  

contained in this Section 6.17 shall operate to release or otherwise limit any
obligations of the Equityholders arising under this Agreement, including the
indemnification obligations in Article 9.

 

280G Approval.

 

 If required to avoid the imposition of Taxes under Section 4999 of the Code
or the loss of deduction under Section 280G of the Code with respect to any
payment or benefit in connection with any of the transactions contemplated by
this Agreement, at least three (3) Business Days prior to the Closing, in a
manner that complies with Section 280G of the Code and the Treasury
Regulations promulgated thereunder ("Section 280G"), the Company shall seek
approval by its stockholders, to the extent entitled to vote under Section
280G, of the right of any "disqualified individual" (within the meaning of
Section 280G) to receive or retain any and all payments that might otherwise
constitute "parachute payments" within the meaning of Section 280G. Prior to
seeking such approval, the Company shall obtain waivers from each disqualified
individual such that, unless such payments are approved by the Company's
stockholders, to the extent required by and in the manner that complies with
Section 280G, neither the Company nor any of its Subsidiaries shall make such
payments and the disqualified individual shall have no right or entitlement
with respect thereto. The form and substance of (a) all stockholder approval
documents contemplated by this Section 6.18, including any disclosure
statement or written consent, (b) waivers contemplated by this Section 6.18,
and (c) any mathematical analysis of the Section 280G payments, in each case
shall be subject to the prior review and approval of Parent. The Company
shall provide such documentation and information to Parent for its review and
approval (provided that such approval shall not be unreasonably withheld by
Parent) prior to soliciting waivers from the disqualified individuals, and the
Company shall implement all reasonable and timely comments from Parent
thereon. No payment of any such waived payment shall be made unless (i) such
requisite Section 280G approval has been obtained and (ii) prior to payment,
the Company has delivered to Parent evidence of such approval.

 

Cayman Subsidiary.

 



 

(a)As soon as reasonably practicable (and in any event no later than fifteen
(15) days prior to the anticipated Closing Date), the Company shall cause the
Cayman Subsidiary to file with the IRS a valid election on Form 8832 to be
classified as a disregarded entity for U.S. federal income tax purposes (such
election on Form 8832, the "Cayman Subsidiary Tax Election"), with such
election to be effective on or before the date of such filing; provided that
such filing shall be subject to prior review and approval by Parent.

 

(b)From the date of this Agreement until the earlier to occur of the Effective
Time and the termination of this Agreement pursuant to its terms, the Company
shall use its commercially reasonable efforts to cause all Intellectual
Property of the Cayman Subsidiary (including all Intellectual Property owned
by or licensed to the Cayman Subsidiary) to be validly and effectively
transferred to the Company, so that, as of the Effective Time, (x) all such
Intellectual Property shall be owned by (or, in the case of Intellectual
Property that the Cayman Subsidiary currently licenses from a Person that is
not an Affiliate of the Cayman Subsidiary, otherwise held by) the Company and
(y) the Cayman Subsidiary shall have ceased to hold any rights therein;
provided that:

 

(i)the Company shall cause any and all such transfers to be effected in a
manner that (A) is consistent with any Contracts applicable to such
Intellectual Property and with applicable Law, (B) would not reasonably be
expected to give rise (before or after the Effective Time) to any material
Liability of the Company, Parent, the Surviving Corporation or any of their

 

77  

respective Affiliates, (C) would not reasonably be expected to impair (before
or after the Effective Time), in any material respect, such Intellectual
Property (or the value thereof to, or use thereof by, the Company, Parent, the
Surviving Corporation or any of their respective Affiliates) or the business,
operations or assets of the Company, Parent, the Surviving Corporation or any
of their respective Affiliates, and (D) is otherwise reasonably satisfactory
to Parent;

 

(ii)all Contracts and other instruments governing, effecting or memorializing
such transfers (and all filings with, or notices or other submissions to, any
Governmental Authority or other third party with respect to such transfers)
shall be subject to prior review and approval by Parent (which shall not be
unreasonably withheld or delayed); and

 

(iii)no such transfer shall be effected, and no Contract or other instrument
governing, effecting or memorializing any such transfer shall be executed or
otherwise entered into (and no filing shall be made with, and no notice or
other submission shall be provided to, any Governmental Authority or other
third party with respect to any such transfer), before the Cayman Subsidiary
Tax Election has been filed with the IRS and become effective.

 

Further Assurances.

 

 Subject to the terms and conditions of this Agreement, each Party shall (at
its own cost and expense, subject, in the case of the Equityholders'
Representative, to the Equityholders' Representative's rights under Section
9.5(d) and paragraph (c) of Exhibit M) at any time and from time to time, upon
reasonable request, (a) do, execute, acknowledge and deliver, and cause to be
done, executed, acknowledged and delivered, all such further acts, transfers
or assignments as may be required (x) to consummate the transactions in
accordance with the terms hereof or (y) to cause to be fulfilled the Closing
conditions set forth in Article 7 (provided that this clause (y) shall not
apply to the Equityholders' Representative), and (b) take such other actions
as may be reasonably required in order to carry out the intent of this
Agreement; provided that in no event shall any Party be required to take any
action which (i) increases in any way the Liabilities or obligations of such
Party, (ii) in the opinion of its counsel, is unlawful or would or could
constitute a violation of any applicable Law or require the approval of any
Governmental Authority or (iii) could reasonably be expected to prevent or
materially impede, interfere with or delay the transactions contemplated by
this Agreement.

 

Article 7 
CONDITIONS

 



 

Conditions to Each Party's Obligation to Consummate the Merger.

 

 The respective obligations of each Party to consummate the Merger and the
other transactions contemplated by this Agreement shall be subject to the
satisfaction or waiver by Parent and the Company at or prior to the Closing of
the following conditions:

 

(a)Stockholder Approval. The Stockholder Approval shall have been obtained.

 

(b)No Injunctions or Restraints. No temporary restraining order, preliminary
or permanent injunction or other Order (whether temporary, preliminary or
permanent) issued by any Governmental Authority of competent jurisdiction or
other legal restraint or prohibition shall be in effect which prevents the
consummation of the Merger and the other transactions contemplated hereunder
on the same terms and conferring on Parent and Merger Sub all the rights and
benefits as contemplated herein.

 

78  

(c)Illegality. There shall not be any Law or Order enacted, entered or
enforced which makes the consummation of the Merger on the same terms and
conferring on Parent all the rights and benefits as contemplated herein
illegal.

 

(d)Regulatory Clearance. Any required waiting period under the HSR Act or any
agreement with any Governmental Authority not to consummate the transactions
contemplated hereby shall have expired or been terminated and any required
clearances under any applicable Foreign Competition Laws shall have been
obtained, and shall each be in full force and effect.

 

Additional Conditions to Obligations of Parent and Merger Sub

 

. The obligations of Parent and Merger Sub to consummate the Merger and the
other transactions contemplated by this Agreement and by the Escrow Agreement
shall also be subject to the satisfaction or waiver (by Parent in its sole
discretion) at or prior to the Closing of the following conditions:

 

(a)Representations and Warranties. (i) Each of the representations and
warranties made by the Company in this Agreement (other than the Fundamental
Representations and the Specified Representations) that are qualified as to
materiality (including the words "material" or "Material Adverse Effect")
shall be true and correct in all respects, and those representations and
warranties (other than the Fundamental Representations and the Specified
Representations) not so qualified shall be true and correct in all material
respects, as of the date hereof and as of the Closing Date as if made on and
as of the Closing Date (without giving effect to any supplements or amendments
to the Company Disclosure Schedule delivered hereunder), except, in each case,
to the extent that such representations and warranties refer specifically to
an earlier date, in which case they shall be so true and correct as of such
date, and (ii) each of the Fundamental Representations and the Specified
Representations shall be true and correct in all respects as of the date
hereof and as of the Closing Date as if made on and as of the Closing Date
(without giving effect to any supplements or amendments to the Company
Disclosure Schedule delivered hereunder), except to the extent that such
representations and warranties refer specifically to an earlier date, in which
case such representations and warranties shall be so true and correct as of
such date. 

 

(b)Agreements and Covenants. The Company shall have performed and complied
with in all material respects each agreement and covenant required by this
Agreement to be performed or complied with by it on or prior to the Closing
Date.

 

(c)Officer's Certificate. Parent and Merger Sub shall have received a
certificate as to the fulfillment of the conditions in Sections 7.2(a), 7.2(b)
and 7.2(i) signed by the Chief Executive Officer of the Company, which
certificate shall have the effect (including for purposes of Article 9) of the
Company making its representations and warranties under this Agreement as of
the Closing Date (other than such representations that are made as of a
specified date, which shall be remade at the Closing Date as of such specified
date).

 

(d)Stockholder Consents, Etc. Parent shall have received (i) a duly executed
and delivered Stockholder Consent and Agreement from (A) each of the holders
of outstanding shares of Preferred Stock and Common Stock listed on Exhibit G,
(B) holders of no less than eightynine percent (89%) of the outstanding
shares of the Series C Preferred Stock as of the date hereof and as of
immediately prior to the Closing Date, and (C) holders of no less than ninety
percent (90%) of the outstanding shares of the Series C-1 Preferred Stock as
of the date hereof and as of immediately prior to the Closing Date, and (ii)
with respect to holders of no less than ninety-five percent (95%) of the

 

79  

outstanding shares of Series C Preferred Stock, Series C-1 Preferred Stock and
Common Stock as of immediately prior to the Closing Date, either (A)
Stockholder Consents and Agreements duly executed and delivered by such
holders, or (B) evidence, in form and substance reasonably satisfactory to
Parent, that such holders have (x) failed to perfect Appraisal Rights for such
shares and Dissenters' Rights for such shares in accordance with the Appraisal
Rights Statutes or (y) otherwise effectively waived such rights.

 

(e)No Governmental Restriction, Etc. There shall not be any pending or
threatened Claim asserted by any Governmental Authority (i) challenging or
seeking to restrain or prohibit the consummation of the Merger or any of the
other transactions contemplated by this Agreement or seeking to obtain from
Parent or any of its Subsidiaries or Affiliates any damages in connection with
this Agreement, (ii) seeking to prohibit or limit the ownership, operation or
conduct by the Company, Parent or any of their respective Subsidiaries or
Affiliates of any portion of the business or assets of the Company, Parent or
any of their respective Subsidiaries or Affiliates, or seeking the disposal or
holding separate of any portion of the business or assets of the Company,
Parent or any of their respective Subsidiaries or Affiliates, as a result of
the Merger or any of the other transactions contemplated by this Agreement,
(iii) seeking to impose any limitations on the ability of Parent or Merger Sub
to acquire or hold, or exercise full rights of ownership of, any shares of
capital stock (or other equity interests) of the Company, the Surviving
Corporation or any of their Subsidiaries or Affiliates, including the right to
vote such capital stock on all matters properly presented to the stockholders
of the Company or the Surviving Corporation, respectively, or (iv) seeking to
prohibit Parent or any of its Subsidiaries or Affiliates from effectively
controlling in any respect the business or operations of the Company or its
Subsidiaries or Affiliates.

 

(f)Approvals; Notices. Parent shall have received evidence, in form and
substance reasonably satisfactory to it, that (i) all Approvals, filings and
notifications listed in Section 4.6(b) of the Company Disclosure Schedule (or
that would be required to be listed therein in order for the representation
and warranty in Section 4.6(b) of this Agreement to be true and correct in all
respects as of the date hereof and as of the Closing Date) have been obtained
(in the case of Approvals) or made (in the case of filings or notifications),
in each case in form and substance reasonably satisfactory to Parent, and (ii)
all Approvals and notices listed on Exhibit J have been obtained (in the case
of Approvals) or given (in the case of notices), in each case in form and
substance reasonably satisfactory to Parent.

 

(g)Secretary's Certificate Regarding Stockholder Approval. Parent shall have
received the certificate of the Secretary of the Company required to be
delivered by the Company pursuant to Section 6.7(a).

 

(h)Escrow Agreement. The Equityholders' Representative and the Escrow Agent
shall have executed and delivered to Parent the Escrow Agreement.

 

(i)No Material Adverse Effect. No Material Adverse Effect shall have occurred
since the date of this Agreement.

 

(j)Company Transaction Expenses. Parent shall have received from the Company
the invoices and other documentation required pursuant to Section 6.11.

 

(k)Pay-Off Letters. Parent shall have received a pay-off letter (each, a
"Pay-Off Letter"), in form and substance reasonably satisfactory to Parent,
from each lender (including from

 

80  

each holder of any Convertible Note that is subject to clause (i) of the first
sentence of Section 3.2(c)) with respect to any Indebtedness of the Company
or any of its Subsidiaries outstanding as of immediately prior to the Closing,
setting forth (i) the amount of such Indebtedness owed to such lender
(including any interest accrued thereon and any prepayment or similar
penalties, expenses or reimbursements) (such amounts, in the aggregate, the
"Debt Pay-Off Amount") and (ii) an agreement that, if such amount so
identified is paid to such lender on the Closing Date, such Indebtedness shall
be paid in full, and all Liabilities thereunder and all Liens or guarantees
affecting any assets of the Company or any of its Subsidiaries will be
terminated and released.

 

(l)Payout Schedule. Parent shall have received (i) the Payout Schedule in
accordance with Section 6.15 and (ii) a certificate signed by the Chief
Executive Officer of the Company stating that such Payout Schedule is true,
correct and complete in all respects and complies with the Charter and Company
Equity Plans (as in effect immediately prior to the Effective Time).

 

(m)280G Vote. If required pursuant to Section 6.18, the "parachute payments"
shall have been submitted to the stockholders of the Company for approval or
disapproval and such payments will have been approved or disapproved by such
stockholders and, if disapproved, such payments shall have been waived by the
recipients thereof and shall not have been made.

 

(n)Resignation of Directors and Officers. Parent shall have received letters
of resignation and release, effective as of the Effective Time, in form and
substance reasonably satisfactory to Parent, from each of the directors and
officers of the Company and each person holding a comparable position with any
of the Company's Subsidiaries, in each case other than those officers, if any,
designated in writing by Parent prior to the Closing.

 

(o)Employee Agreements. Each of the Employee Agreements executed and
delivered on the date of this Agreement (i) shall be in full force and effect
as of the Closing, (ii) shall not have been modified or amended in any way
(except as expressly consented to in writing by Parent), and (iii) shall not
have been breached or repudiated by, or subject to dispute by, the employee
that is party thereto (nor shall any such breach, repudiation or dispute have
been threatened to the Company or any of its Subsidiaries or to Parent or any
of its Affiliates).

 

(p)Estoppel Certificates. With respect to each Lease listed on Exhibit L,
Parent shall have received an estoppel certificate from the lessor thereof in
form and substance acceptable to Parent.

 

(q)FIRPTA. Parent shall have received from the Company, in a form reasonably
acceptable to Parent, a written statement in accordance with Treasury
Regulations  1.897-2(h) and 1.1445-2(c)(3) certifying that interests in the
Company are not U.S. real property interests, together with a copy of the
notice sent to the Internal Revenue Service in conformity with the
requirements of Treasury Regulation section 1.897-2(h)(2).

 

(r)Secretary's Certificate Regarding Organizational Matters. Parent shall
have received a certificate, validly executed by the Secretary of the Company,
certifying as to (i) the terms and effectiveness of the Charter and Bylaws,
(ii) the valid adoption of, and the continuing effectiveness of, resolutions
of the Board of Directors of the Company whereby this Agreement, the Merger
and the other documents and transactions contemplated hereby were approved by
the Board of Directors, (iii) the valid adoption of this Agreement and
approval of the Merger and the other documents and transactions contemplated
hereby by the holders of the outstanding Preferred Stock

 

81  

and Common Stock, and (iv) the absence of any resolutions or written consents
of the Board of Directors of the Company or of the holders of Preferred Stock
or Common Stock in connection with the Merger or the other transactions
contemplated hereby, other than (A) the resolutions and consents attached to
such certificate and (B) the Stockholder Consents and Agreements.

 

(s)Certificates of Good Standing. Parent shall have received (i) a long-form
certificate of good standing from the Secretary of State of Delaware, dated
within three (3) calendar days prior to Closing, evidencing that the Company
is in good standing and that all applicable Taxes and fees of the Company
through and including the date of such certificate have been paid, (ii) a
certificate from the Secretary of State of California and each other
jurisdiction in which the Company is qualified to do business as a foreign
corporation, dated as of a recent date prior to Closing (but in no event more
than three (3) Business Days prior to the Closing), evidencing that the
Company is in good standing and that all applicable Taxes and fees of the
Company through and including the date of such certificate have been paid, and
(iii) a certificate, issued by a competent Governmental Authority, from the
jurisdiction of formation of each Subsidiary of the Company, and from each
other jurisdiction in which any Subsidiary of the Company is qualified to do
business, dated as of a recent date prior to Closing (but in no event more
than ten (10) calendar days prior to the Closing), evidencing that such
Subsidiary is in good standing and that all applicable Taxes and fees of such
Subsidiary through and including the date of such certificate have been paid;

 

(t)Investor Agreements. The Company shall have delivered to Parent evidence,
in form and substance reasonably satisfactory to Parent, that each of the
Investor Agreements has been validly and effectively terminated and is of no
further force or effect.

 

(u)Cayman Subsidiary. The Company shall have delivered to Parent evidence, in
form and substance satisfactory to Parent, of (i) the filing of a valid and
effective Cayman Subsidiary Tax Election with the IRS in accordance with
Section 6.19(a) and (ii) the valid and effective transfer of all Intellectual
Property of the Cayman Subsidiary (including all Intellectual Property owned
by or licensed to the Cayman Subsidiary) to the Company in accordance with
Section 6.19(b).

 

(v)Termination of Warrants. The Company shall have delivered to Parent
evidence, in form and substance reasonably satisfactory to Parent, of the
termination, effective at or before the Effective Time, of each of the MS
Warrant, the SVB Warrant, the VLL Warrants and any other Warrant outstanding
at or before the Effective Time, in each case in accordance with Section
3.2(e).

 

(w)Redemption of Series D Preferred Stock. The Company shall have delivered
to Parent evidence, in form and substance reasonably satisfactory to Parent,
of (i) the redemption of all shares of Series D Preferred Stock issued and
outstanding immediately prior to the Effective Time in accordance with Section
3.2(a), (ii) the surrender to the Company of, and the cancellation of, all
certificates representing shares of Series D Preferred Stock in accordance
with Section 3.2(e) and (iii) the cancellation and retirement of all shares of
Series D Preferred Stock in accordance with Section 3.2(e).

 

(x)2017 Audited Financial Statements. The Company shall have delivered to
Parent the 2017 Audited Financial Statements, together with (i) an unqualified
opinion of Ernst and Young LLP on the 2017 Audited Financial Statements, and
(ii) a written consent, substantially in the form set forth on Exhibit R (or
otherwise in form and substance reasonably satisfactory to Parent),

 

82  

from Ernst and Young LLP to the inclusion of the 2017 Audited Financial
Statements and Ernst and Young LLP's unqualified opinion thereon in Orthofix
International N.V.'s filings with and submissions to the United States
Securities and Exchange Commission.

 

(y)Termination of Certain Contracts and Arrangements. The Company shall have
delivered to Parent evidence, in form and substance reasonably satisfactory to
Parent, of the termination, effective at or before the Effective Time, of each
Contract or other arrangement listed on Exhibit N (each such Contract or
arrangement, a "Specified Terminated Arrangement").

 

Additional Conditions to Obligations of the Company

 

. The obligation of the Company to consummate the Merger and the other
transactions contemplated by this Agreement shall also be subject to the
satisfaction or waiver at or prior to the Closing of the following conditions:

 

(a)Representations and Warranties. (i) Each of the representations and
warranties made by Parent or Merger Sub in this Agreement (other than the
representations and warranties in Sections 5.1, 5.2 and 5.3(a)(i)) that are
qualified as to materiality (including the word "material") shall be true and
correct in all respects, and those representations and warranties (other than
the representations and warranties in Sections 5.1, 5.2 and 5.3(a)(i)) not so
qualified shall be true and correct in all material respects, as of the date
hereof and as of the Closing Date as if made on and as of the Closing Date,
except, in each case, to the extent that such representations and warranties
refer specifically to an earlier date, in which case they shall be so true and
correct as of such date, and (ii) each of the representations and warranties
in Sections 5.1, 5.2 and 5.3(a)(i) shall be true and correct in all respects
as of the date hereof and as of the Closing Date as if made on and as of the
Closing Date, except to the extent that any such representations and
warranties refer specifically to an earlier date, in which case such
representations and warranties shall be so true and correct as of such date. 

 

(b)Agreements and Covenants. Each of Parent and Merger Sub shall have
performed and complied with in all material respects each agreement and
covenant required by this Agreement and, in the case of Parent, by the Escrow
Agreement to be performed or complied with by it on or prior to the Closing
Date.

 

(c)Officer's Certificate. The Company shall have received a certificate as to
the fulfillment of the conditions in Sections 7.3(a) and 7.3(b) signed by an
authorized officer of Parent, which certificate shall have the effect of
Parent and Merger Sub making their representations and warranties under this
Agreement as of the Closing Date (other than such representations that are
made as of a specified date, which shall be remade at the Closing Date as of
such specified date).

 

(d)Escrow Agreement. Parent and the Escrow Agent shall have executed and
delivered the Escrow Agreement to the Equityholders' Representative.

 

Article 8 
TERMINATION, AMENDMENT AND WAIVER

 



 

Termination

 

. This Agreement may be terminated and the Merger contemplated hereby may be
abandoned at any time prior to the Effective Time:

 

(a)By mutual written consent of the Parties;

 

83  

(b)By either Parent or the Company if the Merger shall not have been
consummated on or before July 31, 2018; provided, that the right to terminate
this Agreement under this Section 8.1(b) shall not be available to any Party
whose willful failure to fulfill any obligation under this Agreement has been
the cause of, or resulted in, the failure of the Merger to have been
consummated on or before such date;

 

(c)By either Parent or the Company, if a Governmental Authority shall have
issued an Order or taken any other action, in each case which has become final
and non-appealable and which restrains, enjoins or otherwise prohibits the
Merger; provided, that the right to terminate this Agreement under this
Section 8.1(b) shall not be available to any Party whose willful failure to
fulfill any obligation under this Agreement has been the cause of, or resulted
in, the issuance of such Order;

 

(d)By Parent, if (i) any of the representations or warranties of the Company
herein (A) is, on the date hereof, untrue or inaccurate such that Section
7.2(a) would not be satisfied, or (B) at any time becomes untrue or inaccurate
such that Section 7.2(a) would not be satisfied (treating such time as if it
were the Effective Time for purposes of this Section 8.1(d)) or (ii) there has
been a breach on the part of the Company of any of its covenants or agreements
contained in this Agreement such that Section 7.2(b) would not be satisfied
(treating such time as if it were the Effective Time for purposes of this
Section 8.1(d)), and, in each case of the foregoing clauses (i) and (ii), such
breach (if curable) has not been cured within fifteen (15) days after written
notice to the Company by Parent; provided, however, that no such cure period
shall be required for a breach which by its nature cannot be cured through the
exercise of reasonable efforts or if the Company fails to exercise such
reasonable efforts;

 

(e)By the Company, if (i) any of the representations or warranties of Parent
or Merger Sub here (A) is, on the date hereof, untrue or inaccurate such that
Section 7.3(a) would not be satisfied, or (B) at any time becomes untrue or
inaccurate such that Section 7.3(a) would not be satisfied (treating such time
as if it were the Effective Time for purposes of this Section 8.1(e)) or (ii)
there has been a breach on the part of Parent or Merger Sub of any of its
covenants or agreements contained in this Agreement such that Section 7.3(b)
would not be satisfied (treating such time as if it were the Effective Time
for purposes of this Section 8.1(e)), and, in each case of the foregoing
clauses (i) and (ii), such breach (if curable) has not been cured within
fifteen (15) days after written notice to Parent by the Company; provided,
however, that no such cure period shall be required for a breach which by its
nature cannot be cured through the exercise of reasonable efforts or if the
Parent or Merger Sub, as applicable, fails to exercise such reasonable
efforts; or

 

(f)By Parent, prior to the receipt of executed Stockholder Consents and
Agreements evidencing the receipt of the Stockholder Approval, if the
Stockholder Approval shall not have been obtained by the Written Consent First
Deadline.

 

Effect of Termination; Termination Fee

 

.

 

(a)In the event of the termination of this Agreement pursuant to Section 8.1
(which termination will be effective immediately upon the delivery of written
notice of the terminating Party to the other Parties), this Agreement (other
than this Section 8.2, Sections 6.3(c), 6.8 and 11.1 through 11.12, and
paragraph (c) of Exhibit M, and any related definitions, which shall survive
such termination) will forthwith become void and be of no further force and
effect, and there will be no liability on the part of Parent, Merger Sub or
the Company or any of their respective

 

84  

officers or directors to the other and all rights and obligations of any Party
hereto will cease, except that nothing herein will relieve any Party from
liability for any breach, prior to termination of this Agreement in accordance
with its terms, of any representation, warranty, covenant or agreement
contained in this Agreement.

 

(b)In the event of a termination of this Agreement by Parent pursuant to
Section 8.1(f), the Company shall pay Parent a termination fee equal to
Parent's documented out of pocket charges and expenses (including attorneys'
fees) incurred in connection with the transactions contemplated hereby, within
seven (7) Business Days after such termination, and, if the Company enters
into a definitive agreement relating to an Acquisition Proposal within twelve
(12) months of such termination, then the Company shall pay Parent an
additional termination fee of One Million Fifty Thousand Dollars ($1,050,000)
(such additional termination fee to be paid prior to the time of execution of
such definitive agreement).

 

(c)In the event of a termination of this Agreement by Parent pursuant to
Section 8.1(d), if, within twelve (12) months following such termination, the
Company enters into a definitive agreement relating to an Acquisition Proposal
providing for consideration to the holders of Preferred Stock and Common Stock
of greater economic value, taken as a whole, than that which would have been
provided pursuant to this Agreement and the transactions contemplated hereby,
then the Company shall pay Parent a termination fee of Two Million Five
Hundred Thousand Dollars ($2,500,000), such fee to be paid prior to the time
of execution of such definitive agreement.

 

(d)All payments under this Section 8.2 shall be made by wire transfer of
immediately available funds to an account designated in writing by Parent.

 

(e)The Parties acknowledge that (i) the fees and the other provisions of this
Section 8.2 are an integral part of the transactions contemplated by this
Agreement, (ii) the fees payable pursuant to this Section 8.2 are not a
penalty but rather constitute liquidated damages in a reasonable amount that
will compensate Parent and Merger Sub for the efforts and resources expended
and opportunities foregone while negotiating this Agreement and on the
expectation of the consummation of the transactions contemplated hereby, and
(iii) without the agreements set forth in this Section 8.2, Parent and Merger
Sub would not enter into this Agreement. Accordingly, if the Company fails to
pay any fee specified in Section 8.2(b) or Section 8.1(c) when due, and, in
order to obtain such payment, Parent commences a Claim that results in a
judgment against the Company for such fee, the Company shall pay to Parent,
together with such fee, (A) interest on such fee from the date such fee was
due hereunder at a rate per annum equal to the Prime Rate and (B) Parent's
costs and expenses (including reasonable attorneys' fees) in connection with
such Claim.

 

Amendment

 

. This Agreement may be amended to the fullest extent permitted by Law by
Parent, Merger Sub and the Company by action taken by or on behalf of their
respective Board of Directors at any time prior to the Effective Time, whether
before or after approval of this Agreement by their respective stockholders,
but after any such stockholder approval (including the Stockholder Approval),
no amendment shall be made which by Law requires the further approval of
stockholders without obtaining such further approval. This Agreement may be
amended to the fullest extent permitted by Law by Parent, the Surviving
Corporation and the Equityholders' Representative at any time after the
Effective Time, but no amendment shall be made which by Law requires the
further approval of the Stockholders without obtaining such further approval.
This Agreement may not be amended except by an instrument in writing signed by
(i)

 

85  

prior to the Effective Time, the Parties, and (ii) after the Effective Time,
Parent, the Surviving Corporation and the Equityholders' Representative.

 

Waiver

 

. At any time prior to the Effective Time, Parent and Merger Sub, on the one
hand, and the Company, on the other, may, to the extent permitted by Law,
extend the time for the performance of any of the obligations or other acts
required by the other Party hereunder, waive any inaccuracies in the
representations and warranties made to such Party and contained herein or in
any document delivered pursuant hereto and waive compliance with any of the
agreements or conditions for the benefit of such Party contained herein. Any
such extension or waiver shall be valid only if set forth in an instrument in
writing signed by the Party or Parties to be bound thereby. The waiver of any
condition based on the accuracy of any representation or warranty, or on the
performance of or compliance with any covenant or obligation, or the waiver of
the fulfillment of any such condition, shall not affect the right to
indemnification under Article 9 or other remedy based on such representation,
warranty, covenant or obligation.

 

Article 9 
INDEMNIFICATION AND ESCROW

 



 

Survival of Representations, Warranties, Agreements and Covenants

 

. All representations and warranties in this Agreement, and all
representations, warranties and certifications in the certificates delivered
pursuant to Sections 7.2 and 7.3 or any other certificate or document
delivered pursuant to this Agreement, shall survive the Merger and continue
for a period beginning on the Closing Date and ending twenty-four (24) months
after the Closing Date; provided, however, that (a) (i) the Fundamental
Representations (other than the representations and warranties in Section
4.16), (ii) the Specified Representations and (iii) Claims for fraud or
intentional misrepresentation that are based upon any representation or
warranty of the Company contained in this Agreement (or any representation,
warranty or certification contained in any certificate or document delivered
pursuant to this Agreement) shall, in each case of the foregoing clauses (i),
(ii) and (iii), survive the Merger and continue for a period beginning on the
Closing Date and ending on the expiration of the applicable statute of
limitations (giving effect to any waiver, mitigation or extension thereof),
and (b) the representations and warranties in Section 4.16 shall survive the
Merger and continue for a period beginning on the Closing Date and ending on
the date that is sixty (60) days after the expiration of the applicable
statute of limitations (giving effect to any waiver, mitigation or extension
thereof). The Parties intend that the statute of limitations referenced in
the foregoing sentence shall be the longest statute of limitations permitted
by applicable Law. The covenants and agreements of the Parties contained in
this Agreement to be performed after the Closing shall survive in accordance
with their terms. Notwithstanding anything herein to the contrary, if an
Indemnified Person shall timely have asserted a Claim in respect of any
representation, warranty, certification, agreement or covenant on or prior to
the date of the termination of the applicable survival period specified above,
such Claim shall survive until finally resolved (and until any amount due
hereunder in respect thereof is satisfied). No Claim shall be made for any
breach, untruth or inaccuracy of any representation, warranty or certification
contained in this Agreement (or in any certificate or document delivered
pursuant to this Agreement), or for any breach or default of any agreement or
covenant contained in this Agreement, after the date on which such
representation, warranty, certification, agreement or covenant terminates as
set forth above.

 

86  

Indemnification; Remedies

 

.

 

(a)Indemnification of Parent and Merger Sub. Subject to the limitations set
forth in this Article 9, Parent and Merger Sub and their respective Affiliates
(including, from and after the Effective Time, the Surviving Corporation and
its Subsidiaries) and each of their respective officers, directors, agents,
representatives, employees, successors and assigns (hereinafter referred to
individually as a "Parent Indemnified Person" and collectively as "Parent
Indemnified Persons") shall be indemnified, compensated and held harmless by
the Equityholders (on a joint and several basis, to the extent of the Escrow
Fund and any offset against Earnout Consideration, and otherwise on a several
and not joint basis, allocated among the Consenting Equityholders based on
their respective Indemnity Pro Rata Shares, in each case as further provided
in Section 9.2(c)), as set forth in this Article 9, from and against any and
all actions or causes of action, proceedings, settlements, judgments, amounts
payable, payments, Taxes, diminutions in value, and Liabilities, including
interest, penalties, restitution, disgorgement, fines and fees (including
reasonable attorneys' and consultants' fees and reasonable costs of
investigation and Claims) (collectively, "Losses"), arising out of or
resulting from any of the following:

 

(i)any breach, untruth or inaccuracy of (A) any representation or warranty of
the Company contained in this Agreement as of the date hereof or as of the
Closing Date as though such representation or warranty were made on the
Closing Date, determined, in each case, without regard to any material,
materiality, or Material Adverse Effect qualification contained therein, or
(B) any representation, warranty or certification of the Company (or any
officer thereof) contained in any certificate delivered pursuant to Section
7.2 or any other certificate or document delivered pursuant to this Agreement
as of the date such representation, warranty or certification is made,
determined, in each case, without regard to any material, materiality, or
Material Adverse Effect qualification contained therein;

 

(ii)any breach or non-performance by the Company or the Equityholders'
Representative of any of its covenants or agreements contained in this
Agreement;

 

(iii)any fraud or intentional misrepresentation by or on behalf of the
Company, any Equityholders or any Series D Holders under or relating to this
Agreement or related to the Company, any of its Subsidiaries or the
transactions contemplated hereby;

 

(iv)any Indebtedness of the Company or any of its Subsidiaries to the extent
not paid prior to Closing or deducted from the Closing Merger Consideration as
contemplated in the definition thereof;

 

(v)any Company Transaction Expenses (including, regardless of any disclosure
on the Company Disclosure Schedule, any broker's, financial advisor's,
finder's or other fee or commission in connection with the transactions
contemplated by this Agreement) to the extent not paid prior to the Closing or
deducted from the Closing Merger Consideration as contemplated in the
definition thereof;

 

(vi)any Claim relating to the exercise or purported exercise of Appraisal
Rights or Dissenters' Rights under the Appraisal Rights Statutes (including
all legal fees and expenses and other court cost and expenses), as well as any
obligation to pay additional consideration in respect of any Dissenting
Shares, with such Losses to include the amount equal to the excess, if any, of
(A) any amounts Parent, Merger Sub, the Company or the Surviving Corporation
are required

 

87  

by a court of competent jurisdiction to pay, or pay in settlement, in respect
of any Dissenting Shares (to the extent a Governmental Authority determines
that any Appraisal Rights Statute is applicable to the Merger) over (B) the
amount of the portion of the Merger Consideration into which such Dissenting
Shares would have been converted in the Merger had such shares not been
Dissenting Shares;

 

(vii)any Claim (A) that any Stock Option, Warrant, Convertible Note or share
of Preferred Stock or Common Stock entitles the holder thereof to anything
other than the cash payments specified in Sections 3.1 or 3.2, (B) that any
Stock Option was not validly cancelled, or any Warrant was not validly
terminated, as of the Effective Time, (C) that any share of Series D Preferred
Stock was not validly redeemed prior to, or cancelled at or prior to, the
Effective Time, (D) that any Convertible Note was not validly converted into
capital stock of the Company prior to the Closing, or that any Convertible
Note was not validly redeemed or repaid in connection with Closing (other than
as a result of Parent's failure to comply with Section 3.11(a)), (E) made by
or on behalf of any Equityholder, alleged Equityholder or any other Person
(including any Series D Holder) who asserts that they were entitled to any of
the Merger Consideration (or any additional or incremental amount of Merger
Consideration) by virtue of any Contract (including any Warrant or Convertible
Note), ownership of capital stock of the Company (including any shares of
Series D Preferred Stock) or otherwise, or (F) challenging, disputing or
objecting to the amount of the portion of the Merger Consideration received or
to be received by any such Equityholder or alleged Equityholder;

 

(viii)any Claim (A) challenging, disputing or objecting to the Merger or the
Merger Consideration, (B) alleging violations of fiduciary duty by any
director, officer or agent of the Company in connection with the Merger or the
other transactions contemplated by this Agreement or (C) by any Equityholder
relating to (I) any alleged action or failure to act on its behalf by the
Equityholders' Representative or (II) the authority of the Equityholders'
Representative;

 

(ix)any (A) errors, inaccuracies or omissions in the Payout Schedule or any
Updated Payout Schedule, or (B) failure of the Payout Schedule or any Updated
Payout Schedule to comply with or conform to the Charter or the Company Equity
Plans as in effect immediately prior to the Effective Time;

 

(x)the obligations of the Surviving Corporation pursuant to Section 6.17
(including any indemnification of, or payments or advancements to, any Covered
Person in compliance therewith, but excluding any indemnification of, or
payments or advancements to, any Covered Person to the extent arising out of
any conduct, acts or omissions of such Covered Person after the Closing Date
in his or her capacity as a director, manager, managing director or officer of
the Surviving Corporation or any Subsidiary of the Surviving Corporation);

 

(xi)regardless of any disclosure on the Company Disclosure Schedule, any
transaction between the Company or any of its Subsidiaries, on the one hand,
and any Equityholder (or Series D Holder) or any Affiliate of an Equityholder
(or Series D Holder), on the other hand;

 

(xii)regardless of any disclosure on the Company Disclosure Schedule, the
following Taxes and, except as otherwise provided in Section 10.3, any Losses
incurred in contesting or otherwise in connection with any such Taxes: (A)
Taxes imposed on the Company or any of its Subsidiaries with respect to Tax
periods ending on or before the date of the Effective Time; (B) with respect
to Straddle Periods, Taxes imposed on the Company or any of its Subsidiaries
which are

 

88  

allocable, pursuant to Section 10.1, to the portion of such period ending on
the date of the Effective Time; (C) Taxes imposed on or with respect to the
transactions contemplated by this Agreement; (D) Taxes imposed on any Person
other than the Company or any of its Subsidiaries for which the Company or any
of its Subsidiaries is liable by operation of Law or agreement with respect to
any Tax period or any portion of a Tax period occurring on or before the date
of the Effective Time; and (E) Taxes imposed on Parent, the Company or any of
its Subsidiaries or, after the Effective Time, the Surviving Corporation or
any of its Subsidiaries, as a result of any breach of warranty or
misrepresentation under Section 4.16; provided, however, that a Tax shall not
be taken into account for purposes of this clause (xii) if, and to the extent
that, Liability for such Tax (1) has been taken into account as a reduction in
Working Capital for purposes of Section 3.8; or (2) is attributable to any
action of Parent or any of its Affiliates after the Closing on the Closing
Date outside of the ordinary course of business or relates to any Tax
attributable to any Tax period or portion thereof beginning after the Closing
Date;

 

(xiii)regardless of any disclosure on the Company Disclosure Schedule, the
treatment as an "excess parachute payment" (within the meaning of Code Section
280G(b)) of any payment made by the Company on or prior to the Closing Date or
otherwise required to be paid by the Company, the Surviving Corporation or any
of their respective Affiliates or Subsidiaries before, on or after the Closing
Date pursuant to written or oral Contracts or agreements entered into on or
prior to the Closing Date;

 

(xiv)regardless of any disclosure on the Company Disclosure Schedule, any
Liability of the Company under, resulting from or arising out of Section 409A
of the Code, including any Liability of the Company or any of its Subsidiaries
for any Claims from any Person for indemnification or reimbursement of any
taxes, penalties or other liability such Person incurs under, as a result of
or arising out of Section 409A of the Code;

 

(xv)regardless of any disclosure on the Company Disclosure Schedule, (A) the
existence prior to the Effective Time of the Cayman Subsidiary, (B) any
action, omission, election, decision or conduct prior to the Effective Time by
or with respect to (including by the Company or any of its Subsidiaries with
respect to) the Cayman Subsidiary, including the preparation or filing of (or
any failure to prepare or file) Tax Returns, or the payment of (or any failure
to pay) Taxes, by or with respect to the Cayman Subsidiary, (C) any fact,
event, development, circumstance or condition in respect of the Cayman
Subsidiary existing prior to the Effective Time, (D) any Contract or
arrangement entered into by or with (including by the Company or any of its
Subsidiaries with) the Cayman Subsidiary prior to the Effective Time (except
to the extent such Losses arise from or result from a breach of such Contract
or arrangement by the Surviving Corporation or any of its Subsidiaries after
the Effective Time), or (E) the performance of, or any actions taken in
furtherance of or in compliance with, Section 6.19;

 

(xvi)regardless of any disclosure on the Company Disclosure Schedule, any
failure, prior to the Closing, by the Company, any Subsidiary of the Company
or any of their respective officers, directors, managers, managing directors
or employees, or by any other Person acting on behalf of the Company or any
Subsidiary of the Company, to comply with applicable Health Care Laws or
Improper Payment Laws; and

 

(xvii)items listed on Exhibit Q.

 

89  

(b)Effect on Liability After Termination. Nothing in this Article 9 or
elsewhere in this Agreement shall limit the liability of any Party for any
breach of any representation, warranty, covenant or agreement in this
Agreement if this Agreement is terminated.

 

(c)Certain Limitations on Recovery by Parent Indemnified Persons. Subject to
the terms of this Section 9.2(c), the indemnification obligations of the
Equityholders pursuant to this Article 9 shall be (x) joint and several, but
only to the extent such obligations are to be satisfied by recovery from the
Escrow Fund or by offset against Earnout Consideration, as provided below, and
(y) in all other cases, borne by the Consenting Equityholders (subject to the
limitations set forth in this Section 9.2(c), including Section
9.2(c)(iii)(B)), on a several and not joint basis, based on their respective
Indemnity Pro Rata Shares, as provided below. Subject to the terms of this
Article 9:

 

(i)amounts payable to Parent Indemnified Persons pursuant to Section 9.2(a)
shall be recoverable (A) first, (I) from the Escrow Fund or (II) by offset
against Earnout Consideration then owing or payable, if any (or, at Parent's
option, by offset against Earnout Consideration potentially owing in the
future following achievement of the FDA Milestone Consideration, the First
Revenue Milestone or the Second Revenue Milestone), in accordance with Section
3.10(f), and (B) following depletion or distribution in full of the Escrow
Fund and offset in full of the Earnout Consideration then owing or payable (if
any), except as otherwise provided in Section 9.2(c)(iii)(B), directly from
the Consenting Equityholders, on a several (and not joint) basis, in
accordance with their respective Indemnity Pro Rata Shares;

 

(ii)for the avoidance of doubt (and without limiting Section 9.2(c)(i)(A) or
the right of any Parent Indemnified Person to recover from the Escrow Fund or
by offset against Earnout Consideration), no amounts payable to Parent
Indemnified Persons pursuant to Section 9.2(a) shall be recoverable directly
from any Equityholder other than the Consenting Equityholders;

 

(iii)(A) the maximum amount that the Parent Indemnified Persons may recover
pursuant to Section 9.2(a)(i) (except with respect to any breach, untruth or
inaccuracy of any Fundamental Representations or any Specified
Representations) shall be limited to and shall in no event exceed an amount
equal to the Ordinary RandW Cap, and (B) amounts payable to Parent Indemnified
Persons pursuant to Section 9.2(a)(i) (except with respect to any breach,
untruth or inaccuracy of any Fundamental Representation), Section 9.2(a)(xvi)
and Section 9.2(a)(xvii) shall be recoverable solely (I) from the Escrow Fund
or (II) by offset against Earnout Consideration then owing or payable, if any
(or, at Parent's option, by offset against Earnout Consideration potentially
owing in the future following achievement of the FDA Milestone Consideration,
the First Revenue Milestone or the Second Revenue Milestone), in accordance
with Section 3.10(f); and

 

(iv)the maximum amount that the Parent Indemnified Persons may recover
directly from any Consenting Equityholder pursuant to Section 9.2(a)(i)
(solely with respect to any breach, untruth or inaccuracy of any Fundamental
Representations) or Sections 9.2(a)(ii) through 9.2(a)(xv) shall be limited to
and shall in no event exceed an amount equal to one hundred percent (100%) of
the Merger Consideration received by such Consenting Equityholder pursuant to
this Agreement (whether received in respect of Preferred Stock, Common Stock
or Stock Options); provided, however, nothing in this Section 9.2(c)(iv) shall
in any way limit Section 9.2(c)(i)(A) or the right of any Parent Indemnified
Person to recover from the Escrow Fund or by offset against Earnout
Consideration.

 

90  

(d)No Right of Contribution. No Equityholder, and no Affiliate of any
Equityholder, shall have any right of contribution, indemnification or
advancement from the Surviving Corporation, Parent or any of their respective
Subsidiaries with respect to any Loss claimed by any Parent Indemnified
Person.

 

(e)Characterization of Claims. Notwithstanding anything in this Article 9 to
the contrary, if any Claim by a Parent Indemnified Person under this Article 9
may be properly characterized in multiple ways in accordance with this Article
9 such that such Claim may or may not be subject to different caps, time
limitations and other limitations depending on such characterization, then
such Parent Indemnified Person shall have the right to characterize such
indemnifiable matter in a manner that maximizes the recovery and time to
assert claims permitted in accordance with this Article 9.

 

Calculation of Losses; Mitigation

 

. 

 

(a)For the purposes of calculating the amount of Losses pursuant to Section
9.2(a)(i), the representations and warranties in this Agreement (and the
representations, warranties and certifications in any certificate or document
delivered pursuant to this Agreement) shall be read without any materiality
(including the word "material"), Material Adverse Effect or similar
qualifiers.

 

(b)The Parent Indemnified Persons shall not be entitled to indemnification
pursuant to Section 9.2(a)(i) (other than with respect to any breach, untruth
or inaccuracy of any Fundamental Representation or Specified Representation,
as to which the limitation in this Section 9.3(b) shall not apply) (i) for any
Losses until the aggregate amount of all Losses incurred by the Parent
Indemnified Persons with respect thereto exceeds Four Hundred Fifty Thousand
Dollars ($450,000) (the "Threshold Amount"), in which case the Parent
Indemnified Persons shall be entitled to indemnification for all Losses
incurred by such Parent Indemnified Persons in excess of the Threshold Amount,
or (ii) for any Losses with respect to any individual claim thereunder, until
the aggregate amount of all Losses with respect to such Claim (or, if such
Claim is among a series of Claims that arise from the same or substantially
similar facts or circumstances, with respect to such series of Claims) exceeds
Twenty-Five Thousand Dollars ($25,000) (the "Individual Claim Threshold"), in
which case the Parent Indemnified Persons shall be entitled to indemnification
for all Losses incurred by such Parent Indemnified Persons with respect to
such Claim regardless of the Individual Claim Threshold.

 

(c)Notwithstanding anything herein to the contrary, for purposes of
calculating or determining the amount of Losses indemnifiable under Section
9.2(a), (i) no Parent Indemnified Person shall be entitled to double recovery
under this Agreement for any such indemnifiable Losses, even though such
Losses may have resulted from the breach of more than one of the
representations, warranties, covenants or agreements in this Agreement, or
been indemnifiable under more than one subsection of Section 9.2(a), and (ii)
if and solely to the extent that such indemnifiable Losses were taken into
account in the calculation of the Final Working Capital, Final Debt Pay-Off
Amount or Final Company Transaction Expenses, the same amount of such Losses
may not be recovered under Section 9.2(a).

 

(d)Notwithstanding anything to the contrary herein, no Parent Indemnified
Person shall be entitled to make any claim for Losses pursuant to this
Agreement with respect to Taxes allocable to any Tax period (or portion of a
Tax period) occurring subsequent to the date of the

 

91  

Effective Time to the extent related to or arising from (i) the amount, value
or condition of any Tax asset or attribute (e.g. net operating loss
carryforward or Tax credit carryforward) of the Company or any of the
Subsidiaries, or (ii) the ability of Parent, the Surviving Corporation or any
of their Affiliates to utilize such Tax asset or attribute in any Tax period
or portion thereof beginning on or after the Closing Date.

 

(e)Notwithstanding anything to the contrary contained herein, the amount of
any Losses for which indemnification is provided under this Article 9 shall be
reduced by the amount of any insurance proceeds actually recovered by the
applicable Parent Indemnified Person with respect to such Losses (net of
actual out-of-pocket and reasonable costs of enforcement, deductibles, premium
increases and retro-premium adjustments related to such Losses), and Parent
and the applicable Parent Indemnified Person shall use their respective
commercially reasonable efforts to realize such proceeds; provided, that the
foregoing shall not require any Parent Indemnified Person to file suit or
initiate litigation, mediation or other proceedings against any Person.

 

Escrow Fund

 

.

 

(a)Promptly after the Effective Time, Parent shall deposit the Escrow Amount
with JPMorgan Chase Bank, N.A. (or another institution mutually acceptable to
Parent and the Company), as escrow agent in connection with this Agreement
(the "Escrow Agent"), such deposit (together with interest and other income
thereon) to constitute the Escrow Fund and to be governed by the terms set
forth herein and in the Escrow Agreement.

 

(b)Within three (3) Business Days following the date that is twenty-four (24)
months after the Closing Date, Parent and the Equityholders' Representative
shall, by delivery of a joint release certificate to the Escrow Agent in
accordance with the Escrow Agreement, instruct the Escrow Agent to deliver to
the Payments Administrator (for distribution, in accordance with the
Applicable Updated Payout Schedule, to (i) the Stockholders who have duly
surrendered their Certificates and delivered duly completed and validly
executed Transmittal Letters and (ii) the Optionholders, after giving effect
to any required withholding Taxes) any remaining amounts in the Escrow Fund,
less amounts that would be necessary to satisfy fully any then pending and
unsatisfied or unresolved Claims for indemnification timely asserted by any
Parent Indemnified Person in accordance with this Article 9 and the Escrow
Agreement as if such Claims were resolved in favor of Parent or such other
Parent Indemnified Person. Amounts not distributed under the foregoing in
respect of pending and unsatisfied or unresolved Claims shall remain in the
Escrow Fund until the related Claims have been resolved or until any such
portion of such amounts is determined pursuant to Section 9.6 to be no longer
necessary to satisfy such Claims. As soon as all such Claims have been
resolved or any such portion of such amounts is determined pursuant to Section
9.6 to be no longer necessary to satisfy such Claims, the Escrow Agent shall
deliver to the Payments Administrator (for distribution, in accordance with
the Applicable Updated Payout Schedule, to (A) the Stockholders who have duly
surrendered their Certificates and delivered duly completed and validly
executed Transmittal Letters and (B) the Optionholders, after giving effect to
any required withholding Taxes) the remaining portion of such undistributed
amount, if any, not required to satisfy such Claims. All payments made to
Equityholders under this Article 9 shall be made in accordance with their
respective Transmittal Letters and other Exchange Documents, or other
appropriate documentation.

 

92  

Equityholders' Representative

 

.

 

(a)Appointment. By virtue of any of (i) voting in favor of the adoption of
this Agreement, (ii) the approval of the principal terms of the Merger, (iii)
the consummation of the Merger or (iv) participating in the Merger and
receiving the benefits thereof (including the right, or, as the case may be,
contingent right, to receive consideration payable, or that may become
payable, in connection with the Merger), from and after the Effective Time,
each Equityholder shall be deemed to have approved the designation of, and
hereby designates, Shareholder Representative Services LLC as the
representative, agent and attorney-in-fact for each Equityholder (the
"Equityholders' Representative") for all purposes in connection with this
Agreement and the agreements ancillary hereto (including the Escrow
Agreement), including full power and authority to take the actions and make
the determinations contemplated or permitted to be taken by the Equityholders'
Representative pursuant to this Agreement and the agreements ancillary hereto
(including the Escrow Agreement) and to represent all of the Equityholders and
their successors with respect to all matters arising under this Agreement and
the agreements ancillary hereto (including the Escrow Agreement), with full
powers of substitution, and all actions taken by the Equityholders'
Representative hereunder and thereunder shall be binding upon all such
Equityholders and their successors as if expressly confirmed and ratified in
writing by each of them and no Equityholder shall have the right to object,
dissent, protest or otherwise contest the same. The rights, duties,
obligations and other provisions set forth on Exhibit M (A) are an integral
part of this Agreement, (B) shall apply with respect to the Equityholders'
Representative for all purposes under this Agreement and (C) notwithstanding
anything in this Agreement to the contrary, shall apply to and be binding
upon, and enforceable against, all Equityholders and, to the extent applicable
thereto in accordance with their terms, each other Party to this Agreement.

 

(b)Parent's Reliance. Parent, the Surviving Corporation, the Escrow Agent,
the Payments Administrator and their respective Affiliates shall be entitled
to rely on any action, instruction, waiver, consent or decision of the
Equityholders' Representative. Parent and its Affiliates shall not be obliged
to inquire into the authority of the Equityholders' Representative, and Parent
and its Affiliates shall be fully protected relying upon the Equityholders'
Representative's authority to act on behalf of the Equityholders.

 

(c)Binding Appointment. The provisions of this Agreement, including Exhibit M
(including the obligation of the Equityholders to indemnify the Equityholders'
Representative set forth therein) and Article 9, shall be binding upon each
Equityholder and the executors, heirs, legal representatives and successors of
each Equityholder, and any references in this Agreement to an Equityholder or
the Equityholders shall mean and include the successors to the Equityholders'
rights hereunder, whether pursuant to testamentary disposition, the Laws of
descent and distribution or otherwise

 

(d)Expense Fund. The Expense Amount shall be used by the Equityholders'
Representative for the purposes of paying directly, or reimbursing the
Equityholders' Representative for, any third party expenses pursuant to this
Agreement and the agreements ancillary hereto (including the Escrow
Agreement). The Equityholders' Representative shall be entitled to any
interest, dividends, earnings or other income received in respect of the
Expense Amount (or any remaining portion thereof), and such interest,
dividends, earnings or other income shall be treated as income earned by the
Equityholders' Representative for Tax purposes. No Equityholder shall be
entitled to, or have any right to receive, any interest, dividends, earnings
or other income received in respect of the Expense Amount (and, to the fullest
extent permitted by applicable Law, each

 

93  

Equityholder shall be deemed to have irrevocably transferred and assigned to
the Equityholders' Representative any ownership right that such Equityholder
otherwise may now have or may in the future have in any such interest,
dividends, earnings or other income). The Equityholders' Representative shall
not be liable for any loss of principal of the Expense Amount other than as a
result of its gross negligence, fraud or willful misconduct. The
Equityholders' Representative shall hold the Expense Amount (or any remaining
portion thereof) separate from its corporate funds, shall not use the Expense
Amount (or any remaining portion thereof) for its operating expenses or any
other corporate purposes and shall not voluntarily make the Expense Amount (or
any remaining portion thereof) available to its creditors in the event of
bankruptcy. As soon as practicable following the completion of the
Equityholders' Representative's responsibilities, the Equityholders'
Representative shall deliver any remaining balance of the Expense Fund to the
Payments Administrator (for distribution, in accordance with the Applicable
Updated Payout Schedule, to (i) the Stockholders who have duly surrendered
their Certificates and delivered duly completed and validly executed
Transmittal Letters and (ii) the Optionholders, after giving effect to any
required withholding Taxes). The Parties agree that amounts distributed to
Stockholders from the Expense Fund will be treated for tax purposes as
deferred payments of purchase price, except to the extent treated as payments
of interest pursuant to Section 483 or Section 1274 of the Code.

 

Indemnification Claims

 

.

 

(a)In the event a Claim is made by a Parent Indemnified Person entitled to
indemnification under this Agreement (an "Indemnified Person"), such
Indemnified Person (or a representative thereof) must give written notice (the
"Claim Notice") of such Claim to the Indemnifying Person. The Claim Notice
shall (i) state that an indemnification Claim (or indemnification Claims)
pursuant to Section 9.2(a) or any other provision of this Agreement is being
made, (ii) describe the basis for such Claim with reasonable specificity and
(iii) set forth in reasonable detail the Losses (or reasonably anticipated
Losses) in respect of such Claim (provided that the Indemnified Person shall
not be bound by any estimate of Losses contained in such Claim Notice);
provided that the Claim Notice need only specify such information to the
knowledge of such Indemnified Person (or such representative thereof) as of
the date thereof, shall not limit any of the rights or remedies of any
Indemnified Person, and may be updated and amended from time to time by the
Indemnified Person by delivering an updated or amended Claim Notice to the
Indemnifying Person; provided further, no Indemnified Person's rights or
remedies shall be prejudiced as a result of limitations on disclosure in such
Claim Notice, where such limitations are made in good faith to preserve the
attorney-client privilege, the work product doctrine, or any other privileges.
The Claim Notice shall be provided to the Indemnifying Person as soon as
reasonably practicable after the Indemnified Person becomes aware that it has
incurred or suffered a Loss. Notwithstanding the foregoing but subject to
Section 9.1, any failure to provide the Indemnifying Person with a Claim
Notice, or any failure to provide a Claim Notice in a timely manner as
aforesaid (or to include in such Claim Notice the information required above),
shall not relieve any Indemnifying Person from any liability that it may have
to the Indemnified Person under this Section 9.6 except to the extent, if at
all, that the ability of such Indemnifying Person to defend such Claim is
materially prejudiced by the Indemnified Person's failure to give such Claim
Notice. If the Claim Notice relates to a Third Party Claim, the procedures
set forth in Section 9.7 will be applicable.

 

(b)If the Claim Notice does not relate to a Third Party Claim, within thirty
(30) Business Days after receipt of such notice, the Indemnifying Person shall
provide a written notice to Parent, indicating whether the Indemnifying Person
objects to the indemnification Claim and describing the basis for any
objection with reasonable specificity. If no such objection notice is

 

94  

received by Parent within such thirty (30) Business Day period, the
Indemnifying Person shall be deemed to be entirely liable for indemnification
of the indemnification Claim pursuant to this Agreement (subject to the
limitations set forth in Sections 9.2(d) and 9.2(e)). If such notice of
objection is provided within such period, the Indemnifying Person and the
Indemnified Person or its representative(s) shall then attempt in good faith
for twenty-five (25) Business Days to agree upon a resolution of such
indemnification Claim. If no such resolution can be reached after good faith
negotiation during such twenty-five (25) Business Day period, unless otherwise
agreed to in writing by the Indemnifying Person and the Indemnified Person,
the Indemnified Person may institute proceedings in a court of competent
jurisdiction (in accordance with Section 11.8) to resolve any such dispute,
and the Indemnified Person and the Indemnifying Person shall seek to resolve
such dispute in as expeditious a manner as practicable. In the case of any
such proceeding, the Indemnified Person and the Indemnifying Person shall each
be responsible for the payment of its own fees and expenses.

 

Third Party Claims

 

. The following additional provisions shall apply with respect to any Claims
or demands by third parties as to which any Indemnified Person seeks
indemnification hereunder (a "Third Party Claim"). 

 

(a)Unless such Indemnified Person affirmatively elects not to control the
defense of such Third Party Claim by delivering a written notice (such notice,
a "Non-Defense Election") to the Indemnifying Person within thirty (30)
Business Days after giving the Indemnifying Person the applicable Claim Notice
in respect of such Third Party Claim, such Indemnified Person shall defend,
contest, negotiate or settle each such Third Party Claim through counsel of
its own selection (who shall be reasonably acceptable to the Indemnifying
Person), at the expense and for the account of the Indemnifying Person (and
the Indemnifying Person shall cooperate with and provide reasonable assistance
to any such Indemnified Person in the defense of such Claim or demand);
provided, however, that

 

(i)the Indemnifying Person shall be entitled to receive copies of such
pleadings, notices and communications with respect to any Third Party Claim as
the Indemnifying Person may reasonably request and participate in such
defense, at its own expense, with counsel of its choosing, and such
Indemnified Person and its counsel shall cooperate with the Indemnifying
Person in doing so, and

 

(ii)such Indemnified Person will not settle, compromise, or offer to settle or
compromise any such Third Party Claim unless (A) the Indemnifying Person
provides prior written consent, which consent will not be unreasonably
withheld, conditioned or delayed, or (B) no indemnification under this Article
9 is sought by any Indemnified Person in connection with the Third Party Claim
covered by the settlement.

 

(b)If, within thirty (30) Business Days after the Indemnified Person (or its
representative) gives the Indemnifying Person the applicable Claim Notice in
respect of such Third Party Claim, both (i) the Indemnifying Person delivers a
written notice to the Indemnified Person stating that, subject to delivery of
a Non-Defense Election by the Indemnified Person, the Indemnifying Person
elects to control the defense of such Third Party Claim, and (ii) the
Indemnified Person delivers a Non-Defense Election to the Indemnifying Person,
then, subject to Section 9.7(d), the Indemnifying Person shall be entitled to
defend, contest, negotiate or settle such Third Party Claim, at the expense
and for the account of the Indemnifying Person, through counsel of its own
selection (who shall be reasonably acceptable to the Indemnified Person).

 

95  

(c)Notwithstanding anything to the contrary in this Section 9.7, in the event
and for so long as a Third Party Claim (i) relates solely to the payment of
monetary damages in an aggregate amount that does not exceed the amount then
available under the Escrow Fund (excluding amounts in the Escrow Fund that are
otherwise the subject of pending indemnification claims under this Article 9),
which amount must remain in escrow pending final resolution of such Third
Party Claim, (ii) does not relate to criminal conduct or the payment of Taxes,
(iii) was not instituted by a Governmental Authority, and (iv) does not seek
equitable, injunctive or other non-monetary relief, subject to Section 9.7(d),
the Indemnifying Person shall be entitled to defend, contest, negotiate or
settle such Third Party Claim, at the expense and for the account of the
Indemnifying Person, through counsel of its own selection (who shall be
reasonably acceptable to the Indemnified Person), if the Indemnifying Person
provides written notice of its election to assume such defense pursuant to
this Section 9.7(c) within thirty (30) Business Days after the Indemnified
Person first delivers the applicable Claim Notice in respect of such Third
Party Claim to the Indemnifying Person and the Indemnifying Person
acknowledges in such written notice that any Losses that may be asserted
against the Indemnified Person in such Third Party Claim constitute Losses for
which the Indemnified Person is entitled to indemnification pursuant to this
Article 9. 

 

(d)In the event that the Indemnifying Person has assumed the defense of any
Third Party Claim pursuant to either Section 9.7(b) or (c), in each case all
of the following shall apply:

 

(i)The Indemnified Person shall cooperate with and provide reasonable
assistance to the Indemnifying Person in the defense of such Third Party
Claim;

 

(ii)the Indemnified Person shall be entitled to receive copies of all
pleadings, notices and communications with respect to such Third Party Claim
as the Indemnified Person may reasonably request and participate in such
defense, at its own expense, with counsel of its choosing, and such
Indemnifying Person and its counsel shall cooperate with the Indemnified
Person in doing so;

 

(iii)the Indemnified Person shall be entitled to immediately assume control of
the defense, contest, negotiation and settlement of such Third Party Claim in
the event any of the conditions in clauses (i) through (iv) of Section 9.7(c)
are not satisfied with respect to such Third Party Claim, or if the
Indemnifying Person fails to diligently defend such Third Party Claim, in
which case such costs and expenses associated with such defense by the
Indemnified Person may be sought in a claim for indemnification hereunder; and

 

(iv)the Indemnifying Person shall not be entitled to settle, compromise, or
offer to settle or compromise such Third Party Claim without the prior written
consent of the Indemnified Person, which consent will not be unreasonably
withheld, conditioned or delayed so long as (A) the conditions in clauses (i)
through (iv) of Section 9.7(c) are satisfied with respect to such Third Party
Claim, (B) such settlement or compromise includes only the payment of monetary
damages (which are fully paid at the time of such settlement or compromise by
the Indemnifying Person), and (C) such settlement or compromise releases the
Indemnified Person completely in connection with such Third Party Claim, with
no statement as to or an admission of fault by or on behalf of the Indemnified
Person or any of its Affiliates and no monetary or nonmonetary relief granted
by or imposed upon the Indemnified Person or any of its Affiliates. The
Indemnifying Person shall notify the Indemnified Person in writing prior to
effecting any settlement or compromise

 

96  

pursuant to this Section 9.7(d)(iv) and shall make available a copy of the
settlement agreement for the Indemnified Person's review prior to execution
thereof. 

 

Payment

 

. Upon a determination of liability under this Article 9, (a) with respect to
any amounts payable to a Parent Indemnified Person that are to be recovered
from the Escrow Fund pursuant to Section 9.2(c), Parent and the Equityholders'
Representative shall promptly deliver joint written instructions to the Escrow
Agent directing the Escrow Agent to release such funds to Parent from the
Escrow Fund, and (b) with respect to any amounts payable to an Indemnified
Person that are to be recovered directly from the Indemnifying Person pursuant
to Section 9.2(c)(i)(B), the Indemnifying Person shall pay or cause to be paid
to the Indemnified Person the amount so determined within ten (10) Business
Days after the date of such determination. If there should be a dispute as to
the amount or manner of determination of any indemnity obligation owed under
this Agreement, any portion of such amount that is not subject to dispute
shall nevertheless be paid as set forth above.

 

Remedy

 

. Notwithstanding anything to the contrary herein, the existence of this
Article 9 and of the rights, limitations and restrictions set forth herein do
not limit any legal or other remedy with respect to Claims based on fraud,
intentional misrepresentation or willful misconduct.

 

Article 10 
TAX

 



 

Tax Allocation.

 

 In the case of Taxes that are payable with respect to a taxable period that
begins before the date of the Effective Time and ends after the date of the
Effective Time, the portion of any such Tax that is allocable to the portion
of the period ending on the date of the Effective Time shall be:

 

(a)in the case of Taxes that are either (i) based upon or related to income,
receipts, payroll or other compensation for services or (ii) imposed in
connection with any sale or other transfer or assignment of property (real or
personal, tangible or intangible), deemed equal to the amount which would be
payable if the taxable year ended at the end of the date of the Effective Time
(except that, solely for purposes of determining the marginal tax rate
applicable to income or receipts during such period in a jurisdiction in which
such tax rate depends upon the level of income or receipts, annualized income
or receipts may be taken into account if appropriate for an equitable sharing
of such Taxes); and

 

(b)in the case of Taxes not described in Section 10.1(a) that are imposed on a
periodic basis and measured by the level of any item, deemed to be the amount
of such Taxes for the entire period (or, in the case of such Taxes determined
on an arrears basis, the amount of such Taxes for the immediately preceding
period) multiplied by a fraction the numerator of which is the number of
calendar days in the period ending on the date of the Effective Time and the
denominator of which is the number of calendar days in the entire period.

 

Section 10.2Returns and Payments. 

 

(a)The Company shall, and shall cause its Subsidiaries to, prepare and file in
a timely manner all Tax Returns relating to the Company or any of its
Subsidiaries that are due on or before the date of the Effective Time. The
Company shall, and shall cause its Subsidiaries to, pay in

 

97  

a timely manner all Taxes that are due on or before the date of the Effective
Time. Such Tax Returns shall be true, correct and complete and, except as
otherwise required by a change in applicable Law, (i) shall be prepared, and
each item thereon treated, in a manner consistent with past practices employed
with respect to the Company and its Subsidiaries, and (ii) shall utilize
accounting methods, elections and conventions that do not have the effect of
distorting the allocation of income or expense between the Tax periods covered
by such Tax Returns and subsequent Tax periods. Parent shall have the right
to review such Tax Returns for thirty (30) days prior to the filing of such
Tax Returns that are income Tax Returns and a reasonable period prior to the
filing of such Tax Returns that are not income Tax Returns, and the Company
agrees to discuss with Parent in good faith the items reflected on such Tax
Returns and any adjustments reasonably requested by Parent.

 

(b)The Surviving Corporation shall prepare and file, or cause to be prepared
and filed, in a timely manner all Tax Returns relating to the Company and its
Subsidiaries that are due after the date of the Effective Time with respect to
Tax periods ending on or before the date of the Effective Time and Straddle
Periods. Except as otherwise required by a change of applicable Law, (i) such
Tax Returns shall be prepared, and each item thereon treated, in a manner
consistent with past practices employed with respect to the Company and its
Subsidiaries (except to the extent counsel for the Surviving Corporation
determines there is no reasonable basis in Law therefor or determines that a
Tax Return cannot be so prepared and filed or an item so reported without
being subject to penalties) and (ii) shall utilize accounting methods,
elections and conventions that do not have the effect of distorting the
allocation of income or expense between the Tax periods covered by such Tax
Returns and subsequent Tax periods. The Equityholders' Representative shall
have the right to review such Tax Returns for thirty (30) days prior to the
filing of such Tax Returns that are income Tax Returns and a reasonable period
prior to the filing of such Tax Returns that are not income Tax Returns, and
the Surviving Corporation shall discuss in good faith the items reflected on
such Tax Returns and any adjustments reasonably requested by the
Equityholders' Representative. The Surviving Corporation shall be reimbursed
promptly out of amounts on deposit in the Escrow Fund for (A) Taxes due with
respect to such Tax Returns that relate to Tax periods that end on or before
the date of the Effective Time, and (B) Taxes due with respect to Tax Returns
that relate to Tax periods that end after the date of the Effective Time to
the extent that such Taxes are allocable (pursuant to the provisions of
Section 10.1) to the portion of such Tax periods ending on the date of the
Effective Time; provided, however, that the Surviving Corporation shall not be
reimbursed for such a Tax to the extent that such Tax has been taken into
account as a reduction in Working Capital for purposes of Section 3.8.

 

(c)For the avoidance of doubt, Parent and the Surviving Corporation shall have
the sole right to prepare and file, or cause to be prepared and filed, all Tax
Returns relating to the Surviving Corporation and its Subsidiaries with
respect to Tax periods beginning on or after the date of the Effective Time.
Notwithstanding the foregoing, none of Parent or any of its Affiliates shall
(i) amend any Tax Return of the Company or any of its Subsidiaries with
respect to any Tax periods ending on or before the date of the Effective Time
or enter into any voluntary disclosure agreement, engage in any voluntary
compliance procedures or make any other similar voluntary contact with any
Governmental Authority with respect to any Tax Return of the Company or any of
its Subsidiaries for such Tax periods, (ii) consent to the extension or waiver
of the limitations period applicable to any Tax claim or assessment with
respect to the Company or any of its Subsidiaries for any Tax periods ending
on or before the date of the Effective Time, or (iii) make any Tax election
with respect to the Company or any of its Subsidiaries that has effect for any
Tax periods ending on or before the date of the Effective Time, in each case
without the prior written consent of the Equityholders' Representative, which
consent shall not be unreasonably withheld, conditioned or delayed.

 

98  

Section 10.3Contests.

 

(a)After the date of the Effective Time, Parent shall promptly notify the
Equityholders' Representative in writing of any written notice of a proposed
adjustment or Claim in an audit or administrative or judicial proceeding
involving Parent or the Company or its Subsidiaries which, if determined
adversely to the taxpayer, would be grounds for indemnification under Article
9; provided, however, that a failure to give such notice will not affect
Parent's right to indemnification thereunder except to the extent, if any,
that, but for such failure, the Equityholders would have avoided the Tax
Liability in question.

 

(b)The procedures set forth in Section 9.7 shall control in the case of Third
Party Claims relating to Taxes or an audit or administrative or judicial
proceeding that relates solely to taxable periods ending on or before the date
of the Effective Time.

 

Cooperation and Exchange of Information.

 

 The Equityholders' Representative, the Company and Parent will each provide
the others with such cooperation and information as any of them reasonably may
request of the others in filing any Tax Return, amended Tax Return or claim
for refund, determining a Liability for Taxes or a right to a refund of Taxes,
participating in or conducting any audit or other proceeding in respect of
Taxes or making representations to or furnishing information to parties
subsequently desiring to acquire either of the Surviving Corporation or a part
of the business acquired from the Company by Parent. Such cooperation and
information shall include providing copies of relevant Tax Returns or portions
thereof, together with accompanying schedules, related work papers and
documents relating to rulings or other determinations by Tax authorities. The
Equityholders' Representative and Parent shall (and Parent after the Effective
Time will cause the Surviving Corporation and its Subsidiaries, if any, to)
retain all Tax Returns, schedules and work papers, records and other documents
in their possession relating to Tax matters of the Surviving Corporation and
its Subsidiaries, if any, for the taxable period that includes the date of the
Effective Time and for all prior taxable periods until the later of (a) the
expiration of the statute of limitations of the taxable periods to which such
Tax Returns and other documents relate, or (b) six (6) years following the due
date (without extension) for such Tax Returns. Any information obtained under
this Section 10.4 shall be kept confidential except as may be otherwise
necessary in connection with the filing of Tax Returns or claims for refund or
in conducting an audit or other proceeding; provided, however, the foregoing
shall not prohibit the Equityholders' Representative from disclosing such
information on a need-to-know basis to (i) its advisors and representatives
that are subject to confidentiality restrictions with respect to such
information that are at least as restrictive as the confidentiality
restrictions applicable to the Equityholders' Representative with respect
thereto, and (ii) those Equityholders that comprise the "Advisory Committee"
established under the Equityholders' Representative's engagement letter,
provided that each such Equityholder has executed a confidentiality agreement
with respect such information in form and substance reasonably satisfactory to
Parent.

 

Characterization of Payments.

 

 Parent and the Equityholders agree to treat all payments made by any of them
to or for the benefit of the others (including any payments to the Company or
any of its Subsidiaries) under Article 9 or other indemnity provisions of this
Agreement and for any misrepresentations or breach of warranties or covenants
as adjustments to the purchase price or as capital contributions for Tax
purposes and that such treatment shall govern for purposes hereof except to
the extent that the Laws of a particular jurisdiction provide otherwise, in
which case such payments shall be made in an amount sufficient to indemnify
the relevant party on an after-Tax basis. 

 

99  

Transfer Taxes.

 

 All transfer, documentary, sales, use, registration and any other such Taxes
and related fees (including any penalties, interest and additions to Tax)
("Transfer Taxes") arising out of or incurred in connection with this
Agreement shall be borne one-half by Parent and one-half by the Equityholders.
The Person that is legally required to file a Tax Return relating to Transfer
Taxes shall be responsible for preparing and timely filing such Tax Return and
Parent and the Equityholders shall each be responsible for reimbursing the
other for any portion of such Transfer Taxes that the other has paid in excess
of its 50% share (as determined pursuant to the foregoing sentence) within ten
(10) days after receiving notice that the other has paid such Transfer Taxes
(provided that, if Parent has paid more than its 50% share of any Transfer
Taxes, Parent shall be reimbursed for the Equityholders' portion of such
Transfer Taxes promptly out of amounts on deposit in the Escrow Fund). The
Parties shall reasonably cooperate with each other to minimize any liability
relating to Transfer Taxes, including in preparing any filings or elections
with any Governmental Authority, as applicable.

 

Tax Records.

 

 Prior to the Effective Time, the Company shall deliver to Parent (a) a
notice setting forth the name and contact information of each third party
provider of tax services that has been engaged by the Company or any of its
Subsidiaries at any time within the four (4) years preceding the Closing Date,
and (b) copies of all books and records of, and all other documents and
materials in the possession or control of, the Company and its Subsidiaries
that contain information required for the preparation of any Tax Returns
(other than Tax Returns that have been filed prior to the Effective Time)
relating to the Company and its Subsidiaries with respect to (i) Tax periods
ending on or before the date of the Effective Time or (ii) Straddle Periods.

 

Article 11 
MISCELLANEOUS

 



 

Fees and Expenses

 

. Except as specifically provided to the contrary in this Agreement, all
costs and expenses incurred in connection with this Agreement and the
transactions contemplated hereby shall be paid by the Party incurring such
expenses, whether or not the Merger is consummated.

 

Notices

 

. All notices and other communications that are required or permitted
hereunder shall be in writing and shall be delivered personally or sent by
nationally recognized overnight courier, by registered or certified mail
(postage prepaid, return receipt requested), or by facsimile or telecopier, in
each case to the Party to whom such notice or other communication is being
given at the address or telecopy number shown below, or to such other address
or telecopy number as such Party may have designated to the other Parties by
written notice delivered in accordance with this Section 11.2. All such
notices or communications shall be deemed to be received (a) in the case of
personal delivery, nationally recognized overnight courier or registered or
certified mail, on the date of such delivery, and (b) in the case of facsimile
or telecopier, upon receipt of the appropriate facsimile or telecopier
confirmation. A copy of any notice or other communication may also be
provided to a Party by email, but the Parties acknowledge and agree that no
such email shall constitute notice or otherwise satisfy the requirements of
this Section 11.2.

 

If to Parent, Merger Sub, or (following the Effective Time) the Surviving
Corporation, to:

 

Blackstone Medical, Inc.

 

3451 Plano Parkway

 

Lewisville, TX 75056

 

100  

Attention: Chief Legal Officer

 

Telecopy: (214) 937-3096

 



 

with a copy (which shall not constitute notice) to:

 



 

Hogan Lovells US LLP

 

Columbia Square

 

555 Thirteenth Street, N.W.

 

Washington, DC 20004

 

Attention: Joseph E. Gilligan and Brian C. O'Fahey

 

Telecopy: (202) 637-5910

 



 

If to the Company (prior to the Effective Time), to:

 

Spinal Kinetics, Inc.

 

501 Mercury Drive

 

Sunnyvale, CA 94085

 

Attention: Tom Afzal

 

email: TAfzal@SPINALKINETICS.COM

 



 

with copies (which shall not constitute notice) to:

 



 

Rich Ferrari

 

rich@denovovc.com

 



 

and

 



 

Wilson Sonsini Goodrich and Rosati, P.C.

 

650 Page Mill Road

 

Palo Alto, CA 94304

 

Attention: Scott K. Murano

 

Telecopy: (650) 493-6811

 



 

If to the Equityholders' Representative, to:

 

Shareholder Representative Services LLC

 

950 17th Street, Suite 1400

 

Denver, CO 80202

 

Attention: Managing Director

 

Email: deals@srsacquiom.com

 

Facsimile: (303) 623-0294

 

Telephone: (303) 648-4085

 



 

Severability.

 

 If any term or other provision of this Agreement, or the application
thereof, is invalid, illegal, void or incapable of being enforced by any rule
of Law, or public policy, all other terms and provisions of this Agreement
shall nevertheless remain in full force and effect so long as the economic or
legal substance of the transactions contemplated hereby is not affected in any
manner adverse to any Party. Upon such determination that any term or other
provision is invalid, illegal, void or incapable of being enforced, the
Parties shall negotiate in good

 

101  

faith to modify this Agreement so as to effect the original intent of the
Parties as closely as possible in an acceptable manner to the end that
transactions contemplated hereby are fulfilled to the extent possible.

 

Entire Agreement.

 

 This Agreement and the Escrow Agreement (including all exhibits, annexes and
schedules hereto and thereto), the Equityholders' Representative's engagement
letter and the other documents and instruments delivered pursuant hereto or
thereto constitute the entire agreement among, and supersede all prior
representations, agreements, understandings and undertakings (other than the
Confidentiality Agreement), both written and oral, among, the Parties (or any
of them) with respect to the subject matter hereof and thereof and no Party is
relying on any prior oral or written representations, agreements,
understandings or undertakings (other than the Confidentiality Agreement) with
respect to the subject matter hereof and thereof.

 

Assignment.

 

 This Agreement shall not be assigned by operation of Law or otherwise,
except that (a) Parent and Merger Sub may assign all or any of their rights
hereunder to any Affiliate (provided that no such assignment shall relieve the
assigning Party of its obligations hereunder), and (b) without limiting
Section 3.9(e), from and after the Effective Time, Parent may assign all of
its rights and obligations hereunder to a Person that directly or indirectly
acquires all of the capital stock, substantially all of the assets, or all or
part of the business, of the Surviving Corporation, so long as such Person
assumes this Agreement, in writing, and agrees to be bound by and to comply
with all of the terms and conditions hereof. 

 

Parties in Interest.

 

 Subject to Section 11.5 hereof, this Agreement shall be binding upon and
inure solely to the benefit of the Equityholders and each Party and each of
their respective permitted successors and assigns, and nothing in this
Agreement, express or implied, is intended to or shall confer upon any other
Person (other than the Indemnified Persons, who shall be third party
beneficiaries hereof to the extent set forth in Article 9) any right, benefit
or remedy of any nature whatsoever under or by reason of this Agreement.

 

Failure or Indulgence Not Waiver; Remedies Cumulative.

 

 No failure or delay on the part of any Party in the exercise of any right
hereunder will impair such right or be construed to be a waiver of, or
acquiescence in, any breach of any representation, warranty or agreement
herein, nor will any single or partial exercise of any such right preclude
other or further exercise thereof or of any other right. All rights and
remedies existing under this Agreement are cumulative to, and not exclusive
of, any rights or remedies otherwise available.

 

Section 11.8Governing Law; Jurisdiction. 

 

(a)This Agreement and all disputes, controversies, or claims relating to,
arising out of or under, or in connection with this Agreement or the other
transactions contemplated hereby, including the negotiation or execution
hereof and performance hereunder, shall be governed by, and construed in
accordance with, the laws of the State of Delaware, regardless of the laws
that might otherwise govern under applicable principles of choice of law or
conflicts of law rules or provisions (whether of the State of Delaware or any
other jurisdiction). Each of the Parties irrevocably and unconditionally
submits to the sole and exclusive personal jurisdiction of (i) the state
courts of the State of Delaware, and (ii) the United States District Court for
the District of Delaware (and appropriate appellate courts therefrom), for the
purposes of any dispute, claim, controversy, suit, action, or other proceeding
relating to, arising out of or under, or in connection with this Agreement or
the Escrow Agreement or any transaction contemplated hereby or thereby. Each
of the Parties

 

102  

further agrees and covenants (A) to commence any such action, suit or
proceeding either in the United States District Court for the District of
Delaware or, if such suit, action or other proceeding may not be brought in
such court for jurisdictional reasons, in any state court located in the State
of Delaware and (B) to not attempt to deny or defeat such personal
jurisdiction by motion or other request for leave from any such court.
Notwithstanding clause (A) of the foregoing sentence, each of the Parties
further agrees and covenants that if subject matter jurisdiction over any
action, suit, or proceeding in connection with any dispute, Claim, or
controversy relating to, arising out of or under, or in connection with this
Agreement, the Escrow Agreement, or the transactions contemplated hereby or
thereby exists in the Court of Chancery of the State of Delaware by reason of
Section 111 of the Delaware General Corporation Law or if there otherwise
exists a good faith basis for concluding that the Court of Chancery of the
State of Delaware would have subject matter jurisdiction in connection with
any such action, suit, or proceeding, then any such action, suit, or
proceeding shall be brought exclusively in the Court of Chancery of the State
of Delaware, and each Party agrees that it shall not attempt to deny or defeat
subject matter jurisdiction over such action, suit, or proceeding in the Court
of Chancery of the State of Delaware. Each Party hereby irrevocably and
unconditionally consents to service of any process, summons, notice or
document by U.S. certified or registered mail (postage prepaid, return receipt
requested) to the address to which notices and other communications to such
Party are required to be sent pursuant to Section 11.2, and each Party agrees
that such service shall be effective service of process for any action, suit
or proceeding in Delaware with respect to any matters to which it has
submitted to jurisdiction in this Section 11.8. Nothing herein shall be
deemed to limit or prohibit service of process by any other manner as may be
permitted by applicable Law. Each of the Parties irrevocably and
unconditionally waives any objection to the laying of venue of any action,
suit or proceeding relating to, arising out of or under, or in connection with
this Agreement or the transactions contemplated hereby in (1) the United
States District Court for the District of Delaware, or (2) any state court
located in the State of Delaware, and hereby further irrevocably and
unconditionally waives and agrees not to plead or claim in any such court that
any such action, suit or proceeding brought in any such court has been brought
in an inconvenient forum. Each of the Parties hereby agrees that this
Agreement involves at least $100,000 and that this Agreement has been entered
into in express reliance on 6 Del. C.  2708.

 

(b)Each of the Parties hereby agrees that a final judgment in any dispute,
claim, controversy, suit, action or other proceeding relating to, arising out
of or under, or in connection with this Agreement or the Escrow Agreement or
any transaction contemplated hereby or thereby shall be conclusive and may be
enforced in other jurisdictions by suit on the judgment or in any other manner
provided by Law.

 

(c)EACH PARTY HEREBY IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY
APPLICABLE LAW ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION, PROCEEDING OR
COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) RELATING TO,
ARISING OUT OF OR UNDER, OR IN CONNECTION WITH THIS AGREEMENT, THE
TRANSACTIONS CONTEMPLATED HEREBY, OR THE ACTIONS OF SUCH PARTY IN THE
NEGOTIATION, EXECUTION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF.
EACH OF THE PARTIES (I) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF
ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY
WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THAT FOREGOING WAIVER
AND (II) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HAVE BEEN INDUCED TO ENTER
INTO THIS AGREEMENT AND THE MERGER BY,

 

103  

AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION
11.8(c).

 

Enforcement of Agreement; Specific Performance.

 

The Parties agree that irreparable damage would occur in the event that any of
the provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached. It is accordingly agreed that the
Parties shall be entitled to an injunction to prevent breaches of this
Agreement and to enforce specifically the terms and provisions of this
Agreement in the state courts of the State of Delaware or any court of the
United States located in the State of Delaware, this being in addition to any
other remedy to which such Party is entitled at law or in equity.

 

Counterparts.

 

 This Agreement may be executed and delivered in one or more counterparts,
and by the different Parties in separate counterparts, each of which when
executed and delivered shall be deemed to be an original but all of which
taken together shall constitute one and the same agreement. Any facsimile or
electronically transmitted copies hereof or signatures hereon shall, for all
purposes, be deemed originals.

 

Due Diligence Materials.

 

 For purposes of this Agreement, the phrases "provided to Parent" or "made
available to Parent" shall mean the posting by the Company of the various
materials, documents and information produced by the Company throughout
Parent's due diligence review process to a virtual data room managed by the
Company, up until 3:00 pm Central Time on the calendar day prior to the date
of this Agreement; provided that no material, document or information shall be
deemed to have been posted to such virtual data room until such time as such
material, document or information is visible therein to, and accessible
therein by, Parent Representatives. The Company shall deliver to Parent, on
one or more USB electronic storage devices, (a) a complete and accurate (as of
the date of this Agreement) electronic copy of such virtual data room within
seven (7) Business Days after the date of this Agreement and (b) if any
additional materials, documents or information are added to such virtual data
room after the date of this Agreement, a complete and accurate (as of the
Closing Date) electronic copy of such virtual data room at or before the
Closing.

 

Time is of the Essence.

 

 Time is of the essence in this Agreement. Whenever this Agreement refers to
a number of days, such number shall refer to calendar days unless Business
Days are specified. Whenever any action must be taken hereunder on or by a
day that is not a Business Day, then such action may be validly taken on or by
the next day that is a Business Day. Relative to the determination of any
period of time, "from" means "including and after," "to" means "to but
excluding" and "through" means "through and including." When calculating the
period of time "before" which, "prior to" which, "within" which, "following"
which or "after" which any act is to be done or step taken pursuant to this
Agreement, the date that is the reference date in calculating such period
shall be excluded. 

 

[The remainder of this page is intentionally left blank.]

 



 

104  

IN WITNESS WHEREOF, Parent, Merger Sub, the Company and the Equityholders'
Representative have executed and delivered this Agreement and Plan of Merger
or caused this Agreement and Plan of Merger to be executed and delivered by
their respective officers thereunto duly authorized as of the date first
written above.

 

COMPANY:

 



 

SPINAL KINETICS, INC.

 



 



 



 

By: /s/ Thomas Azfal

 

Name: Thomas Azfal

 

Title: CEO

 



 



 

PARENT:

 



 

BLACKSTONE MEDICAL, INC.

 



 



 



 

By: /s/ Bradley R. Mason

 

Name: Bradley R. Mason

 

Title: President and Chief Executive Officer

 



 



 

MERGER SUB:

 



 

SUMMIT DEVELOPMENT, INC.

 



 



 



 

By: /s/ Bradley R. Mason

 

Name: Bradley R. Mason

 

Title: President

 



 



 

Equityholders' Representative:

 



 

SHAREHOLDER REPRESENTATIVE SERVICES LLC, solely in its capacity as the
Equityholders' Representative

 



 



 



 

By: /s/ Sam Riffe

 

Name: Sam Riffe

 

Title: Executive Director

 



 



 



 

  



 

EXHIBIT C

 

DEFINITIONS

 



 

"2016 Bridge Notes" means all convertible promissory notes issued pursuant to
the 2016 Note Purchase Agreement.

 

"2016 Note Purchase Agreement" means that certain 2016 Note Purchase
Agreement, dated as of October 28, 2016, as amended by Amendment No. 1 to 2016
Note Purchase Agreement, dated as of December 14, 2016, by and among the
Company and the persons and entities listed on the schedule of investors
attached thereto as Schedule I.

 

"2017 Audited Financial Statements" means consolidated financial statements of
the Company and its Subsidiaries for the fiscal year ended December 31, 2017,
which (a) consist of (i) a consolidated balance sheet of the Company and its
Subsidiaries as of December 31, 2017, (ii) consolidated statements of (A)
operations and comprehensive income, (B) stockholders' equity and (C) cash
flows, in each case of the Company and its Subsidiaries for the fiscal year
ended December 31, 2017, and (iii) all related notes and schedules, (b) are
prepared in accordance with (i) GAAP applied on a basis consistent with the
past practices of the Company and its Subsidiaries and (ii) Regulation S-X (17
C.F.R. Part 210), and (c) are audited by Ernst and Young LLP.

 

"Accounting Rules" means, collectively, (a) the method of calculating working
capital used in the illustrative calculation of working capital set forth on
Exhibit H, subject to any additional adjustments described on Exhibit H (the
"Working Capital Calculation Method"), (b) GAAP, and (c) the Company's past
practices used in preparing the Financial Statements (the "Financial Statement
Principles"); provided that in the event of any conflict among the Working
Capital Calculation Method, GAAP and the Financial Statement Principles, the
Working Capital Calculation Method shall take precedence, followed by GAAP,
followed by the Financial Statement Principles.

 

"Acquisition Proposal" means any inquiry, proposal or offer from any Person
(other than Parent, Merger Sub or any of their Affiliates) relating to (a) any
merger, consolidation, reorganization or other direct or indirect business
combination involving, or any recapitalization, liquidation or winding-up of,
or any similar transaction involving, the Company or any of its Subsidiaries,
(b) the issuance or acquisition of shares of capital stock or other equity
securities (or of options or warrants to purchase, or other securities or
instruments convertible into or exchangeable for, shares of capital stock or
other equity securities) of the Company or any of its Subsidiaries
representing ten percent (10%) or more of (i) any class or series of the
outstanding capital stock of the Company or any of its Subsidiaries or (ii)
the outstanding voting power of the Company or any of its Subsidiaries, (c)
any tender, exchange offer or other offer or bid for any shares of capital
stock or other equity securities of the Company or any of its Subsidiaries,
(d) the sale, lease, exchange, license (whether exclusive or not) or other
disposition of a substantial portion of the Intellectual Property of the
Company or any of its Subsidiaries or a substantial portion of the business or
other assets of the Company or any of its Subsidiaries, or (e) any other
transaction, the consummation of which would reasonably be expected, directly
or indirectly, to impede, interfere with, prevent or materially delay the
consummation of the Merger or any of the other transactions contemplated
hereby or which would reasonably be expected, directly or indirectly, to
diminish significantly the benefits to Parent or its Affiliates of the Merger
or any of the other transactions contemplated hereby. Notwithstanding
anything to the contrary in this Agreement, neither (i) the conversion of any
Convertible Notes or shares of Preferred Stock into Common Stock, nor (ii) the
valid exercise of

 

C-1  

Stock Options or Warrants to purchase Common Stock or Series C Preferred
Stock, shall constitute an Acquisition Proposal.

 

"Affiliate" means any Person that directly, or indirectly through one or more
intermediaries, controls, is controlled by or is under common control with the
Person specified. For purposes of this definition, control of a Person means
the power, direct or indirect, to direct or cause the direction of the
management and policies of such Person, whether through ownership of voting
securities or ownership interests, by contract or otherwise, and specifically
with respect to a corporation, partnership or limited liability company, means
direct or indirect ownership of more than fifty percent (50%) of the voting
securities in such corporation or of the voting interest in such partnership
or limited liability company.

 

"Affiliated Group" has the meaning set forth in Section 4.16(a)(iii).

 

"Agreement" has the meaning set forth in the Preamble.

 

"Anti-Boycott Regulations" has the meaning set forth in Section 4.30(a).

 

"Antitrust Laws" means the Sherman Act, as amended, the Clayton Act, as
amended, the HSR Act, as amended, the Federal Trade Commission Act, as
amended, and all other Laws that are designed or intended to prohibit,
restrict or regulate actions having the purpose or effect of monopolization or
restraint of trade or lessening of competition.

 

"Applicable Privacy Laws" has the meaning set forth in Section 4.27(a).

 

"Applicable Updated Payout Schedule" means, with respect to any payment,
distribution or delivery of funds by the Payments Administrator to the
Equityholders, the Updated Payout Schedule delivered to Parent and the
Payments Administrator by the Equityholders' Representative pursuant to
Section 6.15(d) in connection with such payment, distribution, delivery or
release.

 

"Appraisal Rights" has the meaning set forth in Section 3.7.

 

"Appraisal Rights Statutes" has the meaning set forth in Section 3.7.

 

"Approvals" has the meaning set forth in Section 4.1(a).

 

"Base Merger Consideration" means Forty-Five Million Dollars ($45,000,000).

 

"Baseline Working Capital" means an amount equal to Four Million Dollars
($4,000,000).

 

"Business Day" means any day other than a Saturday, Sunday or day on which
banks are required or permitted to close in the State of New York or
California.

 

"Bylaws" means the bylaws of the Company, as amended.

 

"Cancelled Shares" has the meaning set forth in Section 3.1(a).

 

"Cash" means all cash and cash equivalents of the Company and its
Subsidiaries.

 

C-2  

"Cayman Subsidiary" means Spinal Kinetics Cayman Islands, an exempted company
incorporated in the Cayman Islands.

 

"Cayman Subsidiary Tax Election" has the meaning set forth in Section 6.19(a).

 

"CCC" means the California Corporations Code.

 

"Certificate of Merger" has the meaning set forth in Section 2.2.

 

"Certificates" has the meaning set forth in Section 3.4(d).

 

"Charter" means the Amended and Restated Certificate of Incorporation of the
Company, as amended.

 

"Claim" means any claim, suit, action, arbitration, mediation, petition, cause
of action, complaint, charge, allegation, criminal prosecution, investigation,
demand letter, hearing or proceeding, whether civil, criminal, administrative
or investigative, at law or at equity, before or by any Governmental
Authority, arbitrator, other tribunal, or any other Person, and any
information request from a Governmental Authority.

 

"Claim Notice" has the meaning set forth in Section 9.6(a).

 

"Closing" has the meaning set forth in Section 2.2.

 

"Closing Date" has the meaning set forth in Section 2.2.

 

"Closing Date Statement" has the meaning set forth in Section 3.8(b).

 

"Closing Merger Consideration" shall equal (a) Base Merger Consideration, plus
(b) if the Estimated Working Capital is greater than the Baseline Working
Capital, the difference between the Estimated Working Capital and the Baseline
Working Capital, minus (c) if the Estimated Working Capital is less than the
Baseline Working Capital, the difference between the Baseline Working Capital
and the Estimated Working Capital, minus (d) the Estimated Debt Pay-Off
Amount, minus (e) the Estimated Company Transaction Expenses minus (f) the
Escrow Amount, minus (g) the Expense Amount, plus (h) the Estimated Cash.

 

"COBRA Coverage" has the meaning set forth in Section 4.13(e).

 

"Code" means the U.S. Internal Revenue Code of 1986, as amended, from time to
time, and the Regulations promulgated and rulings issued thereunder.

 

"Commercially Reasonable Efforts" means, for purposes of Section 3.9(d), the
expenditure of efforts and resources consistent with the usual practice of
Parent and its Subsidiaries with respect to development or commercialization
of products of similar commercial potential at a similar stage in product
lifecycle, taking into account: (a) issues of efficacy, safety, and expected
and actual approved labeling, (b) the risks inherent in the development and
commercialization of the product, (c) the expected and actual competitiveness
of alternative products sold by third parties in the marketplace, (d) the
expected and actual product profile, (e) the expected and actual patent and
other proprietary position of the product, (f) the likelihood and difficulty
of obtaining FDA and other regulatory approval given the regulatory structure
involved, (g) the regulatory status of the product and scope of

 

C-3  

any marketing approval, (h) pending or actual legal proceedings with respect
to the product, (i) whether the product is subject to a clinical hold, recall
or market withdrawal, (j) input from regulatory experts and any guidance or
developments from the FDA or similar Governmental Authority affecting the data
required to obtain premarket approval from the FDA or any similar approval
from another Governmental Authority; and (k) the expected and actual
profitability and return on investment of the product, taking into
consideration, among other factors, the expected and actual (1) third-party
costs and expenses, (2) royalty and other payments, and (3) pricing and
reimbursement relating to the product(s), but in each case not including
payments made or to be made pursuant to this Agreement.

 

"Common Stock" has the meaning set forth in Section 4.3(a).

 

"Company" has the meaning set forth in the Preamble.

 

"Company 401(k) Plan" has the meaning set forth in Section 6.5(c).

 

"Company Balance Sheet Date" has the meaning set forth in Section 4.9.

 

"Company Distributor" has the meaning set forth in Section 4.34.

 

"Company Equity Plans" means all stock option plans or equity-related plans or
arrangements of the Company, including the Company's 2003 Stock Plan and the
Company's 2014 Equity Incentive Plan.

 

"Company Representatives" has the meaning set forth in Section 6.2(a).

 

"Company Transaction Expenses" means all costs, fees and expenses incurred
(whether or not billed or invoiced) by or on behalf of the Company or any of
its Subsidiaries in connection with this Agreement and the transactions
contemplated hereby, including (a) any broker's, financial advisor's, finder's
or other fee or commission arising out of, relating to or in connection with
the transactions contemplated hereby, (b) fees and expenses payable to
advisors and consultants (including investment bankers, lawyers and
accountants) arising out of, relating to or incidental to the discussion,
evaluation, negotiation, documentation or effectuation of the transactions
contemplated hereby, (c) fees and costs related to the repayment of any
Indebtedness (including prepayment fees and penalties), to the extent not
included in the Final Debt Pay-Off Amount, (d) the maximum amount of any bonus
or other payment (including any "stay" or "sale" bonus) paid or payable to any
director, manager, managing director, officer or employee or Affiliate of the
Company or any of its Subsidiaries as a result of the transactions
contemplated by this Agreement, (e) any amounts payable pursuant to any
management carve-out plan in connection with the transactions contemplated by
this Agreement, (f) the employer-paid portions of applicable federal, state or
local payroll, employment or similar Taxes due with respect to the payments
described in the foregoing clause (d) or clause (e) and with respect to the
treatment of the Stock Options pursuant to Section 3.2, (g) the aggregate
amount of the premium paid to purchase the "tail" or "run-off" policy
contemplated in Section 6.17, (h) any "Liquidation Bonus" payable pursuant to
any VLL Warrant, (i) any fees, expenses or other Liabilities arising out of,
relating to or in connection with the termination of any Specified Terminated
Arrangement, (j) any amounts payable in respect of shares of Series D
Preferred Stock, including amounts payable to redeem any such shares, (k) any
assignment fee payable pursuant to Section 14.3 of that certain Exclusivity
Agreement, dated as of February 10, 2004, as amended by Amendment No. 1, dated
as of June 4, 2013, and Amendment No. 2, dated as of August 16, 2016, by

 

C-4  

and between the Board of Trustees of the Leland Stanford Junior University and
the Company, and (l) any fees, expenses or other Liabilities due to the
Equityholders' Representative.

 

"Confidentiality Agreement" means that certain Mutual Confidentiality / Non-
Disclosure Agreement, effective as of August 16, 2017, between Parent and the
Company.

 

"Consenting Equityholders" means all Equityholders that duly execute
Stockholder Consents and Agreements.

 

"Contingent Consideration" means (a) only to the extent paid to Equityholders
pursuant to Section 3.8(d), the Equityholders Final Closing Adjustment
Consideration, (b) only to the extent paid to Equityholders pursuant to
Section 3.10, the First Revenue Milestone Consideration, (c) only to the
extent paid to Equityholders pursuant to Section 3.10, the Second Revenue
Milestone Consideration, (d) only to the extent paid to Equityholders pursuant
to Section 3.10, the FDA Milestone Consideration, (e) only to the extent paid
to Equityholders pursuant to Section 9.4, the amounts deposited under the
Escrow Agreement, and (f) only to the extent paid to the Equityholders
pursuant to Section 9.5(d), the amounts held in the Expense Fund.

 

"Contract" means any contract, plan, undertaking, understanding, agreement,
purchase order, license, sublicense, consent, lease, note, mortgage or other
binding commitment, whether written or oral.

 

"Contract Workers" means individual independent contractors, individual
consultants, temporary employees, leased employees, retired persons entitled
to payment from the Company, or other service providers employed or used by
the Company or any of its Subsidiaries who are not (a) classified by the
Company or any of its Subsidiaries as employees or (b) compensated by the
Company or any of its Subsidiaries through wages reported on a Form W-2.

 

"Convertible Note" means any evidence of indebtedness of the Company that is
convertible into or exchangeable for capital stock of the Company, including
the De Novo Standalone Note and each 2016 Bridge Note.

 

"Covered Person" has the meaning set forth in Section 6.17(a).

 

"Data Subject Consents" has the meaning set forth in Section 4.27(c).

 

"De Novo Standalone Note" means that certain Subordinated Convertible
Promissory Note, dated December 19, 2016, issued by the Company in favor of De
Novo Ventures II, L.P., as amended.

 

"Debt Pay-Off Amount" has the meaning set forth in Section 7.2(l).

 

"DGCL" has the meaning set forth in the Recitals.

 

"Disputed Claim Losses" has the meaning set forth in Section 3.10(f).

 

"Dissenters' Rights" has the meaning set forth in Section 3.7.

 

"Dissenting Shares" has the meaning set forth in Section 3.7.

 

C-5  

"EAR" has the meaning set forth in Section 4.30(a).

 

"Earnout Consideration" has the meaning set forth in Section 3.9(a). 

 

"Earnout Period" has the meaning set forth in Section 3.9(a).

 

"Earnout Period End Date" has the meaning set forth in Section 3.9(a).

 

"Effective Time" has the meaning set forth in Section 2.2.

 

"Employee Agreements" has the meaning set forth in the Recitals.

 

"Employee Plans" has the meaning set forth in Section 4.13(a).

 

"Employees" has the meaning set forth in Section 6.5(a).

 

"Employment Laws" means, to the extent enacted prior to the Closing and as in
effect on the Closing, all Laws and Orders concerning (a) hiring, (b)
termination, (c) collective bargaining, (d) compensation, (e) harassment,
discrimination or retaliation in employment, (f) affirmative action, (g)
immigration, (h) work authorization, (i) terms and conditions of employment,
(j) payroll Tax withholding and deductions, (k) unemployment compensation, (l)
worker's compensation, (m) worker classification (including the proper
classification of workers as contingent workers, independent contractors and
consultants), (n) privacy, (o) records and files, (p) social security
contributions, (q) wages, (r) hours of work, (s) occupational safety and
health, or (t) any other employment practices.

 

"Environmental Laws" means any and all Laws, Orders, codes, or other legally
enforceable requirements (including common law) of the United States, or any
state, local, municipal or other U.S. Governmental Authority, regulating,
relating to or imposing liability or standards of conduct concerning Hazardous
Materials, or the protection of the environment, human health, employee health
and safety, or natural resources, including the Comprehensive Environmental
Response, Compensation, and Liability Act, 42 U.S.C.  9601 et seq.

 

"Environmental Permits" means any and all permits, licenses, registrations,
notifications, exemptions and any other Approvals under any Environmental
Laws.

 

"Equityholders" means, collectively, all Stockholders and Optionholders.

 

"Equityholders Final Closing Adjustment Consideration" has the meaning set
forth in Section 3.8(d).

 

"Equityholders' Representative" has the meaning set forth in the Section
9.5(a).

 

"ERISA" has the meaning set forth in Section 4.13(a).

 

"ERISA Affiliate" has the meaning set forth in Section 4.13(a).

 

"Escrow Agent" has the meaning set forth in Section 9.4(b).

 

"Escrow Agreement" has the meaning set forth in Section 6.12.

 

C-6  

"Escrow Amount" means Four Million Five Hundred Thousand Dollars ($4,500,000).

 

"Escrow Fund" has the meaning set forth in Section 3.4(g).

 

"Escrowed Stockholder Consents and Agreements" has the meaning set forth in
the Recitals.

 

"Escrow/Set-Off Remedy End Date" means the later of (a) the date on which the
Escrow Fund has been depleted or distributed in full, or (b) the date on which
all Earnout Consideration has been deposited with the Payments Administrator
for distribution to the Equityholders in accordance with Section 3.10 (or
offset against Losses of Parent or the Surviving Corporation in accordance
with Section 3.10(f)) or is otherwise no longer capable of becoming payable to
the Equityholders pursuant to Section 3.10.

 

"Estimated Cash" has the meaning set forth in Section 3.8(a).

 

"Estimated Closing Balance Sheet" has the meaning set forth in Section 3.8(a).

 

"Estimated Closing Statement" has the meaning set forth in Section 3.8(a).

 

"Estimated Company Transaction Expenses" has the meaning set forth in Section
3.8(a).

 

"Estimated Debt Pay-Off Amount" has the meaning set forth in Section 3.8(a).

 

"Estimated Working Capital" has the meaning set forth in Section 3.8(a).

 

"EU" means the European Union.

 

"EU Medical Device Directives" means Council Directive 90/385/EEC on active
implantable medical devices, Council Directive 93/42/EEC concerning medical
devices, and Directive 98/79/EC on in vitro diagnostic medical devices.

 

"Exchange Documents" has the meaning set forth in Section 3.4(c).

 

"Exchange Rate Methodology" means Orthofix International N.V.'s then current
standard exchange rate methodology (which, as of the date of this Agreement,
is (a) with respect to total sales in any foreign currency during any calendar
month, translation of such total sales into U.S. Dollars using the average of
the applicable exchange rate reported by Bloomberg at 5:00 pm New York time on
each trading day during such calendar month, and (b) with respect to total
sales in any foreign currency during any twelve (12) calendar month period,
the sum of the monthly translated sales in such foreign currency (as
translated to U.S. Dollars in accordance with the foregoing clause (a)) for
each calendar month during such period).

 

"Existing Indebtedness" has the meaning set forth in Section 4.26.

 

"Expense Amount" means Seventy-Five Thousand Dollars ($75,000).

 

"Expense Fund" has the meaning set forth in Section 3.4(g).

 

C-7  

"FCPA" means the U.S. Foreign Corrupt Practices Act and all rules, regulations
and guidance promulgated thereunder.

 

"FDandC Act" has the meaning set forth in Section 4.28(a).

 

"FDA" means the United States Food and Drug Administration.

 

"FDA Law and Regulation" has the meaning set forth in Section 4.28(a).

 

"FDA M6-C Approval" means approval by the FDA, by order issued under Section
515 of the FDandC Act, of the premarket application (PMA) (P170036) for the M6-C
Disc with approved indications allowing commercial distribution in the United
States of the M6-C Disc for single level disc replacement.

 

"FDA Milestone" has the meaning set forth in Section 3.9(a). 

 

"FDA Milestone Consideration" has the meaning set forth in Section 3.9(a). 

 

"Final Cash" has the meaning set forth in Section 3.8(b).

 

"Final Closing Adjustment Amount" means an amount equal to (a) Zero Dollars
($0), plus (b) if the Final Working Capital is greater than the Estimated
Working Capital, the difference between the Final Working Capital and the
Estimated Working Capital, minus (c) if the Final Working Capital is less than
the Estimated Working Capital, the difference between the Estimated Working
Capital and the Final Working Capital, minus (d) if the Final Debt Pay-Off
Amount is greater than the Estimated Debt Pay-Off Amount, the difference
between the Final Debt Pay-Off Amount and the Estimated Debt Pay-Off Amount,
plus (e) if the Final Debt Pay-Off Amount is less than the Estimated Debt Pay-
Off Amount, the difference between the Estimated Debt Pay-Off Amount and the
Final Debt Pay-Off Amount, minus (f) if the Final Company Transaction Expenses
are greater than the Estimated Company Transaction Expenses, the difference
between the Final Company Transaction Expenses and the Estimated Company
Transaction Expenses, plus (g) if the Final Company Transaction Expenses are
less than the Estimated Company Transaction Expenses, the difference between
the Estimated Company Transaction Expenses and the Final Company Transaction
Expenses, minus (h) if the Final Cash is less than the Estimated Cash, the
difference between the Estimated Cash and the Final Cash, plus (i) if the
Final Cash is greater than the Estimated Cash, the difference between the
Final Cash and the Estimated Cash.

 

"Final Company Transaction Expenses" has the meaning set forth in Section
3.8(b).

 

"Final Debt Pay-Off Amount" has the meaning set forth in Section 3.8(b).

 

"Final Working Capital" has the meaning set forth in Section 3.8(b).

 

"Financial Statement Principles" has the meaning set forth in the definition
of Accounting Rules.

 

"Financial Statements" has the meaning set forth in Section 4.9(a).

 

"First Revenue Milestone" has the meaning set forth in Section 3.9(a). 

 

C-8  

"First Revenue Milestone Consideration" has the meaning set forth in Section
3.9(a). 

 

"Foreign Competition Laws" means any non-U.S. Laws or Orders that are designed
or intended to prohibit, restrict or regulate actions having the purpose or
effect of monopolization, lessening of competition or restraint of trade.

 

"Foreign Plan" has the meaning set forth in Section 4.13(a).

 

"Fundamental Representations" means the representations and warranties set
forth in Sections 4.1, 4.2, 4.3, 4.4, 4.5, 4.6(a)(i), 4.16, and 4.22.

 

"GAAP" means generally accepted accounting principles in the United States.

 

"GLBA" has the meaning set forth in Section 4.27(a).

 

"Governmental Authority" means any (a) nation or government (whether foreign
or domestic), including any federal, state, provincial or local municipality,
principality, commonwealth, province, territory, county, district or other
jurisdiction of any nature or other political subdivision, instrumentality or
authority thereof, or (b) department, commission, bureau, agency, authority,
board, court, arbitrator, arbitration tribunal, official, officer, self-
regulatory authority or organization, or other entity or body, domestic or
foreign (including any multinational, supra-national or quasi-governmental
entity, body or authority), exercising executive, judicial, regulatory,
administrative, enforcement, police, military or taxing governmental
functions. 

 

"Governmental Damages" means (a) any civil, administrative or criminal
penalties, assessments or fines paid or payable to a Governmental Authority,
(b) any restitution, penalties or damages paid to a third party, in each case,
resulting from the (i) conviction (including as a result of the entry of a
guilty plea, a consent judgment or a plea of nolo contendere) of the Company
or any of its Subsidiaries of a crime or (ii) settlement or resolution with a
Governmental Authority for the purpose of closing a Governmental
Investigation, or (c) any administrative sanctions, injunctive relief,
deferred prosecution agreement, non-prosecution agreement, corporate integrity
agreement or requirement to alter business practices imposed by or entered
into with any Governmental Authority.

 

"Governmental Investigation" means an investigation or issuance of a subpoena,
civil investigative demand or other formal or informal request for information
or documents by a Governmental Authority for the purpose of investigating
violations of any applicable Laws (including any Health Care Laws) or imposing
criminal sanctions or civil or administrative penalties, fines, damages,
sanctions or injunctions on the Company or any of its Subsidiaries.

 

"Group Health Plan" has the meaning set forth in Section 4.27(a).

 

"Hazardous Materials" means any wastes, substances, radiation, or materials
(whether solids, liquids or gases) (a) which are hazardous, toxic, infectious,
explosive, radioactive, carcinogenic, or mutagenic; (b) which are or become
defined as "pollutants," "contaminants," "hazardous materials," "hazardous
wastes," "hazardous substances," "chemical substances," "radioactive
materials," "medical waste," "infectious substances," "regulated waste,"
"solid wastes," or other similar designations in, or otherwise subject to
regulation under, any Environmental Laws; (c) which contain without limitation
polychlorinated biphenyls (PCBs), mold, methyl-tertiary butyl ether (MTBE),
asbestos or asbestos-containing materials, lead-based paints, urea-
formaldehyde foam

 

C-9  

insulation, or petroleum or petroleum products (including crude oil or any
fraction thereof); or (d) which pose a hazard to human health, safety, natural
resources, employees, or the environment.

 

"Health Care Laws" has the meaning set forth in Section 4.29(a).

 

"HIPAA" means the Health Insurance Portability and Accountability Act of 1996,
as amended, and the Regulations promulgated and rulings issued thereunder.

 

"HSR Act" means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as
amended, and the regulations promulgated thereunder.

 

"Improper Payment Laws" means the FCPA and any other applicable Laws regarding
corruption, bribery, money laundering or illegal payments or gratuities,
including the U.K. Bribery Act 2010,  299, 299a/b and 331 et seq. of the
German Criminal Code (Strafgesetzbuch), and anti-bribery laws of all other
jurisdictions in which the Company or any of its Subsidiaries directly or
indirectly does business.

 

"Indebtedness" means (a) all indebtedness (whether or not contingent) for
borrowed money, including any indebtedness incurred to finance the purchase of
equipment or other property; (b) all obligations (contingent or otherwise) for
the deferred purchase price of assets, property or services, including any
potential earn-out, purchase price adjustment, releases of "holdbacks" or
similar payments, but excluding any Company Transaction Expenses and any
accounts payable or deferred liabilities included in the calculation of
Working Capital, (c) all obligations evidenced by notes, bonds, debentures or
other similar instruments (whether or not convertible) or arising under
indentures, (d) all indebtedness created or arising under any conditional sale
or other title retention agreement with respect to property, (e) all
indebtedness incurred under or in connection with any real property lease to
finance, in whole or in part, the purchase, construction or installation of
improvements, equipment, fixtures or other property (including any tenant
improvement allowance or similar allowance that is required to be repaid to
the landlord under or in connection with any real property lease), (f) all
obligations under capital leases, (g) all obligations, contingent or
otherwise, as an account party under acceptance, letter of credit or similar
facilities, (h) all obligations in connection with any letter of credit,
banker's acceptance, guarantee, surety, performance or appeal bond, or similar
credit transaction, (i) all obligations under any currency, interest rate or
other hedge agreement or any other hedging arrangement, (j) the aggregate
amount of all prepayment premiums, penalties, breakage costs, "make whole
amounts" costs, fees, expenses and other payment obligations that would arise
(whether or not then due and payable) if all such items referred to in clauses
(a) through (i) above were prepaid, extinguished, unwound and settled in full,
and (k) all obligations of the kind referred to in clauses (a) through (i)
above secured by (or for which the holder of such obligation has an existing
right, contingent or otherwise, to be secured by) any Lien on property
(including accounts and Contract rights) owned by the Company or any of its
Subsidiaries, whether or not the Company or any of its Subsidiaries has
assumed or become liable for the payment of such obligation.

 

"Indemnified Person" has the meaning set forth in Section 9.6(a).

 

"Indemnifying Person" means, in relation to any Claim for indemnification
under this Agreement, (a) if such indemnification is sought from the
Equityholders prior to the Escrow/Set-Off Remedy End Date (including where
recovery is sought directly from the Consenting Equityholders pursuant to
Section 9.2(d)(i)(B)), the Equityholders' Representative, acting on behalf of
the

 

C-10  

Equityholders (provided that where this Agreement refers to liability of, or
requires payment by, the Indemnifying Person, "Indemnifying Person" shall
refer to the Equityholders, rather than to the Equityholders' Representative,
and in no event shall the Equityholders' Representative have any liability to
any Parent Indemnified Person for any amounts payable pursuant to Section
9.2(a)), or (b) if such indemnification is sought from the Equityholders on or
after the Escrow/Set-Off Remedy End Date, each Consenting Equityholder from
whom recovery is sought pursuant to Section 9.2(d)(i)(B).

 

"Indemnity Pro Rata Share" means, with respect to each Consenting
Equityholder, and as of any date, the ratio (expressed as a percentage)
calculated by dividing (a) the Merger Consideration received by such
Consenting Equityholder on or prior to such date (whether received in respect
of Preferred Stock, Common Stock or Stock Options), by (b) the aggregate
Merger Consideration received by all Consenting Equityholders on or prior to
such date (whether received in respect of Preferred Stock, Common Stock or
Stock Options).

 

"Individual Claim Threshold" has the meaning set forth in Section 9.3(b).

 

"Intellectual Property" means any and all intellectual property, including (a)
patents and provisional and non-provisional patent applications, and all
continuations, continuations-in-part, extensions, reissues, divisions or
invention disclosures relating thereto; (b) trademarks, trade names, service
marks, logos, trade dress, domain names, and social media accounts and
handles, together with all goodwill in any of the foregoing and all
applications and registrations of the same; (c) copyrights (including software
in source code or object code form) and all applications and registrations of
the same; (d) moral rights, including the right to the integrity of the work,
the right to be associated with the work as its author by name or under a
pseudonym and the right to remain anonymous; (e) rights of publicity and
privacy; (f) mask works, schematics, technology, know-how, Trade Secrets,
customer lists, technical information, technical data, process technology,
specifications, plans, drawings and blue prints, inventions, improvements
thereto, ideas, algorithms, devices, systems, processes, and any and all other
tangible or intangible proprietary information; (g) rights analogous to those
set forth above; and (h) rights to sue for past, present, and future
infringement, misappropriation or other unauthorized use of the rights set
forth above.

 

"Investor Agreements" means that certain (a) Amended and Restated Voting
Agreement, dated as of May 20, 2014, by and among the Company and the other
signatories thereto, (b) Amended and Restated Right of First Refusal and Co-
Sale Agreement, dated as of May 20, 2014, by and among the Company and the
other signatories thereto, (c) Amended and Restated Investors' Rights
Agreement, dated as of May 20, 2014, by and among the Company and the other
signatories thereto, and (d) letter agreement, dated October 13, 2017, by and
between KCOF Management VII, L.L.C. and the Company.

 

"IRS" means the United States Internal Revenue Service.

 

"IT Assets" has the meaning set forth in Section 4.27(d).

 

"Knowledge", "Knowledge of the Company" and similar formulations means the
actual knowledge of a particular fact or other matter of any individual set
forth on Exhibit O, or the knowledge any such individual would reasonably be
expected to have obtained upon reasonable inquiry in light of such
individual's position within the Company. 

 

C-11  

"Law" means any law, statute, common law, rule, code, executive order,
ordinance, Regulation, requirement, administrative ruling or judgment of any
Governmental Authority or any Order, whether preliminary or final, entered by
any Governmental Authority.

 

"Lease" has the meaning set forth in Section 4.15(c).

 

"Leased Real Property" has the meaning set forth in Section 4.15(c).

 

"Liability" or "Liabilities" mean debts, liabilities, commitments, losses,
deficiencies, duties, charges, claims, damages, demands, costs, fees, expenses
and obligations (including guarantees, endorsements and other forms of credit
support), whether accrued or fixed, absolute or contingent, matured or
unmatured, known or unknown, on- or off-balance sheet, including those arising
under any Contract, law, statute, ordinance, regulation, rule, code, common
law or other requirement or rule enacted or promulgated by any Governmental
Authority or any litigation, court action or proceeding, lawsuit, originating
application to an employment tribunal, or binding arbitration.

 

"Lien" means any mortgage, pledge, security interest, attachment, encumbrance,
lien (statutory or otherwise), license, claim, option, conditional sale
agreement, right of first refusal, first offer, termination, participation or
purchase or charge of any kind (including any agreement to give any of the
foregoing).

 

"Losses" has the meaning set forth in Section 9.2(a).

 

"M6-C Disc" means the product described on Exhibit P-1, as such product may be
modified or improved from time to time.

 

"M6-L Disc" means the product described on Exhibit P-2, as such product may be
modified or improved from time to time.

 

"Material Adverse Effect" means any fact, event, change, development,
condition, circumstance or effect that, individually or in the aggregate, (a)
is, or would reasonably be expected to be, materially adverse to the business,
operations, condition (financial or otherwise), assets (whether tangible or
intangible), liabilities, capitalization or results of operations of the
Company or its Subsidiaries, taken as a whole, or (b) would materially impair
or delay the ability of the Company to perform its obligations hereunder,
including the consummation of the Merger; provided that, in the case of the
foregoing clause (a), "Material Adverse Effect" shall not include any such
fact, event, change, development, condition, circumstance or effect to the
extent it results or arises from (i) any acts of terrorism, sabotage, military
action or war (whether or not declared) or any escalation or worsening
thereof, (ii) changes generally affecting (A) the industry in which the
Company and its Subsidiaries operate ,(B) the United States or worldwide
economy, (C) financial markets in the United States or worldwide, or (D)
political conditions in the United States or worldwide, (iii) changes in
applicable Law or GAAP, (iv) any action required to be taken by the Company
pursuant to the terms of this Agreement, (v) failure of the Company to meet
internal forecasts or financial projections (it being understood that any
fact, event, change, development, condition, circumstance or effect underlying
or contributing to such failure shall not be excluded, and may be taken into
account, in determining whether a Material Adverse Effect has occurred), or
(vi) the public announcement of the Merger, except, in each case of the
foregoing clauses (i), (ii) and (iii), if such event, change, development,
condition, circumstance or effect disproportionately affects (relative to
other participants in the Company's industry) the Company.

 

C-12  

"Material Company Trade Secrets" has the meaning set forth in Section 4.18(k).

 

"Material Compliance Violation" means any violation that by its nature could
reasonably require voluntary disclosure to a Governmental Authority occurring
as a result of any action or omission by any officer, director, manager,
managing director, employee, agent or Contract Worker of the Company or any of
its Affiliates in respect of any applicable Law (including Improper Payment
Laws, the International Emergency Economic Powers Act, the Arms Export Control
Act, the United Nations Participation Act, the Comprehensive Iran Sanctions,
Accountability and Divestment Act, the Iran and Syria Nonproliferation Act,
EAR, OFAC Regulations, other Trade Control Laws, Anti-Boycott Regulations, or
Money Laundering Laws, including the criminal money laundering provisions set
forth in Title 18 of the Code).

 

"Material Contracts" has the meaning set forth in Section 4.7(a).

 

"Merger" has the meaning set forth in the Recitals.

 

"Merger Consideration" shall mean the aggregate amount of (a) the Closing
Merger Consideration, plus (b) to the extent paid to Equityholders pursuant to
Section 3.8(d), the Equityholders Final Closing Adjustment Consideration, plus
(c) to the extent paid to Equityholders pursuant to Section 3.10, the First
Revenue Milestone Consideration, plus (d) to the extent paid to Equityholders
pursuant to Section 3.10, the Second Revenue Milestone Consideration, plus (e)
to the extent paid to Equityholders pursuant to Section 3.10, the FDA
Milestone Consideration, plus (f) to the extent paid to Equityholders pursuant
to Section 9.4, the amounts deposited under the Escrow Agreement, plus (g) to
the extent paid to the Equityholders pursuant to Section 9.5(d), the amounts
held in the Expense Fund.

 

"Merger Sub" has the meaning set forth in the Preamble.

 

"Merger Sub Common Stock" has the meaning set forth in Section 3.3.

 

"MEWA" has the meaning set forth in Section 4.13(d).

 

"Milestone" has the meaning set forth in Section 3.9(a).

 

"Milestone Non-Achievement Notice" has the meaning set forth in Section
3.10(c).

 

"Money Laundering Laws" has the meaning set forth in Section 4.31.

 

"MS Warrant" means that certain Warrant to Purchase Stock, issued as of
January 23, 2017, by and between NH Expansion Credit Fund Holdings LP and the
Company, as amended.

 

"Neutral Auditor" means BDO USA, LLP or, if BDO USA, LLP is unable to serve,
an impartial nationally recognized firm of independent certified public
accountants, mutually agreed to by the Equityholders' Representative and
Parent.

 

"Non-Defense Election" has the meaning set forth in Section 9.7(a). 

 

"Objection Notice" has the meaning set forth in Section 3.8(b).

 

"OFAC Regulations" has the meaning set forth in Section 4.30(a).

 

C-13  

"Open Source Software" has the meaning set forth in Section 4.18(o).

 

"Optionholder" means the holder of a Stock Option as of immediately prior to
the Effective Time.

 

"Order" means any judgment, ruling, order, decision, determination, writ,
injunction, ruling or decree of, or any settlement under the jurisdiction of,
any Governmental Authority.

 

"Ordinary RandW Cap" means an amount equal to twenty percent (20%) of the sum of
(a) the Base Merger Consideration, plus (b) if the FDA Milestone is achieved,
the FDA Milestone Consideration, plus (c) if the First Revenue Milestone
achieved, the First Revenue Milestone Consideration, plus (d) if the Second
Revenue Milestone achieved, the Second Revenue Milestone Consideration.

 

"Parent" has the meaning set forth in the Preamble.

 

"Parent Group Entities" has the meaning set forth in Section 3.9(a).

 

"Parent Indemnified Person(s)" has the meaning set forth in Section 9.2(a).

 

"Parent Representatives" has the meaning set forth in Section 6.3(a).

 

"Parties" has the meaning set forth in the Preamble.

 

"Party" has the meaning set forth in the Preamble.

 

"Payments Administrator" has the meaning set forth in Section 3.4(b).

 

"Payments Agreement" means a Payments Administration Agreement to be entered
into at or prior to Closing by and among Parent, the Equityholders'
Representative and the Payments Administrator.

 

"Pay-Off Letter" has the meaning set forth in Section 7.2(l).

 

"Payout Schedule" has the meaning set forth in Section 6.15.

 

"Permitted Liens" means (a) statutory liens for Taxes, which are not yet due
and payable, (b) statutory or common law liens to secure landlords, lessors or
renters under leases or rental agreements confined to the premises rented, (c)
deposits or pledges made in connection with, or to secure payment of, workers'
compensation, unemployment insurance, old age pension or other social security
programs mandated under applicable Laws, (d) statutory or common law liens in
favor of carriers, warehousemen, mechanics and materialmen, to secure claims
for labor, materials or supplies, (e) restrictions on transfer of securities
imposed by applicable state and federal securities Laws, and (f) prior to the
Closing, those Liens to secure the Existing Indebtedness that are listed in
Section 4.26 of the Company Disclosure Schedule, which will be released or
otherwise terminated at or before the Closing.

 

"Person" means an individual, corporation, partnership, association, trust,
unincorporated organization, limited liability company, joint venture or other
entity or group (as defined in Section 13(d)(3) of the Securities Exchange Act
of 1934, as amended).

 

C-14  

"Personal Data" means all financial, health, or other personal information,
including "nonpublic personal information" as defined under GLBA and
"individually identifiable health information" as defined under HIPAA, that
identifies, relates to, describes, is capable of being associated with, or
with respect to which there is a reasonable basis to believe the information
can be used to identify, an individual.

 

"Preferred Stock" has the meaning set forth in Section 4.3(a).

 

"Prime Rate" means the rate per annum published in The Wall Street Journal
from time to time as the prime lending rate prevailing during any relevant
period.

 

"Product" means any product (including any component thereof) manufactured,
shipped, sold, marketed, distributed, or otherwise introduced into the stream
of commerce (including through use in a clinical study) by or on behalf of the
Company or any of its Subsidiaries, including the M6-C Disc, the M6-L Disc and
any other product sold within or outside of the United States by the Company
or any of its Subsidiaries through any distributor or agent or pursuant to any
other contractual relationship with any other Person.

 

"Product Revenue" has the meaning set forth in Section 3.9(a).

 

"Proposed Final Cash" has the meaning set forth in Section 3.8(b).

 

"Proposed Final Company Transaction Expenses" has the meaning set forth in
Section 3.8(b).

 

"Proposed Final Debt Pay-Off Amount" has the meaning set forth in Section
3.8(b).

 

"Proposed Final Working Capital" has the meaning set forth in Section 3.8(b).

 

"Redeemed Series D Share" has the meaning set forth in Section 3.2(a).

 

"Regulation" means any rule, regulation, policy or interpretation of any
Governmental Authority having the effect of Law.

 

"Regulatory Permits" has the meaning set forth in Section 4.28(h).

 

"Release" means any presence or exposure to or emission, spill, seepage, leak,
escape, leaching, discharge, injection, pumping, pouring, emptying, dumping,
disposal, migration, release or threatened release of Hazardous Materials into
or upon the environment, including the air, soil, improvements, surface water,
groundwater, sewer, septic system, storm drain, publicly owned treatment
works, or waste treatment, storage, or disposal systems.

 

"Remediation" means any investigation, clean-up, removal action, remedial
action, restoration, repair, abatement, response action, corrective action,
monitoring, sampling and analysis, installation, reclamation, closure, or
post-closure in connection with the suspected, threatened or actual Release of
Hazardous Materials.

 

"Representatives" means the Company Representatives or the Parent
Representatives, as applicable.

 

C-15  

"Requisite Holders" has the meaning set forth in the Charter.

 

"Restricted Parties" has the meaning set forth in Section 4.30(c).

 

"Scheduled Company Intellectual Property" has the meaning set forth in Section
4.18(b).

 

"Second Revenue Milestone" has the meaning set forth in Section 3.9(a). 

 

"Second Revenue Milestone Consideration" has the meaning set forth in Section
3.9(a). 

 

"Section 280G" has the meaning set forth in Section 6.18.

 

"Selling Party" has the meaning set forth in Section 3.9(a).

 

"Series C Preferred Stock" has the meaning set forth in Section 4.3(a).

 

"Series C-1 Preferred Stock" has the meaning set forth in Section 4.3(a).

 

"Series D Holder" means any holder of shares of Series D Preferred Stock.

 

"Series D Preferred Stock" has the meaning set forth in Section 4.3(a).

 

"Significant Customer" has the meaning set forth in Section 4.34.

 

"Significant Supplier" has the meaning set forth in Section 4.34.

 

"Special Meeting" has the meaning set forth in Section 6.7(b)(i).

 

"Special Meeting Date Deadline" has the meaning set forth in Section
6.7(b)(i).

 

"Specified Products" has the meaning set forth in Section 3.9(a). 

 

"Specified Terminated Arrangement" has the meaning set forth in Section
7.2(y).

 

"Specified Representations" means the representations and warranties set forth
in Sections 4.8(a), 4.13, 4.17, 4.18, 4.28 and 4.29.

 

"Stock-Based Rights" has the meaning set forth in Section 4.3(e).

 

"Stockholder Approval" has the meaning set forth in Section 4.5.

 

"Stockholder Consent and Agreement" means a duly executed Stockholder Consent
and Agreement of Waiver and Release in the form attached hereto as Exhibit I.

 

"Stockholders" means the holders of Preferred Stock and Common Stock as of
immediately prior to the Effective Time (excluding any such Person that holds
only Redeemed Series D Shares).

 

"Stock Option" means any option, right or other security or instrument that is
outstanding and issued under the Company Equity Plans and directly or
indirectly exercisable for shares of Common Stock.

 

C-16  

"Straddle Period" means any Tax period that begins before the date of the
Effective Time and ends after the date of the Effective Time.

 

"Subsidiary" of any Person means any corporation, partnership, joint venture,
limited liability company, trust, unincorporated organization, association or
other legal entity (a) of which such Person owns, directly or indirectly, at
least fifty percent (50%) of the stock or other equity interests the holder of
which is generally entitled to vote as a general partner or for the election
of the board of directors or other governing body of such corporation,
partnership, joint venture, limited liability company, trust, unincorporated
organization, association or other legal entity or (b) with which such Person
has any arrangement, understanding or agreements entitling such Person to vote
as a general partner or for the election of a majority of the board of
directors or other governing body of such corporation, partnership, joint
venture, limited liability company, trust, unincorporated organization,
association or other legal entity.

 

"Surviving Corporation" has the meaning set forth in Section 2.1.

 

"Surviving Corporation Common Stock" has the meaning set forth in Section 3.3.

 

"SVB Warrant" means that certain Warrant to Purchase Stock, issued as of
August 21, 2015, by and between Silicon Valley Bank and the Company.

 

"Systems" has the meaning set forth in Section 4.19(a).

 

"Takeover Statute" has the meaning set forth in Section 4.21.

 

"Tax" or "Taxes" means (i) taxes, duties, fees, premiums, assessments,
imposts, levies and governmental impositions of any kind, payable to any
federal, state, local or foreign Governmental Authority, including (A) those
on or measured by or referred to as income, franchise, profits, gross
receipts, goods and services, capital, ad valorem, advance, corporation,
alternative or add-on minimum, estimated, environmental, disability,
registration, value added, sales, use, service, real or personal property,
capital stock, license, payroll, withholding, employment, social security,
workers' compensation, unemployment compensation, utility, severance,
production, excise, escheat, stamp, occupation, premiums, windfall profits,
transfer or gains, (B) custom duties, and (C) interest, penalties and
additions to tax imposed with respect to any of the foregoing, and (ii) any
transferee liability in respect of any items described in clause (i) payable
by reason of contract, assumption, transferee liability, operation of Law or
Treasury Regulations Section 1.15026(a) (or any predecessor or successor
thereof or any analogous or similar provisions under Law).

 

"Tax Returns" means returns, reports, forms and information statements,
including any schedule or attachment thereto and any amendment thereto, with
respect to Taxes filed or required to be filed with the IRS or any other
Governmental Authority or taxing authority or agency, domestic, state, local
or foreign, including consolidated, combined and unitary tax returns. 

 

"Third Party Claim" has the meaning set forth in Section 9.7.

 

"Third Party Intellectual Property" has the meaning set forth in Section
4.18(b).

 

"Third Party Purchasers" has the meaning set forth in Section 3.9(a). 

 

"Threshold Amount" has the meaning set forth in Section 9.3(b).

 

C-17  

"Trade Control Laws" has the meaning set forth in Section 4.30(a).

 

"Trade Secrets" means information, including know-how, customer lists,
software (source code and object code), technical information, data, process
technology, plans, drawings and blue prints, anywhere in the world that
derives independent economic value, actual or potential, from not generally
being known to, and not being readily ascertainable by proper means by, other
persons who can obtain economic value from its disclosure or use and that is
the subject of efforts that are reasonable under the circumstances to maintain
its secrecy.

 

"Trailing Twelve Month Period" has the meaning set forth in Section 3.9(a). 

 

"Transfer Taxes" has the meaning set forth in Section 10.6.

 

"Transmittal Letter" has the meaning set forth in Section 3.4(d)..

 

"Update Report" has the meaning set forth in Section 3.10(a).

 

"Updated Payout Schedule" has the meaning set forth in Section 6.15(d).

 

"VLL Warrants" means, collectively, (a) that certain Warrant to Purchase
Shares of Preferred Stock of Spinal Kinetics, Inc., issued as of July 30,
2010, by and between Venture Lending and Leasing V, LLC and the Company, as
amended, and (b) that certain Warrant to Purchase Shares of Preferred Stock of
Spinal Kinetics, Inc., issued as of July 30, 2010, by and between Venture
Lending and Leasing VI, LLC and the Company, as amended.

 

"WARN Act" has the meaning set forth in Section 4.14(b).

 

"Warrant" means a warrant to purchase capital stock of the Company. For the
avoidance of doubt, the VLL Warrants, the SVB Warrant and the MS Warrant each
constitute a "Warrant" for purposes of this Agreement.

 

"Working Capital" means the working capital of the Company and its
Subsidiaries (on a consolidated basis) as of 12:01 a.m. Eastern Time on the
Closing Date, as determined in accordance with the Accounting Rules; provided
that in no event shall Cash be included in the calculation of Working Capital.
In the event the Closing does not occur on the last day of a month, then each
item identified as a proration item on Exhibit H and included in the
calculation of Working Capital shall be prorated to the extent applicable as
of the Closing Date by multiplying the amount of each such item for the full
calendar month by a fraction, the numerator of which is the number of days
elapsed from and including the first day of the month in which the Closing
Date occurs to but excluding the Closing Date, and the denominator of which is
the total number of days in such month; provided that to the extent items may
be determined on a daily basis, such amounts will be allocated on a daily
basis.

 

"Written Consent First Deadline" has the meaning set forth in Section 6.7(a).

 

"Written Consent Second Deadline" has the meaning set forth in Section 6.7(b).

 



 

"Working Capital Calculation Method" has the meaning set forth in the
definition of Accounting Rules.

 

* * * * *

 

C-18  

EXHIBIT M

 

EQUITYHOLDERS' REPRESENTATIVE

 

The provisions set forth in this Exhibit M are an integral part of this
Agreement and shall apply to, and be binding upon and enforceable against, all
Parties and the Equityholders.

 

(a)Actions. The Equityholders' Representative may take any action which he,
she or it believes is necessary, advisable or appropriate under this Agreement
or the agreements ancillary hereto (including the Escrow Agreement) for, in
the name and on behalf of the Equityholders, as fully as if the Equityholders
were acting on their own behalf, including (i) executing and delivering the
Escrow Agreement as Equityholders' Representative, (ii) acting for each of the
Equityholders with respect to any post-Closing adjustment of the Working
Capital, Debt Pay-Off Amount, Company Transaction Expenses or Cash pursuant to
Section 3.8, (iii) giving and receiving any notice or instruction permitted or
required under this Agreement or the Escrow Agreement by the Equityholders'
Representative or any Equityholder, (iv) interpreting all of the terms and
provisions of this Agreement and the Escrow Agreement, (v) authorizing
payments to be made with respect hereto or thereto, (vi) obtaining
reimbursement as provided for herein for all out-of-pocket fees and expenses
and other obligations of or incurred by the Equityholders' Representative in
connection with this Agreement and the agreements ancillary hereto (including
the Escrow Agreement), (vii) contesting or defending all indemnity Claims
pursuant to Section 9.2 of this Agreement (a "Parent Indemnity Claim"), (viii)
consenting to, compromising or settling all Parent Indemnity Claims, (ix)
conducting negotiations with Parent and its Affiliates and agents regarding
such Claims, (x) dealing with Parent and the Escrow Agent under this Agreement
and the Escrow Agreement with respect to all matters arising under this
Agreement and the Escrow Agreement, (xi) taking any and all other actions
specified in or contemplated by this Agreement and the Escrow Agreement, (xii)
engaging counsel, accountants or other agents in connection with the foregoing
matters, and (xiii) taking all actions necessary, appropriate or advisable in
the judgment (in its, his or her sole discretion) of the Equityholders'
Representative for the accomplishment of the foregoing. The Equityholders'
Representative shall have authority and power to act in the name and on behalf
of each Equityholder with respect to the disposition, settlement or other
handling of all Claims under Section 9.2 or the Escrow Agreement and all
related rights or obligations arising under this Agreement or the Escrow
Agreement. Without limiting the generality of the foregoing, after the
Effective Time and to the extent permitted by the DGCL (and, to the extent
applicable, the CCC), the Equityholders' Representative shall have full power
and authority for, in the name and on behalf of all such Equityholders and
such successors to interpret all the terms and provisions of this Agreement
and the Escrow Agreement and to consent to any amendment hereof or thereof.
The Equityholders' Representative shall have no duties or obligations except
those expressly set forth in this Agreement and in the Escrow Agreement. No
bond shall be required of the Equityholders' Representative.

 

(b)Authorization. Without limiting the foregoing or any other provision of
this Agreement, the Equityholders' Representative hereby is authorized and
empowered after the Effective Time, for all purposes under this Agreement and
for, in the name and on behalf of the Equityholders, to:

 

(i)receive all notices or documents given or to be given to any of the
Equityholders by Parent or any of its Affiliates or the Escrow Agent pursuant
to this Agreement or to the Escrow Agreement or in connection herewith or
therewith and to receive and accept service of

 

M-1  

legal process in connection with any suit or proceeding arising under this
Agreement or the Escrow Agreement;

 

(ii)engage counsel, and such accountants and other advisors on behalf and for
the benefit of the Equityholders and incur such other expenses on behalf of
any of the Equityholders in connection with this Agreement or the Escrow
Agreement and the transactions contemplated hereby or thereby as the
Equityholders' Representative may in its sole discretion deem necessary,
appropriate and advisable;

 

(iii)take such other action as the Equityholders' Representative or any of the
Equityholders is authorized to take under this Agreement or the Escrow
Agreement;

 

(iv)receive all documents or certificates and make all determinations, on
behalf of any of the Equityholders, required or permitted under this Agreement
or the Escrow Agreement;

 

(v)take all such other actions as the Equityholders' Representative may in its
sole discretion deem necessary or appropriate to consummate this Agreement or
the Escrow Agreement and the transactions contemplated hereby and thereby;

 

(vi)take all such action as may be necessary to carry out any of the
transactions contemplated by this Agreement and the Escrow Agreement;

 

(vii)take all such action as the Equityholders' Representative may in its sole
discretion deem necessary or appropriate in connection with any waiver of any
obligation of Parent or the Surviving Corporation;

 

(viii)take all such action as the Equityholders' Representative may in its
sole discretion deem necessary or appropriate in respect of any post-Closing
adjustment of the Working Capital, Debt Pay-Off Amount, Company Transaction
Expenses or Cash pursuant to Section 3.8; and

 

(ix)take all such action as the Equityholders' Representative may in its sole
discretion deem necessary or appropriate in respect of any Claims for which
indemnification is sought pursuant to Article 9 (including contesting,
disputing or settling any such Claims, or defending (or participating in the
defense of) any Third Party Claims).

 

All actions, decisions and instructions of the Equityholders' Representative
that are within the scope of the authority of the Equityholders'
Representative, as set forth in Section 9.5 and this Exhibit M, shall be
conclusive and binding upon all of the Equityholders.

 

(c)Exculpation and Indemnification of Equityholders' Representative. The
Equityholders' Representative will incur no liability of any kind to any
Equityholder with respect to any action or omission by the Equityholders'
Representative in connection with the Equityholders' Representative's services
pursuant to this Agreement and any agreements ancillary hereto (including the
Escrow Agreement), except in the event of liability directly resulting from
the Equityholders' Representative's fraud or willful misconduct. The
Equityholders' Representative shall not be liable to any Equityholder for any
action or omission pursuant to the advice of counsel. The Equityholders shall
indemnify, defend and hold harmless the Equityholders' Representative from and
against any

 

M-2  

and all losses, liabilities, damages, claims, penalties, fines, forfeitures,
actions, fees, costs and expenses (including the fees and expenses of counsel
and experts and their staffs and all expense of document location, duplication
and shipment) (collectively, "Representative Losses") arising out of or in
connection with the Equityholders' Representative's execution and performance
of this Agreement and any agreements ancillary hereto, in each case as such
Representative Loss is suffered or incurred; provided that in the event that
any such Representative Loss is finally adjudicated to have been directly
caused by the fraud or willful misconduct of the Equityholders'
Representative, the Equityholders' Representative will reimburse the
Equityholders the amount of such indemnified Representative Loss to the extent
attributable to such fraud or willful misconduct. If not paid directly to the
Equityholders' Representative by the Equityholders, any such Representative
Losses may be recovered by the Equityholders' Representative from the funds in
the Expense Fund; provided that while this section allows the Equityholders'
Representative to be paid from the aforementioned source of funds, this does
not relieve the Equityholders from their obligation to promptly pay such
Representative Losses as they are suffered or incurred, nor does it prevent
the Equityholders' Representative from seeking any remedies available to it at
law or otherwise. In no event will the Equityholders' Representative be
required to advance its own funds on behalf of the Equityholders or otherwise.
Notwithstanding anything in this Agreement to the contrary, any restrictions
or limitations on liability or indemnification obligations of the
Equityholders set forth elsewhere in this Agreement are not intended to be
applicable to the indemnities provided to the Equityholders' Representative in
this paragraph. The foregoing indemnities will survive the Closing, the
resignation or removal of the Equityholders' Representative or the termination
of this Agreement.

 

(d)Reasonable Reliance. In the performance of its, his or her duties
hereunder, the Equityholders' Representative shall be entitled to rely upon
any document or instrument reasonably believed by the Equityholders'
Representative to be genuine, accurate as to content and signed by any
Equityholder or by Parent or the Escrow Agent. The Equityholders'
Representative may assume that any Person purporting to give any notice in
accordance with the provisions hereof has been duly authorized to do so.

 

(e)Attorney-in-Fact. 

 

(i)The Equityholders' Representative is hereby appointed and constituted the
true and lawful attorney-in-fact and agent of each Equityholder, with full
power in his, her or its name and on his, her or its behalf to act on his, her
or its behalf in connection with this Agreement and the agreements ancillary
hereto (including the Escrow Agreement) in the absolute discretion of the
Equityholders' Representative, and in general to do all things and to perform
all acts including executing and delivering the Escrow Agreement and any other
agreements, certificates, receipts, instructions, notices or instruments
contemplated by or deemed advisable in connection with this Agreement and the
agreements ancillary hereto (including the Escrow Agreement).

 

(ii)This power of attorney and all authority hereby conferred is granted and
shall be irrevocable and shall not be terminated by any act of any
Equityholder or by operation of Law, whether by such Equityholder's death,
disability, protective supervision or any other event. Without limitation to
the foregoing, this power of attorney is to ensure the performance of a
special obligation and, accordingly, each Equityholder hereby renounces its,
his or her right to renounce this power of attorney unilaterally.

 

(iii)Each Equityholder hereby waives any and all defenses which may be
available to contest, negate or disaffirm the action of the Equityholders'
Representative taken in good

 

M-3  

faith under this Agreement or any agreement ancillary hereto (including the
Escrow Agreement) pursuant to the authority granted in this Exhibit M.

 

(iv)Notwithstanding the power of attorney granted in this Exhibit M, no
agreement, instrument, acknowledgement or other act or document shall be
ineffective by reason only of the Equityholders constituting a Majority in
Interest having signed or given such directly instead of the Equityholders'
Representative. For purposes of this Agreement, the term "Majority in
Interest" shall mean Equityholders representing a majority in interest of the
consideration payable under this Agreement.

 

(f)Removal of Equityholders' Representative; Authority of Successor
Equityholders' Representative. Equityholders who in the aggregate constitute
at least a Majority in Interest shall have the right, upon not less than ten
(10) days' written notice, at any time during the period prior to the
Escrow/Set-Off Remedy End Date to remove the then acting Equityholders'
Representative and to appoint a successor Equityholders' Representative;
provided, however, that neither such removal of the then acting Equityholders'
Representative nor such appointment of a successor Equityholders'
Representative shall be effective until the delivery to the Escrow Agent (so
long as the Escrow Fund remains) of executed counterparts of a writing signed
by each such Equityholder constituting a Majority in Interest with respect to
such removal and appointment, together with an acknowledgment signed by the
successor Equityholders' Representative appointed in such writing that he or
she accepts the responsibility of successor Equityholders' Representative and
agrees to perform and be bound by all of the provisions of this Agreement
applicable to the Equityholders' Representative. Each successor
Equityholders' Representative shall have all of the power, authority, rights
and privileges conferred by this Agreement and the Escrow Agreement upon the
original Equityholders' Representative, and the term "Equityholders'
Representative" as used herein and in the Escrow Agreement shall be deemed to
include any interim or successor Equityholders' Representative.

 

(g)Resignation of Equityholders' Representative. The Person acting as
Equityholders' Representative may resign at any time upon no less than twenty
(20) days' notice to (i) Parent in accordance with Section 11.2 hereof, (ii)
the Equityholders at their respective last known addresses, as reflected in
the records of the Payments Administrator and (iii) if the Escrow Agreement
then remains in effect, the Escrow Agent at the address set forth in the
Escrow Agreement. If the Equityholders' Representative shall give notice of
its, his or her intent to resign, or is unable to or ceases to act as the
Equityholders' Representative for any reason, the holders of twenty-five
percent (25%) or more, in aggregate, of the shares of Preferred Stock and
Common Stock (excluding shares of Series D Preferred Stock) outstanding as of
immediately prior to the Effective Time (with each share of Common Stock
entitled to one vote per share and with each share of Preferred Stock entitled
to the number of votes equal to the largest number of whole shares of Common
Stock into which such share of Preferred Stock could be converted at the
Effective Time) may appoint a successor Equityholders' Representative by
written notice to (A) Parent in accordance with Section 11.2 hereof, (B) each
other former holder of shares of Preferred Stock and Common Stock (other than
any such holders who held only shares of Series D Preferred Stock) at such
former holder's last known address, as reflected in the records of the
Payments Administrator and (C) if the Escrow Agreement then remains in effect,
the Escrow Agent at the address set forth in the Escrow Agreement; provided,
however, that if more than one successor Equityholders' Representative shall
be proposed on or before the date that is twenty (20) days after the
Equityholders' Representative shall give notice of intent to resign, or is
unable to or ceases to act as Equityholders' Representative, by holders of
twenty-five percent (25%) or more, in aggregate, of the shares of Preferred
Stock and

 

M-4  

Common Stock (excluding shares of Series D Preferred Stock) outstanding as of
immediately prior to the Effective Time (with each share of Common Stock
entitled to one vote per share and with each share of Preferred Stock entitled
to the number of votes equal to the largest number of whole shares of Common
Stock into which such share of Preferred Stock could be converted at the
Effective Time), the successor proposed by holders of the largest number of
such shares outstanding as of immediately prior to the Effective Time shall
serve as the successor Equityholders' Representative. After the
Equityholders' Representative's resignation or removal hereunder, the
provisions of this Exhibit M shall continue in effect with respect to the
Equityholders' Representative who resigned or was removed in respect of any
actions taken or omitted to be taken by Equityholders' Representative while
he, she or it was acting as Equityholders' Representative.

 

(h)Actions of Equityholders' Representative. Any action taken by the
Equityholders' Representative pursuant to the authority granted in this
Exhibit M shall be effective and absolutely binding on each Equityholder
notwithstanding any contrary action of, or direction from, any Equityholder,
except in the case of fraud or willful misconduct by the Equityholders'
Representative.

 



 

M-5

 

    '

